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Abstract 
Microparticles (MP) are submicron structures produced by all cells upon activation 
or apoptosis that act as a non-soluble means of communication between cells. They 
ferry proteins, bioactive lipids, RNA and receptors, as well as ridding cells of 
redundant organelles and toxins. They have been recently investigated for their 
pathophysiological role and as potential biomarkers/effectors in many diseases. In 
severe sepsis, studies of MP so far have produced inconsistent and even conflicting 
results. In this project, it was demonstrated that cell derived MP subsets vary 
according to the cause of severe sepsis (community acquired pneumonia (CAP) or 
faecal peritonitis (FP)), where CAP patients had higher levels of circulating MP. 
Surprisingly, FP patients MP levels were comparable to healthy volunteers. Further 
stratification of MP subsets according to their expression of the protein alpha-2-
macroglobulin (A2M) has yielded better differentiation between the two diseases. 
The A2M expressing MP were significantly higher in survivors of community acquired 
pneumonia sepsis, but there was no similar association in patient with FP.  
Granulocyte macrophage colony-stimulating factor (GM-CSF) and interferon γ (IFN- 
γ) are being studied as possible adjuvant therapies in sepsis. They seem to reverse 
the immune-paresis that ensues after the initial insult. MP produced from whole 
blood stimulated with GM-CSF and IFN- γ were studied in this project. Both GM-CSF 
and IFN- γ increased MP expressing A2M over control. These MP elicited a pro-
inflammatory phenotype when incubated with neutrophils or endothelial cells which 
may contribute to the potential benefits of GM-CSF and IFN- γ in severe sepsis. 
 
 4 
Acknowledgments 
 
First, I would like to thank Professor Mauro Perretti my supervisor for his enthusiasm 
and motivation towards this project that was inspiring to me. Also, I would like to 
thank him for giving me the space to develop my project and for his invaluable advice 
at the times when I needed them. 
 
I would like to thank Dr Suchita Nadkarni for teaching me the basic laboratory skills 
and guiding me through the initial steps of this project and for her continued support 
during the latter stages. 
 
I would also like to thank Professor Charles Hinds my second supervisor for allowing 
me the opportunity to do this project and his continued support during it especially 
at the difficult times. Professor Hinds also provided me with invaluable career 
development advice. 
 
Dr Lucy Norling has provided me with great guidance and support during those latter 
stages of this project and during writing of this thesis that would otherwise have been 
immensely difficult. 
 
I would like to thank my colleagues Sarah Headland, Rachel Wright, Patricia De-
Souza, Hefin Jones and Dianne Cooper for their help and support during this project. 
I would like to thank them and everyone else at the department of Biochemical 
pharmacology for all the good times we spent together.  
 
Finally, I would like to thank my wife Diala Lashin and my daughter Yara Lashin for 
their continued unconditional love, support and patience during the course of this 
project. I also am grateful for my mother Dr Zeinab El-Shafey for her encouragement 
and support. 
 
 5 
Table of contents 
 
List of figures …………………………………………………………………………….9 
List of tables ………………………………………………………….…………………12 
List of abbreviations …………………………………………….……………………..13 
1. Introduction …………………………………………………………………………16 
1.1. Inflammation …………………………………………………………………...17 
1.1.1. Overview ………………………………….………………………………17 
1.1.2. Neutrophils in inflammation …………………………………………….18 
1.1.2.1. Neutrophil recruitment …………………………………………..18 
1.1.2.2. Neutrophil antibacterial activities ………….……………………21 
1.1.3. Endothelial response to inflammation …………………………………22 
1.1.3.1. Endothelium at rest …………………………….………………..22 
1.1.3.2. Endothelial activation …………………………………………...23 
1.1.3.3. Resolution of endothelial activation ………………………...…25 
1.1.4. Resolution of inflammation ……………………………………………..27 
1.1.5. Mediators of resolution ………………………………………………….30 
1.2. Severe sepsis …………………..………………………………………………31 
1.2.1. Overview ………………….………………………………………………31 
1.2.2. Pathophysiology of severe sepsis ……………..……………………….35 
1.2.2.1. Pathogen recognition and initiation of immune response …...36 
1.2.2.2. Pro-inflammatory response and cytokine storm ……………...37 
1.2.2.3. Hypo-inflammatory response and immune-paresis …………..38 
1.2.2.4. Mitochondrial dysfunction ……………………………………….40 
1.2.3. Neutrophils in sepsis ………………….…………………………………40 
1.2.4. Endothelium in sepsis ………………….………………………………..43 
1.2.5. Coagulation in sepsis ………………….………………………………...46 
1.2.6. Immuno-modulatory therapies in sepsis ….…………………………...48 
1.2.6.1. Granulocyte-macrophage colony stimulating factor .…………48 
1.2.6.2. Interferon-gamma …………………………………….………….53 
1.3. Microparticles ………………………….………………………………………59 
1.3.1. Introduction ……………………………….………………………………59 
1.3.2. Microparticle formation ………………………………………………….60 
1.3.2.1. Lipid membrane remodelling……………………………...…….61 
1.3.2.2. Cytoskeletal disruption…………………………………………..62 
1.3.2.3. Microparticles content……………………………………………63 
1.3.3. Microparticle function …………………….……………………………...65 
1.3.4. Microparticles in disease ………………….…………………………….67 
1.3.4.1. Microparticles in rheumatic diseases ………………………….67 
1.3.4.2. Microparticles in cardiovascular disease ………….…………..69 
1.3.4.3. Microparticles in cancer …………………………….…………...71 
 6 
1.3.5. Microparticles in sepsis …………………………….……………………72 
1.3.5.1. Characterisation of microparticles ……………………….…….72 
1.3.5.2. Pathophysiological role of microparticles in sepsis …….…….75 
1.3.6. Alpha-2-macroglobulin positive microparticles ……………….………79 
1.3.7. Other extra-cellular vesicles…………………………………………….81 
1.3.7.1. Exosomes…………………………………………………………81 
1.3.7.2. Apoptotic bodies………………………………………………….82 
1.4. Detection of microparticles…………………………………………………..83 
1.4.1. Optical methods…………………………………………………………..83 
1.4.2. Non-optical methods……………………………………………………..86 
1.4.3. Flow-cytometry…………………………………………………………...87 
1.5. The project …..……..………………..…………………………………………92 
1.5.1. Proteins …..…………….…………………………………………………92 
1.5.2. Overview..……………….………………………………………………..96 
1.5.3. Hypothesis ……………….……………………………………………….98 
1.5.4. Objectives ………………….……………………………………………..98 
2. Materials and methods ……………….………………………………………….101 
2.1. Materials ……………………………...……………………………………….101 
2.1.1. Cell culture ………………………………………………………….…..101 
2.1.2. Flow-cytometry antibodies for microparticle characterisation ….….101 
2.1.3. Flow-cytometry antibodies for cell characterisation ……….………..102 
2.1.4. Flow-cytometry proteins for microparticle characterisation …….…..102 
2.1.5. Other media …………………………………………………………….102 
2.1.6. Flow-cytometer …………………………………………………………102 
2.2. Patients and samples ……………………………………………………….103 
2.2.1. GAinS study inclusion criteria ………………………...………………103 
2.2.2. GAinS study exclusion criteria ………………………………………..104 
2.2.3. Sample handling and storage ………………………………………...105 
2.3. Flow-cytometry ………………………………………………………………105 
2.3.1. Sample staining for flow-cytometry ……………………………….….105 
2.3.2. Reducing noise ……………………………………………….………...106 
2.3.3. Further noise reduction …………………………………………….….109 
2.3.4. Flow-cytometry threshold ……………………………………….….....110 
2.3.5. Size calibration in flow-cytometry …………………………………….110 
2.3.6. Particle size resolution in flow-cytometry ……………………………114 
2.3.7. Sample acquisition and microparticle counting formula …………...117 
2.3.8. Gating strategy …………………………………………………………118 
2.4. Microparticle preparation ………………………………………….……….120 
2.4.1. Whole blood stimulation for microparticle production ……….……..120 
2.4.2. Isolation of microparticles from whole blood ………………….…….120 
2.4.3. Microparticle concentration ……………………………………….…..120 
2.4.4. Microparticle sorting ……………………………………………….…..121 
 7 
2.5. Human umbilical vein endothelial cells …………………………………122 
2.5.1. Isolation and culture of primary human umbilical vein endothelial cells 
(HUVEC) ………………………………..…………………………………122 
2.5.2. Stimulation of human umbilical vein endothelial cells with 
microparticles ……………………………………………………………..124 
2.5.3. Assessment of adhesion molecule and tissue factor expression on 
human umbilical vein endothelial cells by flow-cytometry ….………...125 
2.5.4. In-vitro flow chamber assay ………………………………….………..126 
2.5.5. Human umbilical vein endothelial cells permeability assay ….…….129 
2.5.6. Human umbilical vein endothelial cells reactive oxygen species 
production assay ……………………………………….…………………131 
2.5.7. Human umbilical vein endothelial cells nitrite production assay ….132 
2.5.8. Human umbilical vein endothelial cells cytokine production assay 132 
2.5.9. Detection of microparticle uptake by human umbilical vein endothelial 
cells using confocal microscopy ………………………………………134 
2.5.10. Detection of microparticle uptake by human umbilical vein 
endothelial cells using imaging flow-cytometry …..…………………….136 
2.5.11. Inhibition of microparticle uptake by human umbilical vein 
endothelial cells …………………………………………………………..137 
2.6. Polymorphonuclear cells …...…………………………...…………………138 
2.6.1. Isolation of human polymorphonuclear cells from whole blood …...138 
2.6.2. Polymorphonuclear cells stimulation using microparticles …………140 
2.6.3. Polymorphonuclear cells adhesion molecules assay using flow-
cytometry ………………………………………………………………….140 
2.6.4. Polymorphonuclear cells reactive oxygen species (ROS) production 
assay ………………………………………………………………………141 
2.6.5. Polymorphonuclear cells phagocytosis assay ………….………...…142 
2.6.6. Polymorphonuclear cells chemotaxis assay ……………..……...…..143 
2.7. Statistical analysis …..………………………………………………………145 
3. Microparticles characterisation in severe sepsis patients’ plasma……..147 
3.1. Protocol optimisation ………………………………………………………148 
3.1.1. Preparation of plasma for microparticles characterisation ………...148 
3.1.2. Antibody titration ……………………………………………………….149 
3.1.3. Optimisation of annexin V binding to microparticles ……………….150 
3.1.4. Effect of anticoagulant on annexin V binding ……………………….152 
3.2. Characterisation of microparticles in plasma of patient with severe 
sepsis ………………………………………………………………………….153 
3.2.1. Patient characteristics …………………………………………………153 
3.2.2. Effect of severe sepsis on plasma microparticles at day 1 post 
admission to ICU …………………………………………………………156 
 8 
3.2.3. Association between plasma microparticle subsets at day 1 post 
admission to ICU and mortality in severe sepsis secondary to community 
acquired pneumonia ………………………………….…………………..161 
3.2.4. Association between plasma microparticle subsets at day 1 post 
admission to ICU and mortality in severe sepsis secondary to faecal 
peritonitis …………………….…………………………………………….164 
3.2.5. Sequential changes in plasma microparticle subsets of severe sepsis 
secondary to community acquired pneumonia; comparison between 28 
non-survivors and survivors ………..……………………………………167 
4. The effect of granulocyte macrophage colony stimulating factor (GM-CSF) 
and interferon-gamma (IFN) on whole blood microparticles phenotype 
………………………………………………………………………………………..171 
4.1. Concentration response and time course for microparticles production from 
whole blood stimulated with granulocyte-macrophage colony stimulating 
factor and interferon-γ …………………………………………………………172 
4.2. Identification of cell specific microparticles generated from whole blood 
stimulated with granulocyte macrophage colony-stimulating factor or 
interferon-γ ……………………………………………………..………………174 
4.3. Microparticle uptake by human umbilical vein endothelial cells ………….177 
4.4. Effect of whole blood microparticles on human umbilical vein endothelial cells 
adhesion molecule and tissue factor expression …………………………..181 
4.5. Effect of whole blood microparticles on human umbilical vein endothelial cells 
reactive oxygen species (ROS) and nitric oxide (NO) production 
……………………………………………………………………………...……183 
4.6. Effect of whole blood microparticles on human umbilical vein endothelial cells 
cytokine production ……………………………………………………………184 
4.7. Effect of whole blood microparticles on human umbilical vein endothelial cells 
monolayer permeability ……………………………………………………….185 
4.8. Effect of whole blood microparticles on neutrophil function …………..…..186 
4.9. Effect of whole blood microparticles on neutrophil-endothelial interaction 
under flow conditions ………………………………………………..………..189 
5. Discussion …………………………………………………………………………192 
6. Conclusion …………………………………………………………………………214 
7. Reference …………………………………………………………………………..217 
 
 
 
 
 
 
 
 
 9 
List of figures 
 
Figure 1.1. Schematic depicting pathophysiological phases in sepsis, including 
mediators involved, biological effects and clinical manifestations ………………….39 
Figure 1.2. Biological effects of microparticles ………………………………………..60 
Figure 1.3. Microparticle formation …………………………………………………….61 
Figure 1.4. Neutrophil MP A2M levels within 24hr of admission to intensive care are 
elevated in patients that survive a septic event ……………………………………….80 
Figure 1.5. Schematic demonstrating the process of hydrodynamic focusing inside 
a flow-cytometer cell …………………………………………………………………….88 
Figure 1.6. Schematic demonstrating the light system inside a flow cytometer ……89 
Figure 1.7 Schematic representing the excitation and emission curves of a 
fluorochrome ……………………………………………………………………………..90 
Figure 2.1.Flow-cytometry SSC/FSC plots comparing acquisition of 10,000 with 
standard and double filtered degassed sheath fluids ………………………………108 
Figure 2.2. Comparison of double filtered flow-cytometer rinse fluid to standard rinse 
fluid ………………………………………………………………………………………109 
Figure 2.3. Titration of 1 μm polystyrene FITC fluorescent beads …………………112 
Figure 2.4. Titration of 0.5 μm polystyrene FITC fluorescent beads ……………….113 
Figure 2.5. Titration of 0.1 μm polystyrene FITC fluorescent beads ……………….114 
Figure 2.6. SSC/FSC dot plot and FSC histogram of 0.1, 0.5 and 1 μm beads 
acquired on flow-cytometry showing that it is difficult to differentiate between these 
beads using FSC ……………………………………………………………………….115 
Figure 2.7. Two histograms for 0.1, 0.5 and 1 μm beads of the SSC and FITC 
channels showing that these two channels could adequately differentiate between 
all three populations of bead …………………………………………………………..116 
Figure 2.8. SSC/FITC and SSC/FSC of the 0.1, 0.5 and 1 μm bead populations and 
the gate drawn around them using “back gating” to identify the MP population ….117 
Figure 2.9.Gating strategy ….………………………………………………………....119 
Figure 2.10.The effect of microparticle concentration on the number of microparticles 
per microliter ……………………………………………………………………………121 
Figure 2.11. Histograms of the alpha-2-macroglobulin (A2M) sorted microparticles 
and their isotype control ……………………………………………………………….122 
Figure 2.12. Ibidi μ‐Slides containing 6 individual chambers were used for the flow 
chamber assay …………………………………………………………………………126 
Figure 2.13. Schematic illustrating the flow chamber experiment …………………129 
Figure 2.14. Schematic illustrating the human umbilical vein endothelial cell 
(HUVEC) monolayer permeability assay …………………………………………….130 
Figure 2.15. Isolation of polymorph-nuclear cells from whole blood using dextran 
sedimentation …………………………………………………………………………..138 
Figure 2.16. Neubauer Haemocytometer counting grid. PMN were counted in each 
corner as illustrated …………………………………………………………….………139 
Figure 2.17. Polymorph nuclear cells migration assay plate ………………………144 
Figure 2.18. Schematic for polymorph nuclear leucocytes (PMN) chemotaxis assay 
using Neuroprobe ChemoTx® plate ……………………………..…………………...144 
 10 
Figure 3.1. Representative flow-cytometry histogram of microparticles analysed in 
PFP of healthy volunteers produced through an optimized centrifugation protocol 
(1500 x g for 15 minutes followed by 13000 x g for 2 minutes) ……………………148 
Figure 3.2. Antibody titrations for the various monoclonal antibodies used for 
microparticle detection …………………………………………………………………150 
Figure 3.3. The effect of commonly used anticoagulants on annexin V binding to 
microparticles …………………………………………………………………………..152 
Figure 3.4. Microparticle subsets in patient with severe sepsis secondary to 
community acquired pneumonia or faecal peritonitis and in healthy volunteers at day 
1 post admission to ICU ………………………………………………………………159 
Figure 3.5. Number of alpha-2-macroglobulin positive microparticles in patients 
severe sepsis secondary to community acquired pneumonia or faecal peritonitis and 
in healthy volunteers at day 1 post admission to ICU ………………………………160 
Figure 3.6. Microparticle subsets in patient in with severe sepsis secondary to 
community acquired pneumonia 28 day non-survivors compared to survivors at day 
1 post admission to ICU ……………………………………………………………….162 
Figure 3.7. Number of alpha-2-macroglobulin positive microparticles in patients with 
severe sepsis secondary to community acquired pneumonia 28 day non-survivors 
compared to survivors at day 1 post admission to ICU ……………………………163 
Figure 3.8. Microparticle subsets in patient in with severe sepsis secondary to faecal 
peritonitis 28 day non-survivors compared to survivors at day 1 post admission to 
ICU …………………………………………………………………………..................165 
Figure 3.9. Number of alpha-2-macroglobulin positive microparticles in patients with 
severe sepsis secondary to faecal peritonitis 28 day non-survivors compared to 
survivors at day 1 post admission to ICU …………………………………………….166 
Figure 3.10. Sequential changes in microparticle subsets in patients with severe 
sepsis secondary to community acquired pneumonia; comparison between 28 day 
non-survivors and survivors …………………………………………………………...168 
Figure 3.11. Sequential changes in microparticle subsets expressing alpha-2-
macroglobulin in patients with severe sepsis secondary to community acquired 
pneumonia; comparison between 28 day non-survivors and survivors ………….169 
Figure 4.1. Effect of whole blood stimulation with either granulocyte macrophage 
colony-stimulating factor (GM-CSF) or interferon-γ (IFN) on the number of 
microparticles expressing alpha-2-macroglobulin (A2M+MP) ……………………..173 
Figure 4.2. Identification of cell-specific microparticles in whole blood following 
stimulation with granulocyte macrophage colony-stimulating factor (GM-CSF) or 
interferon-γ (IFN-γ) …………………………………………………………………….175 
Figure 4.3. Identification of cell-specific microparticles positive for alpha-2-
macroglobulin (A2M) in whole blood following stimulation with granulocyte 
macrophage colony-stimulating factor (GM-CSF) or interferon-γ (IFN-γ) ………..176 
Figure 4.4. Human umbilical vein endothelial cells (HUVEC) uptake of microparticles 
……………………………………………………………………………..……………..178 
Figure 4.5. Confocal image of human umbilical vein endothelial cells (HUVEC) to 
assess the intracellular uptake of microparticles ……………………………………179 
Figure 4.6. Confocal split images of human umbilical vein endothelial cells (HUVEC) 
to assess the intracellular uptake of microparticles …………………………..…….180 
 11 
Figure 4.7. Confocal Z-stack analysis of human umbilical vein endothelial cells 
(HUVEC) to assess the uptake of microparticles ……………………………………181 
Figure 4.8. Effect of whole blood microparticles on human umbilical vein endothelial 
cells (HUVEC) adhesion molecule …………………………………………………...182 
Figure 4.9. Effect of whole blood microparticles on human umbilical vein endothelial 
cell (HUVEC) production of reactive oxygen species (ROS) and nitiric oxide (NO) 
……………………………………………………………………………………………184 
Figure 4.10. Effect of whole blood microparticles on the human umbilical vein 
endothelial cells cytokine production …………………………………………………185 
Figure 4.11. Effect of whole blood microparticles on human umbilical vein endothelial 
cells monolayer permeability ………………………………………………………….186 
Figure 4.12. Effect of whole blood microparticles on neutrophil CD11b adhesion 
molecule expression …………………………………………………………………...187 
Figure 4.13. Effect of whole blood microparticles on neutrophil phagocytosis …..188 
Figure 4.14. Effect of whole blood microparticles on neutrophil reactive oxygen 
species (ROS) production ……………………………………………………………..188 
Figure 4.15. Effect of whole blood microparticles on neutrophil chemotaxis …….189 
Figure 4.16. Effect of whole blood microparticles on neutrophil-endothelial 
interaction under flow conditions ……………………………………………………...190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
List of tables 
 
Table 1.1. Studies describing microparticle population in sepsis ……….………….73 
Table 2.1. Monoclonal antibodies used for microparticle detection …….…………101 
Table 2.2. Monoclonal antibodies used for cell antigen detection ……..………….102 
Table 2.3. Annexin V used for microparticle detection ……………..…...……….…103 
Table 2.4. Staining combination for microparticles detection by flow-cytometry and 
conjugated fluorochromes ……………………………...……………………………..106 
Table 2.5. The effects of reducing the flow-cytometer threshold on the number of 
microparticles detected ……………………………….……………………………….110 
Table 2.6. The concentrations used for polystyrene bead titration and the optimum 
concentration for each bead size ……………………………………………………..111 
Table 3.1. Optimum concentrations of the monoclonal antibodies employed for 
microparticle detection …………………………………………………………………149 
Table 3.2. Various media and commercial Annexin V binding buffers showing no 
significant difference in the number of Annexin V positive events …………………151 
Table 3.3. Titration of calcium concentration and the resulting annexin V positive 
events demonstrating an increase in count with increasing calcium concentration152 
Table 3.4. Baseline patient parameters on admission to intensive care …………154 
Table 3.5. Baseline community acquired pneumonia patient (non-survivors and 
survivors) demographics on admission to intensive care ………………………….155 
Table 3.6. Baseline faecal peritonitis patient (non-survivors and survivors) 
demographics on admission to intensive care ………………………………………156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
List of abbreviations: 
 
AP-1:  Activator protein 1 
aPC:   Activated Protein C 
AKI:  Acute Kidney Injury 
ARDS:  Adult Respiratory Distress Syndrome 
APC:   Allophycocyanin 
A2M:  Alpha-2-Macroglobulin 
AnxA7: Annexin A7 
AV:   Annexin V 
AMP:   Annexin V positive Microparticles 
BUN:   Blood Urea Nitrogen 
CLP:   Caecal Ligation and Perforation 
CCL:  CC chemokine ligand 
CXCL:  CXC chemokine Ligand  
CXCR:  CXC chemokine Receptor  
COPD: Chronic Obstructive Pulmonary Disease 
CAP:  Community-Acquire Pneumonia 
CARS:  Compensatory Anti-inflammatory Response Syndrome 
CHF:  Congestive Heart Failure 
COX:   Cyclooxygenase 
cMP:   control Microparticles 
DAMP: Danger-associated molecular patterns 
DVT:  Deep venous thrombosis 
DNA:   Deoxyribonucleic Acid 
DM:  Diabetes Mellitus 
DIC:   Disseminated Intravascular Coagulopathy 
eCRF:  electronic Case Report Form 
EC:   Endothelial Cells 
EMP:   Endothelial Microparticles 
EPCR:  Endothelial Protein C Receptor 
ECAM: Epithelial adhesion molecule 
ECM:  Extra-cellular matrix 
FITC:  Fluoroescein Isothocyanate 
Fl-:  Fluoroescence channel 
FMLP:  Formyl-Methionyl-Leucyl-Phenylalanine 
FSC:  Forward Scatter Channel 
eNOS:  Endothelial Nitric Oxide Synthase 
EryMP:  Erythrocyte Microparticles 
GM-CSF: Granulocyte-macrophage colony stimulating factor 
GM-CSFR: Granulocyte-macrophage colony stimulating factor receptor 
GPCR:  G-protein-coupled receptor 
GAinS: Genomic Advances in Sepsis study 
HLA:  Human leucocyte antigen 
HV:  Healthy Volunteers 
HO-1:  Hemoxygenase-1 
 14 
HDU:  High Dependency Unit 
HUVEC: Human Umbilical Vein Endothelial Cells 
IgG:   Immunoglobulin G 
IgM:   Immunoglobulin M 
iNOS:  inducible Nitric Oxide Synthase 
IBD:  Inflammatory Bowel Disease 
ITGAV: Integrin alpha v 
IL:   Interleukin 
ICAM-1:  Intracellular Adhesion Molecule 1 
ICU:   Intensive Care Unit 
JAM:  Junctional adhesion molecule 
LAIR-1: Leucocyte Associated Immunoglobulin like Receptor 1 
LPS:   Lippopolysaccharide 
LRP:  Lipoprotein receptor-related protein 
MAS:  Macrophage activation syndrome 
MFI:  Mean Fluorescence Intensity 
Mel-CAM: Melanoma cell adhesion molecule 
MLS:  Myosin light chain 
MHC:  Major histocompatibility complex 
mRNA:  messenger Ribonucleic Acid 
MSC:   Mesenchymal Stem Cells 
MMP:   Matrix metaloprotinases 
miRNA:  micro Ribonucleic Acid 
MP:   Microparticles 
MARS:  Mixed Anti-inflammatory Response Syndrome 
mAB:   monoclonal Antibody 
MODS:  Multi-Organ Dysfunction Syndrome 
NM:  Nano-medicine 
NLR: Nucleotide-binding oligomerization-domain protein-like receptors 
NADPH:  Nicotinamide Adenine Dinucleotide Phosphate 
NO:   Nitric Oxide 
NFκB:  Nuclear Factor κB 
NK:  Natural killer cells 
NKT:  Natural killer T cells 
NET:   Neutrophil Extra-Cellular Trap 
NMP:  Neutrophil Microparticles 
OSA:   Obstructive Sleep Apnea 
PAK:  p21- activated protein kinase (PAK) 
PAF:  Platelet-activating factor 
PBMC: Peripheral blood mononuclear cells 
PRR:  Pattern recognition receptors 
PVD:  Peripheral Vascular Disease 
PBS:  Phosphate Buffered Solution 
PSGL-1:  P-selectin glycoprotein ligand 1 
PS:   Phosphatidylserine 
PMT:  Photomultiplier tubes 
 15 
PE:  Phycoerythrin 
PE-CY5: Phycoerythrin-Cascade Yellow 5 
PAI-1:  Plasminogen Activator Inhibitor 1 
PAMP: Pathogen Associated Molecular Pattern 
PFP:  Platelet Free Plasma 
PMP:   Platelet MP 
PPP:  Platelet Poor Plasma 
PECAM-1: Platelet Endothelial Cell Adhesion Molecule 1 
PMNs:  Polymorph Nuclear Leucocytes 
PAC-1:  Procaspase Activating Compound 1 
PC:   Protein C 
PtnS:   Protein S 
PRR:  Pattern recognition receptor 
ROS:   Reactive Oxygen Species 
RA:   Rheumatoid Arthritis 
rhGM-CSF: recombinant human granulocyte-macrophage colony stimulating 
factor 
RNA:   Ribonucleic Acid 
sMP:   sepsis Microparticles 
SOFA:  Sequential Organ Failure Assessment 
SS:   Severe Sepsis 
SSC:  Side Scatter Channel 
shMP:  sham Microparticles 
SD:  Standard Deviation 
SEM:  Standard Error of the Mean 
SIRS:   Systemic Inflammatory Response Syndrome 
SLE:   Systemic Lupus Erythematosus  
TB:  Tuberculosis 
Th:  Helper T cells 
TM:   Thrombomodulin 
TF:   Tissue Factor 
TFPI:   Tissue Factor Pathway Inhibitor 
TIMP:  Tissue inhibitors of metalloproteinases 
tPA:   tissue Plasminogen Activator 
TLR:   Toll Like Receptor 
TNF:   Tumour Necrosis Factor 
TNFR: Tumor necrosis factor receptor 
uPA:   urokinase type Plasminogen Activator 
uPAR:  urokinase type Plasminogen Activator receptor 
VEGF: Vascular endothelial growth factor 
VCAM-1: Vascular cell adhesion molecule - 1 
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1.1 Inflammation: 
1.1.1 Overview: 
Inflammation is an adaptive response triggered by noxious stimuli such as infection 
and tissue injury. A controlled inflammatory response is crucial for host protection, 
but when dysregulated it could be harmful as is seen in severe sepsis and septic 
shock.   
 
In microbial triggered inflammation, toll like receptors (TLR) and nucleotide-binding 
oligomerisation-domain protein-like receptors (NLR) of the tissue resident 
macrophages and mast cells are activated leading to the production of chemokines, 
cytokines, eicosanoids and products of proteolytic cascades. This response leads to 
plasma proteins and leucocytes (particularly neutrophils) gaining access to the site 
of inflammation via the activated endothelium. These neutrophils then attempt to kill 
the invading organism by producing reactive oxygen species (ROS) and other toxic 
products, which can also result in local tissue damage1.  
 
When the acute inflammatory response is successful, it results in the elimination of 
the invading pathogen and the processes of resolution and repair are instigated. 
These processes are mediated by resident and recruited macrophages via the 
production of bioactive lipid mediators (e.g. lipoxins, resolvins) and pro-resolving 
peptides. Lipoxins inhibit the recruitment of neutrophils and instead promote the 
recruitment of monocytes, which remove cellular debris and promote local tissue 
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remodelling. Resolvins and protectins along with growth factors (e.g. transforming 
growth factor – β) play a role in resolution of inflammation and initiating tissue repair1.  
 
When the acute inflammatory response fails to eliminate the offending agents, the 
inflammatory process persists and acquires new characteristics. The neutrophil 
infiltrate is replaced by macrophages and T cells. If the combined effect of these 
cells is still not enough to overcome the pathogen a chronic inflammatory process 
ensues involving granuloma and tertiary lymphoid tissue formation 1. 
 
1.1.2 Neutrophils in inflammation 
The neutrophils play a major role in acute inflammation and are a key component of 
the rapid response of the host to danger and injury. These cells are the first 
leucocytes recruited to the site of inflammation and are capable of eliminating the 
invading pathogen via multiple mechanisms that entail release of toxic agents, 
remodelling proteolytic activities and a variety of autacoids and other inflammatory 
mediators. Neutrophils are crucial for clearance of infection.  
 
 
1.1.2.1 Neutrophil recruitment 
Neutrophils are recruited to the site of inflammation via a well-recognised cascade 
involving the following steps: capture, rolling, adhesion, crawling and finally 
transmigration. This process is initiated by changes on the surface of endothelial 
cells that have been activated by inflammatory mediators released by tissue resident 
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macrophages that came in contact with pathogens. Endothelial cells can also be 
activated directly through the activation of their pattern recognition receptors (PRR)2.  
 
Neutrophil capture. Following activation, the endothelial cells expression of the pre-
stored P-selectin from Weibel-Palade bodies is increased within minutes and is 
followed by the de novo production of E-selectin within 90 minutes. Once present on 
the surface of endothelial cells, the selectins bind to their neutrophil ligands (e.g. P-
selectin glycoprotein ligand 1 (PSGL1)) facilitating the tethering (capturing) of free 
flowing neutrophils to the surface of endothelial cells and their rolling in the direction 
of blood flow2.  
 
Neutrophils roll on the endothelial surface at a shear stress of 1 to 10 dyne/cm2 which 
requires the rapid formation and breaking of bonds. P-selectin-PSGL-1 dissociation 
at the rear of the neutrophil is balanced by formation of new bonds at the front of the 
cell to facilitate a smooth process. Also, long membrane tethers are formed at the 
rear end of the neutrophil that catapult to the front of the rolling cell to form a “sling”. 
The sling has PSGL-1 patches distributed along its length which attach to the 
endothelial selectins and as the cell roll forwards these bonds are broken in step like 
fashion2, 3. 
 
Neutrophil adhesion. Full activation of neutrophils is mediated via specific priming by 
pro-inflammatory cytokines (e.g. tumour necrosis factor – α (TNF-α) and IL-1β) and 
also via contact with activated endothelial cells followed by exposure to pathogen-
associated molecular patterns (PAMP), chemoattractants and growth factors. One 
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of these chemokines is IL-8, which plays a crucial role in neutrophil activation and 
adhesion to endothelial cells via the neutrophil receptor CXCR2 resulting in 
conformational change of the neutrophil surface integrins (e.g. CD11b). This results 
in the integrins having higher affinity to their ligands (e.g. intra-cellular adhesion 
molecule 1 (ICAM-1)), which is important for firm adhesion. This binding also 
activates signalling pathways inside the neutrophil, thereby stabilising adhesion and 
initiating cell motility2.  
 
Neutrophil crawling. Transmigration of neutrophils occurs at the endothelial cell-to-
cell junction. The neutrophils actively crawl towards these sites. This crawling under 
shear conditions occurs perpendicular to the direction of blood flow while maintaining 
adhesion to endothelial surface at all times. This process relies upon the interaction 
between ICAM-1 expressed on the endothelial surface and integrin αMβ2 
(CD11b/CD18) expressed on neutrophils4.  
 
Crawling does not require an active chemokine gradient. Under shear conditions in 
vitro, neutrophils still crawl perpendicular to the flow and when the flow is stopped 
the neutrophils crawl in random directions2.  
 
Neutrophil transmigration. In order to reach the site of inflammation or infection, the 
neutrophils have to cross the endothelium in a process called “transmigration”. This 
process requires integrins, CAMs (ICAM-1, ICAM-2 and vascular cell adhesion 
protein 1 (VCAM-1) as well as different junctional proteins such as CD31, CD99, 
junctional adhesion molecules (JAM) and epithelial cell adhesion molecule (ECAM). 
 21 
 
Neutrophil transmigration across the endothelium occurs either para-cellularly 
(between cells) or trans-cellularly (through cells). Para-cellular transmigration occurs 
at junctions between cells where there are less junctional proteins and the alignment 
between cells is less organised5. This process requires the breakdown of junctional 
intercellular protein bonds such those formed by vascular-endothelial (VE)-
cadherin2. In trans-cellular transmigration, endothelial cells form microvilli that 
extend around the adherent neutrophils to form “domes”. These domes shield the 
neutrophils from the blood stream and allow them to pass through the endothelial 
cells in an orderly fashion4, 6.  
 
The neutrophils then cross the basement membrane through areas with low density 
of extra-cellular matrix molecules (<60% of otherwise dense regions). These regions 
had less collagen IV, laminin 10 and nidogen 2 representing the path of least 
resistance for neutrophils7.  
 
1.1.2.2 Neutrophil antibacterial activities 
At the site of infection, neutrophils employ multiple methods to eliminate the invading 
pathogen. When a pathogen is encountered, it is phagocytosed by the neutrophil 
and once it is inside a phagosome, the neutrophil releases reactive oxygen species 
(ROS), cathepsins, defensins, lactoferrin and lysozymes stored in granules into the 
phagosome to kill the invading organism. This process of degranulation can also 
occur in the extracellular vicinity of the cell in order to attack the offending pathogen. 
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The neutrophils can also eliminate extracellular pathogens by releasing neutrophil 
extracellular traps (NETs). NETs are formed of core DNA elements with histones, 
proteins (cathepsins, lactoferrin) and enzymes (metalloproteinase, neutrophil 
elastase). The NETs trap and directly kill pathogens through its own histones, 
proteins and enzymes as well as facilitating phagocytosis of the trapped pathogen8.  
 
1.1.3 Endothelial response to inflammation 
 
1.1.3.1 Endothelium at rest 
The endothelium is a single layer of cells lining all blood vessels. It is considered the 
largest organ of the body covering an area of 4000 – 7000 m2 and weighing 1/5 kg.  
The endothelium contributes to each step of the process of haemostasis as it 
maintains and regulates blood flow, controls vessel permeability and quiesces 
circulating leucocytes9, 10.Blood flow is maintained by the endothelium through 
inhibition of the coagulation system via the expression of tissue factor pathway 
inhibitor (TFPI) which inhibits the initiation of coagulation, the expression of heparin 
sulphate proteoglycan that inactivates thrombin, the expression of thrombomodulin 
which indirectly activates protein C and the production of nitric oxide (NO) and 
prostacyclin that inhibit platelet aggregation10, 11.  
 
The endothelium regulates blood flow through maintaining tight junctions between 
endothelial cells thereby inhibiting the passage of plasma proteins and circulating 
cells to the tissues while maintaining active mechanisms of transport of certain 
plasma proteins through the endothelial barrier12. 
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The endothelial-leucocyte interaction is inhibited at rest as the endothelial cells 
maintain adhesive proteins such as P-selectin and chemokines such as IL-8 within 
secretory vesicles called Weibel-Palade bodies13, 14 and the transcription of E-
selectin, ICAM-1 and VCAM-1 is inhibited. Also the basal production of NO by 
endothelial cells contributes to endothelial and leucocytes quiescence via the 
inhibition of pro-inflammatory gene expression in endothelial cells, inhibition of 
Weibel-Palade bodies’ fusion with the cell surface15 and inhibition of leucocyte 
activation10.  
 
1.1.3.2 Endothelial activation 
Activation of endothelial cells is defined as the acquisition of new capabilities by the 
resting cells. This process is divided into rapid responses that are not dependent on 
new gene expression (Type I activation) and slower responses that depend on up-
regulation of gene expression (Type II activation). Both kinds of activation result in 
increased local blood flow, localised leakage of plasma proteins into the tissues and 
localised recruitment and activation of leucocytes which then enter the site of 
inflammation10.  
 
Type I endothelial activation is typically mediated by ligands that bind the extra-
cellular domains of the G-protein-coupled receptors (GPCR) resulting in the 
intracellular release of Ca+ from the endoplasmic reticulum and RHO activation. 
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Increased cytosolic Ca+ results in enhanced production of prostacyclin and nitric 
oxide (NO) causing increased blood flow locally. Increased vascular leak occurs as 
a results of the interaction between the Ca+ and RHO pathway, this interaction 
increases myosin light chain (MLC) phosphorylation, causing contraction of actin 
filaments that are attached to junctional proteins, with opening of the gaps between 
endothelial cells16. The increase in cytosolic Ca+ also has a role in leucocyte 
recruitment as it initiates the exocytosis of Weibel-Palade bodies brining P-selectin 
to the endothelial cell surface, as well as generating platelet-activating factor (PAF). 
The expression of both P-selectin and PAF on the endothelial surface initiates 
leucocyte tethering (capture) followed by integrin activation that initiates the process 
of neutrophil transmigration10, 17.  
 
Type II endothelial activation. Signalling by GPCR lasts for 10 to 20 minutes and is 
followed by receptor desensitisation, thereby limiting the inflammation and neutrophil 
recruitment induced by this process. A more sustained inflammatory response is 
required to maintain the process of pathogen elimination which is provided by type 
II activation.  
 
The mediators of this type of activation are tumour necrosis factor – α (TNF-α) and 
IL-1 principally derived from activated leucocytes. TNF-α and IL-1 bind to tumour 
necrosis factor receptor -1 (TNFR-1) and IL-1 receptor 1 on the endothelial cell 
surface resulting in activation of the transcription factors nuclear factor-κB (NF-κB) 
and activator protein 1 (AP-1) leading to new gene transcription and protein 
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translation18. This response requires hours rather than minutes making it a slower 
process in comparison to type I activation.  
 
Type II activation causes increased localised blood flow via increased production of 
prostacyclin at a much higher concentration in comparison to type I but still 
depending on the increase in cytosolic Ca+. Vascular leakage induced by type II 
activation is mediated via TNF-α and IL-1 stimulation of endothelial cells to 
reorganise their actin and tubulin cytoskeletons resulting in opening of inter-cellular 
gaps19. The leakage seen with type II activation is of larger plasma proteins in 
comparison to type I and results in the formation of a firm provisional matrix often 
described as “induration” in comparison to the soft oedema produced by type I. The 
synthesis and expression of IL-8 and E-selectin on the surface of endothelial cells 
render type II activation more effective in terms leucocyte recruitment. E-selectin 
(functionally similar to P-selectin and IL-8) triggers firm attachment of neutrophils to 
endothelial cells and induces diapedesis into the tissues. This process can only act 
effectively if the leucocytes are tethered to the endothelial surface, a phenomenon 
which is reliant on type I activation preceding type II10.  
 
Type II activation evolves over time with ICAM-1 and VCAM-1 expression increasing 
while E-selectin expression decreases. Also, there is an increase in chemokine 
ligand 2 (CCL2) production which favours transition to monocyte rich infiltrate over 
the 6 to 24 hours following the initial activation. By 24 hours, leucocyte mediated 
endothelial cell injury contributes to inflammation; TNF-α and IL-1 in conjunction with 
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other mediators such as interferon-γ can induce endothelial cell death through the 
activation of procaspase-8 and the release of cathepsin B20. This injury is also pro-
coagulant through shedding of anticoagulants, exteriorisation of MP expressing 
phosphatidylserine which favours coagulation21, exposure of basement membrane 
collagen which supports the adhesion and activation of platelets and tissue factor 
synthesis and exteriorisation22. This pro-coagulant activity predisposes to thrombus 
formation which helps to sequester the pathogen and at the same time causes 
further damage to the vessel wall with a risk of haemorrhage10.  
 
1.1.3.3 Resolution of endothelial activation 
Type I activation undergoes spontaneous resolution as a result of receptor 
desensitisation but type II activation can persist as long as the stimulating agents 
(e.g. cytokines) are present. Type II activation resolves when cytokines are 
eliminated following successful removal of the pathogen, as well as via several 
negative feedback mechanisms resulting in down-regulation of the genes that 
perpetuate inflammation10. 
 
The process of endothelial activation results in the acquisition of new capabilities by 
endothelial cells. This process starts with the more rapid Type I activation which is 
followed by the slower but more potent Type II activation. The activation process 
results in increased blood flow to the site of inflammation accompanied by increased 
leakage of plasma proteins and leucocyte recruitment to the site of inflammation. 
This inflammation resolves once the pathogen has been eliminated. 
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1.1.4 Resolution of inflammation 
Resolution of inflammation is an active process aimed at restoring tissue integrity 
and function following the achievement of inflammatory goals (e.g. bacterial 
clearance). This is achieved through abolition of chemokine signalling in order to 
block further neutrophil tissue infiltration, as well as the attraction of monocytes and 
macrophages to clear apoptotic neutrophils which results in re-programming of 
macrophages towards a pro-resolution phenotype23.  
 
Chemokine depletion. Chemokines are chemoattractants that orchestrate the 
migration of leucocytes towards the site of inflammation. Abolishing this migration is 
a crucial step to reduce further inflammation and initiation of resolution via 
chemokine cleavage and sequestration. Matrix metalloproteinase (MMP) 12 
secreted by macrophages cleaves CXC-chemokines and also depletes CC-
chemokines, rendering them unable to attract neutrophils and monocytes 
respectively24. In an environment where there are pro- (LPS) and anti-inflammatory 
(IL-10) signals chemokine receptors can be uncoupled from signalling G-proteins to 
form “decoy” receptors25.  Chemokine sequestration is a process by which 
chemokines bind to chemokine “decoy” receptors; this binding does not translate 
into leucocyte trafficking but rather causes chemokine trapping25. IL-10 also inhibits 
down regulation of (CC-chemokine receptor) CCR1, CCR2 and CCR5 resulting in 
further chemokine sequestration26.  
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Neutrophil apoptosis. Neutrophil clearance is another important step in resolution of 
inflammation. Once migrated, neutrophil’s lifespan is modified by multiple factors. 
For example, macrophages secret ligands of death receptor such as Fas-ligand and 
TNF-α which promote neutrophil survival in low concentrations and neutrophil 
apoptosis in high concentrations27. These pathways manipulate ROS production in 
neutrophils which is a key event in initiating neutrophil apoptosis. Neutrophils 
undergoing apoptosis produces protein such as annexin A1 which inhibits further 
neutrophil recruitment through binding formyl peptide receptor (FPR) – 2. Annexin 
A1 also promotes neutrophil apoptosis and clearance by macrophages28. Lactoferrin 
is another protein secreted by neutrophils with similar effects to annexin A129.  
 
Macrophage reprogramming. Macrophages ingest apoptotic neutrophils via 
efferocytosis which switches off pro-inflammatory mediator production and initiates 
production of anti-inflammatory mediators (e.g. IL-10 and transforming growth factor 
(TFG) – β)30. These “resolution-phase” macrophages possess high levels of antigen 
processing and presentation capabilities, as well as producing lymphocyte 
chemoattractants such as XCL1, CCL5 and CXCL1331, 32. Certain subtypes of 
lymphocytes (B1, NK, γδT, CD4+CD25+, B2) migrate to the site of resolving 
inflammation and exert protective effects33. These resolution-phase macrophages 
express lower levels of CD11b, have reduced responses to toll like receptor (TLR)-
4 ligands and have enhanced capacity to ingest apoptotic neutrophils34. 
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Restoration of tissue function.  Tissue recovery following inflammation is a complex 
process that involves coordination between macrophages, stem cells, progenitor 
cells and stromal cells to prevent fibrosis and restore function.  
 
In this phase, macrophages produce anti-inflammatory and pro-repair mediators 
such as IL-1 receptor antagonist, IL-10, transforming growth factor (TGF)-β and 
vascular endothelial growth factor (VEGF)35. TGF-β promotes tissue repair and 
wound healing via enhanced fibroblast differentiation into myofibroblasts, expression 
of tissue inhibitors of metalloproteinases (TIMP) that regulate remodelling of extra-
cellular matrix (ECM) and collagen synthesis by myofibroblasts36. VEGF promotes 
angiogenesis and restoration of oxygen supply in healing wounds37. Macrophages 
also produce metalloproteinases and TIMPs to control ECM turnover. 
 
Furthermore, macrophages engage in cross-talk with mesenchymal stem cells 
(MSC) where macrophages promote MSC growth and motility. In turn MSC promote 
macrophage differentiation into a pro-resolution, pro-repair phenotype35, 38. 
 
Once pathogen elimination has been achieved, the process of resolution of 
inflammation ensues. This is an active process aiming to restore tissue integrity and 
function that is mediated through blocking of further neutrophil infiltration and 
attracting monocytes and macrophages to clear the apoptotic neutrophils. These 
macrophages now undergo a process of reprogramming to attain a pro-resolution 
phenotype. 
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1.1.5 Mediators of resolution 
Resolution of inflammation is controlled by several classes of mediators such as 
autacoids, bioactive lipids and proteins. Below is a succinct focus on a few of the 
pro-resolution mediators.  
 
Lipid mediators of resolution. Lipid mediators play a role in balancing inflammation 
and resolution. Prostaglandin (PG) – E2 and D2 play a pro-inflammatory role, while 
in the resolution phase the pro-resolution lipoxins, resolvins and protectins become 
predominant. Lipoxins inhibit the migration of neutrophils into sites of resolving 
inflammation and promote monocyte translocation into these same sites. They also 
reduce neutrophil expression of CD11b/CD18, ROS production, NFκB activity and 
production of pro-inflammatory soluble mediators. In monocytes, lipoxins promote 
neutrophil phagocytosis. Resolvins are another class of pro-resolution lipid 
mediators that reduce neutrophil infiltration and reduce monocyte, macrophage and 
dendritic cell NFκB activation in response to TNF-α23, 39. 
 
Peptide mediators of resolution. IL-10 (produced mainly by resident macrophages) 
is a mediator of inflammation resolution as it suppresses the production of pro-
inflammatory mediators such as TNF-α and IL-1, as well as preventing maturation of 
antigen presenting cells (e.g. dendritic cells) resulting in suppressed T-helper cell 
proliferation and differentiation40. This effect protects the tissues from the harmful 
effects of unchecked inflammation and promotes resolution41. TGF-β produced by 
macrophages on phagocytosis of apoptotic neutrophils30 is another important 
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mediator of resolution. TGF-β was found to suppress the production of pro-
inflammatory cytokines by macrophages and other cells, as well as promoting tissue 
repair and wound healing36. VEGF also promotes resolution of inflammation and 
restoration of tissue function by stimulating angiogenesis37. 
 
1.2 Severe sepsis 
1.2.1 Overview 
Severe sepsis (SS) is a systemic inflammatory response to infection associated with 
coagulopathy and acute multi-organ failure.   The incidence of SS is increasing 
worldwide with stubbornly high morbidity and mortality despite recent advances in 
understanding and management of the disease.  In the USA it is estimated that 
750,000 patients develop SS annually of whom 210,000 die42. The incidence of SS 
in the UK was around 66 per 100,000 population in 2003 up from 46 per 100,000 in 
1996 with mortality approaching 30 per 100,000 up from 23 in the same period 43. 
SS accounted for 23.5% of admissions to Intensive Care Units (ICU) across the UK 
in 1996 increasing to 28% in 2004 43.  Non-surgical cases accounted for more than 
70% of all SS admissions to ICU 43.   
 
Sepsis as defined by the Surviving Sepsis Campaign International Guidelines 2012 
refers to infection with systemic manifestations of inflammation and is considered 
severe when associated with sepsis-induced organ dysfunction or tissue hypo-
perfusion. The campaign has devised criteria for the diagnosis of sepsis as follows44: 
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The same guidelines devised a goal-orientated approach to the initial management 
of SS, which is called resuscitation. The aim of this approach is to correct the SS 
induced tissue hypo-perfusion.  The tissue hypo-perfusion is defined, as 
“hypotension after initial fluid challenge” or a blood lactate level of more than or equal 
to 4 mmol/L. Within the first six hours the aim of resuscitation is to achieve:  
 
 
1. Infection, documented or suspected, and some of the following: 
1. General variables 
1. Fever (>38.3°C) 
2. Hypothermia (core temperature <36°C) 
3. Heart rate > 90/min or >2 SD above the normal value for age 
4. Tachypnoea 
5. Altered mental status 
6. Significant oedema or positive fluid balance (>20 mL/kg over 24 
hrs) 
7. Hyperglycaemia (plasma glucose >140 mg/dL or 7.7 mmol/L) in 
the absence of diabetes mellitus 
2. Inflammatory variables 
1. Leucocytosis (WBC count >12,000/μL) 
2. Leucopenia (WBC count <4000 /μL) 
3. Normal WBC count with >10% immature forms 
4. Plasma C-reactive protein >2 SD above the normal value 
5. Plasma procalcitonin >2 SD above the normal value 
3. Hemodynamic variables 
1. Arterial hypotension (SBP <90 mm Hg; MAP <70 mm Hg; or an 
SBP decrease >40 mm Hg in adults or <2 SD below normal for 
age) 
4. Organ dysfunction variables 
1. Arterial hypoxaemia (PaO2/FIO2<300) 
2. Acute oliguria (urine output <0.5 mL/Kg hr or 45 mmol/L for at least 
2 hrs, despite adequate fluid resuscitation) 
3. Creatinine increase >0.5 mg/dL or 44.2 µmol/L 
4. Coagulation abnormalities (INR >1.5 or aPTT >60 seconds) 
5. Ileus (absent bowel sounds) 
6. Thrombocytopaenia (platelet count, <100,000/μL) 
7. Hyperbilirubinaemia (plasma total bilirubin >4 mg/dL or 70 μmol/L) 
5. Tissue perfusion variables 
1. Hyperlactataemia (>upper limit of lab normal) 
2. Decreased capillary refill or mottling  
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The next step is to obtain at least two sets of blood cultures; at least one of them is 
drawn percutaneously before commencing antimicrobial therapy. Also performing 
any necessary imaging to confirm a potential source of infection. 
 
The guidelines then recommend commencing empirical antibiotic therapy of one or 
more agents effective against all likely pathogens. This has to be modified later if 
and when the causative organism is identified. The antibiotic therapy should continue 
typically for 7 to 10 days. Anti-viral agents should be used when viral infections are 
suspected.  
 
Source control is the next step in which anatomical sources of infection are identified 
and dealt with promptly in the least physiologically insulting fashion. 
 
Another important recommendation is initiating selective oral and digestive 
decontamination strategies to reduce the incidence of ventilator-associated 
pneumonia.  
 
The surviving sepsis campaign has formulated a “bundle” to help implement these 
recommendations. The first 4 steps have to be completed within 3 hours of diagnosis 
and the rest within 6 hours. This bundle consists of: 
 
1. Central venous pressure 8 -12 mm Hg 
2. Mean arterial pressure ≥ 65 mm Hg 
3. Urine output ≥ 0.5 ml/kg/hr 
4. Central venous or mixed venous oxygen saturation of 70% or 65% 
respectively 
5. Normalising lactate levels 
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The guideline also offers recommendations on haemodynamic support and 
adjunctive therapy in SS. These are mainly:   
 
 
Other supportive measures which have been advised by the campaign are: 
 
Expect for antibiotics the main management strategy for SS as outlined above 
remains supportive. Many novel therapeutic agents (e.g. anti-TNF and anti-IL1) have 
1. Measure lactate level 
2. Obtain blood cultures prior to administration of antibiotics 
3. Administer broad spectrum antibiotics 
4. Administer 30ml/kg crystalloid for hypo-perfusion or lactate ≥ 4 mmol/L 
5. Apply vasopressors (for hypotension not responding to initial fluid 
resuscitation) to maintain mean arterial pressure ≥ 65 mm Hg 
6. If hypo-perfusion persists despite initial fluid resuscitation measure 
central venous pressure and central venous oxygen saturation 
7. Re-measure lactate if it was initially elevated 
1. Fluid resuscitation of at least 30ml/kg using crystalloids and albumin 
2. Vasopressors use to maintain mean arterial pressure ≥ 65 mm Hg, the 
main vasopressor they advocate is Norepinephrine 
3. Inotropes could be used if myocardial dysfunction is suspected 
4. Hydrocortisone could be used to supplement the treatments above, if the 
required blood pressure could not be reached 
1. Blood products: Red blood cell transfusion to maintain haemoglobin level 
between 7 and 9 gm/dL. Platelets transfusion when count below 10,000x 
109/L or in special situations. 
2. Mechanical ventilation strategies for SS associated acute respiratory 
distress syndrome (ARDS) 
3. Sedation: To be minimised in SS patients 
4. Glucose control: Maintain blood glucose levels between 6 and 10 mmol/L 
5. Renal replacement therapy: Continuous renal replacement strategies are 
advocated in SS patients with acute renal failure 
6. Deep Venous Thrombosis (DVT) prophylaxis: Low molecular weight 
heparin is the first line 
7. Stress ulcer prophylaxis: H2 blockers or proton pump inhibitors could be 
used 
8. Nutrition: Enteral or parenteral nutrition to be commenced as soon as 
possible 
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shown promise in vitro and in animal studies but did not show benefit when tested in 
clinical trials42. Other agents have shown benefits in initial clinical trials but have 
subsequently been found to be ineffective or even harmful (e.g. recombinant human 
Activated Protein C)45.  The repeated failure to discover new therapeutic agents in 
SS at least in part reflects our limited understanding of the underlying mechanisms 
but could also be due to the complexity of the physiological response and the 
heterogeneity of the patient population in terms of age, gender, co-morbidities, 
medications and causative pathogen. Also the timing of therapy varies significantly 
between patients and genetic polymorphisms may be associated with individual 
differences in response to the original insult and therapies 46. 
 
1.2.2 Pathophysiology of severe sepsis 
Sepsis develops when the initial host response to the invading organism is amplified 
and subsequently dysregulated.   This response is driven by multiple factors 
including microbial virulence, the extent of bacterial invasion, the host’s premorbid 
condition as well as their immune phenotype. The host response can cause cell and 
tissue damage as in multiple organ dysfunction syndrome (MODS) and even multi-
organ failure. In severe sepsis, the invading organism triggers both the innate and 
the adaptive immune systems. Innate immunity is the initial defence against the 
pathogen, while the adaptive immune system provides more sophisticated targeted 
defence later in the disease course. The adaptive immune system recognises 
specific pathogens and mounts a stronger response each time the host encounters 
the same organism 47.  
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Following stimulation by an invading organism, innate immune cells produce large 
amounts of cytokines, chemokines, complement-activation mediators and intra-
cellular danger signals (alarmins). Also innate immune cells act directly on the 
invading organism through phagocytosis and killing 48.  
 
Adaptive immunity is activated later through interaction with antigen-presenting cells 
and soluble mediators. The cells of the adaptive system then proliferate to generate 
effector cells that produce a specific repertoire of cytokines 48 . The “cytokine storm” 
is thought to be the trigger for the dysregulated systemic immune response that 
characterises severe sepsis.  
 
1.2.2.1 Pathogen recognition and initiation of immune response 
Cells initially recognise a potential threat through their pattern recognition receptors 
(PRR) which are stimulated with pathogen-associated molecular patterns (PAMPs) 
and danger-associated molecular patterns (DAMPs).  The PAMPs include bacterial 
cell wall components (e.g. Lipopolysaccharide – LPS and peptidoglycan) and 
microbial nucleic acids, while the DAMPs are host related and derived from damaged 
tissue such as DNA, ROS, heat shock proteins and fibrinogen49. 
 
TLRs are a group of PRRs that play an important role in the development of severe 
sepsis. They are expressed mainly by innate immune cells including neutrophils, 
monocytes and macrophages as well as endothelial cells. When they are stimulated 
by their ligands, TLRs induce the production of cytokines via nuclear factor κB 
(NFκB) pathway activation49.  
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1.2.2.2 Pro-inflammatory response and cytokine storm 
Upon activation of PRRs a number of pro-inflammatory cytokines and chemokines, 
includes IL-1β, IL-6, IL-8, interferon (IFN)-γ and tumour necrosis factor (TNF)-α are 
secreted initially mainly by macrophages. IL-1β  (one of the initial cytokines produced 
in response to TLR stimulation) has the capacity to enhance the production of most 
other pro-inflammatory cytokines, chemokines and nitric oxide as well as increasing 
the expression of adhesion molecules.  IL-1β also stimulates the bone marrow to 
produce inflammatory effector cells such as neutrophils and platelets.  The 
complement system also acts to re-inforce and exaggerate the innate immune 
response by opsonising pathogens in order to facilitate their phagocytosis and 
lysis49, 50. 
 
Neutrophils are the first cells recruited to the site of inflammation in order to 
participate in bacterial clearance but subsequently these leucocytes can cause 
tissue damage through cytotoxicity, degranulation, increased vascular permeability 
and release of several pro-inflammatory mediators and proteases. Monocytes follow 
neutrophils to the site of inflammation where they participate in pathogen clearance 
and cytokine production to perpetuate inflammation. They also differentiate locally 
into macrophages and dendritic cells which are professional antigen presenting cells 
driving inflammation further by recruiting cells of the adaptive immune system49, 50. 
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1.2.2.3 Hypo-inflammatory response and immune-paresis 
On the other hand macrophages and neutrophils also release anti-inflammatory 
cytokines such as IL-10 and TGF–β, which play an important regulatory function in 
sepsis. The prolonged release of these mediators may produce the immune-paresis 
seen particularly in the later stages of the disease. This is mirrored by cells of the 
adaptive immune system which tend to release pro-inflammatory mediators at the 
onset of sepsis and anti-inflammatory mediators later on, thereby contributing to host 
susceptibility to nosocomial infections 51.  In addition, immune cells may become 
exhausted in sepsis and chemoattractant receptors can be de-sensitised (through 
phosphorylation of the intracellular tail and/or blockade of recycling), contributing to 
immune-paresis and an inadequate response to xenobiotic agents (see section 
1.2.2). 
 
Achieving a balance between pro- and anti-inflammatory mechanisms is an 
important determinant of outcome in sepsis. The early hyper-immune phase could 
be rapidly fatal whilst the immuno-paresis that develops later in the course of the 
disease predisposes to recurrent infection, persistent organ failure and late deaths. 
The initial surge in pro-inflammatory mediators and the hyper-immune state is 
termed the systemic inflammatory response syndrome (SIRS). This phase is 
important for successful elimination of the invading pathogen but also could cause 
injury (“collateral damage”) to the host. The anti-inflammatory mechanisms that are 
triggered almost simultaneously and as a result of SIRS have been termed the 
compensatory anti-inflammatory response syndrome (CARS) 51, 52.  
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The CARS can limit the damage mediated by SIRS but plays no role in pathogen 
elimination. Thus CARS could be harmful to the patient if poorly regulated or miss-
timed rendering the host susceptible to acquired infections and causing further 
morbidity and mortality51, 53 (Figure 1.1). 
 
 
Figure 1.1. Schematic depicting pathophysiological phases in sepsis, including mediators 
involved, biological effects and clinical manifestations. CARS: Compensatory anti-inflammatory 
response syndrome, G-CSF: granulocyte colony stimulating factor, GM-CSF: granulocyte-
macrophage colony stimulating factor, IL: interleukin, NO: nitric oxide, PPAR-δ: peroxisome 
proliferator-activated receptor δ,   SIRS: Systemic inflammatory response syndrome, TLR: toll like 
receptor 54.  
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1.2.2.4 Mitochondrial dysfunction 
Organ injury in sepsis is multifactorial. Increased tissue oxygen demand in the 
presence of inflammation, diminished oxygen delivery due to microcirculatory 
redistribution, hypovolaemia and myocardial suppression as well as endothelial 
failure and micro-thrombi formation are some of the factors resulting in organ 
dysfunction and failure.  
 
Mitochondrial dysfunction is another mechanism that may contribute to organ failure. 
In sepsis, oxidative stress and the production of nitric oxide, carbon monoxide and 
hydrogen sulphide are implicated in the inhibition of mitochondrial respiration and 
mitochondrial damage55. As a consequence the mitochondria fail to replace depleted 
adenosine triphosphate (ATP) which leads to activation of cell death pathways and 
ultimately organ failure. 
 
1.2.3 Neutrophils in sepsis 
One of the main pathological features of sepsis is neutrophil reprogramming 
associated with dysregulated trafficking and function.  This manifests as impaired 
neutrophil recruitment to sites of infection, neutrophil sequestration in remote sites 
causing local damage (e.g. Acute Respiratory Distress Syndrome (ARDS) 
secondary to sequestration in the lungs) and dysregulation of neutrophil effector 
responses. This impairment of function can cause defective innate immune 
responses. 
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Early in the course of sepsis, the rigidity of the neutrophil cell membrane increases 
and deformability is reduced due to the effect of bacterial endotoxins and pro-
inflammatory cytokines56. This effect is positively correlated with the severity of 
infection and leads to neutrophil sequestration in the capillary beds, particularly in 
the lungs and the liver56. This sequestration results in occlusion of micro-vessels 
contributing to local ischaemia and subsequently organ dysfunction. The increase in 
rigidity may also affect margination and rolling of neutrophils57.  
 
Another effect of the pro-inflammatory cytokines and endotoxins is the up-regulation 
of inducible nitric oxide synthase (iNOS) resulting in increased nitric oxide (NO) 
production. This mediator inhibits adhesion molecule expression on both leucocytes 
(integrins and selectins) and the endothelial cells (selectins and immunoglobulin-
like) resulting in the inhibition of neutrophil migration57, 58. Furthermore, NO 
enhances the expression of hemoxygenase-1 (HO-1), which can interfere with the 
rolling and adhesion of neutrophils59.   
 
In sepsis there is also release of chemoattractants that act at the G-protein-coupled 
receptors (GPCR) expressed by neutrophils. The high concentration of these 
chemoattractants leads to functional desensitisation due to several mechanisms 
including GPCR down-regulation, phosphorylation and inactivation. One of the 
GPCRs that is down regulated is CXCR2, in part due to the internalisation of 
occupied receptors60. This in turn results in decreased binding to CXCL2 and failure 
of neutrophil migration to the site of infection. Sepsis also causes changes in other 
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relevant chemokine receptors such as C-C chemokine receptor 2 (CCR2). This 
receptor is up-regulated in sepsis in response to TLR stimulation resulting in 
increased un-regulated migration and accumulation of neutrophils in distant organs, 
rather than targeted migration towards sites of infection61.  
 
Neutrophils express a number of TLRs, which when stimulated by PAMPs and 
endogenous inflammatory mediators results in the release of pro-inflammatory 
cytokines, chemokines and antimicrobial peptides. In early sepsis TLRs are 
persistently activated leading to excessive production of inflammatory mediators, 
contributing to tissue injury and the overall clinical picture62. The excessive and/or 
prolonged stimulation of the TLRs in sepsis causes receptor down-regulation and 
inhibition of their associated intracellular signalling pathways63. Moreover, the anti-
inflammatory mediators released by other cells such as IL-10 produced by 
macrophages also inhibit TLR mediated neutrophil activation64. These observations 
suggest that overall sepsis is associated with a state of neutrophil hypo-
responsiveness.  
 
Neutrophils also produce extracellular traps (NETs) in response to exposure to 
microbial pathogens.  NETs physically trap the invading pathogens, facilitating the 
antimicrobial effector function of leucocytes, as well as having intrinsic antimicrobial 
properties65. There is also evidence that NETs contribute to excessive inflammation 
and tissue injury66.  
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Sepsis seems to result in neutrophil reprogramming by the suppression of several 
gene clusters and the induction of others, leading to substantial changes in 
neutrophil effector function. This process manifests in the suppression of genes 
responsible for the inflammatory response, immune modulation, oxidant production 
and phagocytosis and the induction of genes regulating the production of 
antimicrobials (e.g. lipocalin and cathelicidins) 67.  
 
In conclusion, neutrophil function is greatly altered by sepsis resulting in 
dysregulated trafficking and anti-microbial effects. These alterations contribute to 
immune dysregulation and the clinical picture of sepsis.  
 
1.2.4 Endothelium in sepsis 
The endothelium is a single layer of cells lining all blood vessels and is considered 
the largest organ of the body covering an area of 4000 – 7000 m2 and weighing 1/5 
kg.  The endothelium contributes to each step of the process of haemostasis9. The 
endothelium also defends the body against invading organisms by recruiting immune 
cells to the site of infection, releasing inflammatory mediators and encouraging local 
activation of the coagulation system to limit the spread of the causative organism9. 
“Endothelial dysfunction” can cause tissue damage when exaggerated and 
widespread.  
 
Endothelial denudation is a feature of sepsis induced endothelial dysfunction and is 
a result of sub-endothelial oedema and detachment of endothelial cells (EC)68, 69. 
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This detachment leads to an increase in the number of circulating EC; the extent of 
the increase is related to illness severity. The EC also undergo changes manifested 
as nuclear vacuolation, protrusion and cytoplasmic fragmentation69. Inflammatory 
mediators released in response to sepsis and hypoxia can trigger EC apoptosis70 
and the apoptotic EC in turn express adhesion molecules71 which play a role in 
attracting more white cells. They also express phosphatidylserine (PS), which acts 
as a pro-coagulant surface21. This denudation impairs the endothelial natural barrier 
facilitating the passage of cells, inflammatory mediators and plasma into the 
interstitial compartment.  This leakage phenotype causes damage to vital organs 
such as the lungs72. 
 
In sepsis there is enhanced expression of endothelial adhesion molecules either on 
the EC or in the plasma. The leucocyte derived inflammatory mediators such as 
TNF-α and IL-1β enhance the expression of endothelial adhesion molecules such 
as endothelial selectin (E-selectin) and intracellular adhesion molecule (ICAM)-173. 
These adhesion molecules promote neutrophil rolling and adherence at the site of 
infection. Furthermore, some studies have shown a positive correlation between the 
levels of circulating E-selectin and ICAM-1 and the severity of sepsis74, 75. This 
overexpression of adhesion molecules in sepsis is another factor leading to 
neutrophil accumulation in vital organs causing tissue damage through the 
production of cytokines, proteases and oxygen free radicals76.  
 
The endothelium normally expresses thrombomodulin (TM) which enhances the 
activation of protein C, a natural anticoagulant. In sepsis, the neutrophils recruited 
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to the site of infection, release elastases and other proteinases that breakdown 
endothelial TM77. Also the inflammatory mediators released by the neutrophils(TNF-
α and IL-1β) and the surrounding inflamed tissue can decrease the endothelial 
expression of TM 78and increase expression of tissue plasminogen activator (tPA). 
The increased expression of tPA results in heterogeneous fibrin deposition and 
contributes to local ischaemia9. These mechanisms contribute to the hyper-
coagulable state seen in sepsis.  
 
Endothelial dysfunction and disordered nitiric oxide (NO) production are the main 
causes of circulatory failure in sepsis. Early in the septic process there is down-
regulation of endothelial nitric oxide synthase (eNOS) induced by the neutrophil 
inflammatory mediators79. Decreased NO production is associated with arteriolar 
vasoconstriction in some organs, such as the digestive tract. As the disease 
progresses there is a vast increase in the production of NO by inducible Nitric Oxide 
Synthase (iNOS) leading to vasodilatation and poor perfusion contributing to organ 
failure80.  
 
In sepsis there is a dramatic increase in the production of reactive oxygen species 
(ROS) by neutrophils, other immune cells and to a lesser extent in the endothelium81. 
Accumulation of ROS in endothelial cells results in increased production of toxic 
compounds that damage proteins and DNA and cause injury to the EC82. ROS also 
reduce NO availability through various mechanisms including inhibition of eNOS83. 
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This process affects vascular tone, platelet adhesion84 and permeability85 leading to 
vascular obstruction and further reductions in organ perfusion.  
 
The endothelium is key player in the pathogenesis of severe sepsis. EC activation 
and dysfunction are important determinants of the host response and help to explain 
the complex clinical picture of sepsis. The inflammatory insult to the endothelium 
leads to loss of cell-cell junctional integrity and vascular leakage.  The breakdown of 
this natural barrier facilitates tissue invasion by microorganisms, leakage of fluid into 
the extravascular compartment leading to hypotension and tissue oedema (tissue 
oedema in vital organs contributes to multi organ failure), impairment of oxygen and 
nutrient transport to the tissues and disruption of the anticoagulant actions of the 
endothelium.  
 
1.2.5 Coagulation in sepsis 
Coagulopathy is the third major component of the pathophysiological changes in 
sepsis. The initial over production of pro-inflammatory mediators stimulates the 
production of tissue factor (TF) from several sources including monocytes and 
endothelial cells, triggering the coagulation cascade86-88. The activated coagulation 
enzymes can affect specific inflammatory and endothelial cell receptors, thereby 
modulating the immune response89. The activation of coagulation and down-
regulation of antithrombotic mechanisms on the endothelium conspire to produce 
coagulopathy.  This coagulopathy can vary in severity from a minor fall in the platelet 
count and a subclinical prolongation of the clotting times to the full picture of a 
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consumption coagulopathy (i.e. Disseminated Intravascular Coagulopathy – DIC)90, 
91. 
 
In sepsis the causative agent and the ensuing immune response affect fibrin 
formation and deposition by up-regulating the pro-inflammatory pathways, down-
regulating the physiological anticoagulants92 and suppressing fibrinolysis93.  
 
Endothelial cells and monocytes are known to express TF in response to a variety 
of stimuli. These cells also exhibit other pro-coagulant properties thus providing a 
surface for initiation and propagation of clotting with fibrin formation. Neutrophils94, 
eosinophils95 and platelets96 also express TF when stimulated. There is some 
evidence to suggest that these cells acquire TF from microparticles (MP)97. However 
the activated monocyte seems to be the main trigger for the clotting cascade in 
sepsis98. In animal models of DIC secondary to sepsis, fibrin deposits in vital organs, 
in these organs TF expression is enhanced99, 100. TF is detected mainly in the 
circulating monocytes and the macrophages infiltrating these organs and in the same 
animals the circulating monocytes and macrophages exhibit strong TF activity100, 101. 
Furthermore monocyte MPs strongly expressed TF and are increased in sepsis100.  
 
In sepsis, suppression of fibrinolysis is mediated by increased levels of plasminogen 
activator inhibitor 1 (PAI-1)102. There is also an increase in tPA in plasma, but the 
balance is towards the PAI-1 and the anti-fibrinolytic activity103. Also the enhanced 
thrombin production might influence fibrin production by producing denser fibrin that 
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resists fibrinolysis. Activated platelets also contribute to this process by altering fibrin 
stability, making it less susceptible to lysis104 as well as reducing the ability of the 
tPA and plasminogen to bind to the fibrin105.  
 
1.2.6 Immuno-modulatory therapies in severe sepsis 
Sepsis morbidity and mortality remain stubbornly high and the management of these 
patients remains mainly supportive. Initially as the harmful effects of sepsis were 
thought to be due to a hyper-immune response, many therapeutic interventions 
aimed at suppressing immunity were tested, but they were all found to be ineffective 
or even harmful. As our understanding of sepsis advanced and the concept of 
immune dysregulation followed by hypo-immunity become more accepted, a new 
approach was adopted where the aim is to reverse the immune-paresis seen in the 
later stages of sepsis. Novel therapeutic agents are being tested to that effect 
including granulocyte macrophage colony stimulating factor (GM-CSF), interferon-γ 
(IFN-γ), IL-7, IL-15, anti-programmed cell-death receptor 1 and anti-B and T 
lymphocyte attenuator106.  
 
1.2.6.1 Granulocyte-macrophage colony stimulating factor (GM-CSF) 
GM-CSF is one of three known colony stimulating factors, namely macrophage-
colony stimulating factor (M-CSF), granulocyte-colony stimulating factor (G-CSF) 
and GM-CSF. GM-CSF is produced from a variety of cells including macrophages, 
dendritic cells, smooth muscle cells, fibroblasts, chondrocytes and T-cells. GM-CSF 
induces dendritic cell maturation, granulocyte activation and microglia proliferation, 
as well as differentiation of natural killer T cells and alveolar macrophage. In addition, 
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both lymphocytes and endothelial cells have GM-CSF receptors but their precise 
function is still unknown.  GM-CSF knockout mice can develop pulmonary alveolar 
proteinosis suggesting that GM-CSF may be necessary for maintaining normal 
pulmonary physiology107.  
 
The GM-CSF receptor (GM-CSFR) is a heterodimer consisting of α subunit which 
contains the binding site for the agonist and a β subunit which it shares with IL-3 and 
IL-5 receptors. This receptor is expressed on haematopoietic cell surfaces in low 
concentrations and it is also expressed on the surface of granulocytes, monocytes, 
macrophage progenitor cells, macrophages, dendritic cells, megakaryocytes, 
plasma cells, T lymphocytes, endothelial cells, uterine cells, gastrointestinal 
epithelial cells, astrocytes, oligodendrocytes and microglia108.     
 
Binding of GM-CSF to its receptor results in the activation of the Janus kinases (JAK) 
resulting in the phosphorylation of signal transducers and activators (STAT) which 
migrate to the nucleus in order to direct the transcription of genes related to cell 
differentiation109. GM-CSF also activates protein kinase C to induce cell proliferation 
and prevents cell death by phosphatidylinositol 3 kinase and JAK/STAT5-Bcl-2 
signalling110. It induces inflammation via NFκB activation111 and regulates toll like 
receptor (TLR)-2 and TLR-4 expression in neutrophils112 and TLR-2 in monocytes112 
as well as inducing IL-12 and TNF-α release by monocytes and monocyte 
chemoattractant protein (MCP)-1 expression113.  
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Function of GM-CSF. GM-CSF plays a role in inflammation, as it enhances the 
survival of monocytes, macrophages and neutrophils and induces production of pro-
inflammatory cytokines by these cells, thereby contributing to pathogen and tumour 
elimination114. GM-CSF increases neutrophil expression of adhesion molecules115, 
and enhances their response to chemotactic factors, phagocytosis and production 
of ROS116. GM-CSF also increases neutrophil survival and enhances its major 
histocompatibility complex (MHC)-II expression, enabling T cell activation117. 
Monocytes and monocyte derived dendritic cells exhibit increased expression of 
MHC-II, along with other antigens in response to GM-CSF thereby enhancing their 
immune response118. Also, M1 macrophages are activated by GM-CSF resulting in 
increased production of TNF-α and interferon γ and suppressed production of IL-
10119.  
 
GM-CSF has been implicated in a variety of diseases such as Felty’s syndrome, 
rheumatoid arthritis and various other autoimmune, metabolic and cardiovascular 
diseases. As an example, local over expression of GM-CSF in the stomach leads to 
autoimmune gastritis and GM-CSF knockout mice are less prone to develop 
encephalitis, myocarditis and arthritis. These knockout mice are on the other hand 
obese, hyperphagic, have a decreased number of macrophages and lower 
expression of pro-inflammatory cytokines107.  
 
GM-CSF as an adjuvant therapeutic agent. GM-CSF is used widely as a 
haemopoietin. The human recombinant GM-CSF (hrGM-CSF) is produced in 
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Saccharomyces cerevisiae120, Escherichia coli121 and Chinese hamster ovary 
cells122. It is used for shortening the time to neutrophil recovery following 
chemotherapy in acute myeloid leukaemia123 and for myeloid reconstitution following 
bone marrow transplant124.  hrGM-CSF is also used as a second line therapy for 
neutropenia as it induces a small increase in neutrophil count as well as in the 
number eosinophils and basophils. It is thought be inferior to G-CSF in terms of 
myeloproliferative function107.  
 
GM-CSF was found to have a protective role in the gastrointestinal tract where it 
maintains the integrity of local innate immunity. Indeed, the lack of GM-CSF activity 
may be related to the immune deficiency typical of Crohn’s disease. Patients with 
this disease have lower levels of GM-CSF125 and clinical trials have shown that the 
subcutaneous injection of hrGM-CSF can induce remission of Crohn’s disease 126, 
127. GM-CSF also has been found to enhance the in vivo and in vitro microbicidal 
activity of neutrophils and macrophages against organisms such as Aspergillus 
fumigatus hyphae, Candida glabrata and Histoplasma capsulatum128, 129. 
Nevertheless, there have been no clinical trials of GM-CSF as an adjuvant treatment 
against invasive fungal infections. This effect was also observed in children with HIV 
where their neutrophils were stimulated in vitro with GM-CSF resulting in an 
enhanced neutrophil bactericidal activity against Staphylococcus aureus130. 
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GM-CSF in sepsis. Following the initial septic insult in, a state of immune-paresis 
ensues rendering the patient vulnerable to hospital acquired infections and causing 
further morbidity and mortality.  
 
Novel therapeutic approaches have been adopted in an attempt to “re-ignite” the 
immune system. GM-CSF has been studied in this context to test its effect as an 
immune-modulatory agent in severe sepsis. In a study examining the effects of GM-
CSF on reversing the immune-paresis observed in trauma, cardiac surgery and 
severe sepsis (impaired immune response was defined as impaired TNF-α 
production following in vitro incubation of ex-vivo whole blood with endotoxins and 
decreased monocyte HLA-DR expression).  In this study, ex-vivo blood was 
incubated with GM-CSF, which resulted in an improvement of both parameters in 
the cardiac surgery cohort comparable and the same trend was observed in the 
sepsis but to a lesser extent. In vivo, GM-CSF was found to also increase monocyte 
HLA-DR expression in septic patients accompanied by a significant rise in white cell 
count131, 132. Moreover, in patients with sepsis GM-CSF was found to increase 
adhesion molecule expression on neutrophils and monocytes and significantly 
protect against nosocomial infections without, reducing illness severity or overall 
mortality.  
 
A clinical trial was undertaken in adults with severe sepsis to further examine the 
effects of GM-CSF. Patients who received the treatment had higher neutrophil, 
monocyte and T lymphocyte counts as well as higher circulating TNF-α levels. 
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Moreover, monocytes had higher HLA-DR expression and they were more 
responsive to endotoxins in vitro in terms of pro-inflammatory cytokine release (TNF-
α, IL6 and IL8). The GM-CSF group also had shorter mechanical ventilation times 
and a tendency towards shorter ICU and hospital stay, but there was no difference 
in severity scores or mortality133. Similar observations were noted in children134. GM-
CSF also seems to improve pulmonary dysfunction related to sepsis, with a 
reduction in alveolar neutrophil count135. 
 
The picture that emerges from these studies suggests that GM-CSF improves 
immune responses in patients with severe sepsis, particularly those who have 
immune-paresis as evidenced by biomarkers, and that this improvement is 
associated with a positive effect on respiratory function, although overall there is no 
alteration in disease severity or mortality. 
 
1.2.6.2 Interferon-gamma 
Interferons were initially described as mediators that interfere with viral replication, 
but now they are understood to play a wider role in innate and adaptive immune 
responses. Interferons are classified as type I and type II; type I includes interferon-
α, -β, -ω and -τ while type II is interferon-γ (IFN-γ). Type I interferons are secreted in 
low levels by all cells including haematopoietic cells, fibroblasts and macrophages 
and they are expressed in response to viral infections, while type II interferon is 
mainly secreted by CD4+ and CD8+ T lymphocytes and natural killer (NK) cells. 
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Recently however, IFN-γ was found to be produced by B cells, natural killer T (NKT) 
cells and antigen presenting cells in response to inflammatory insults136. 
 
Secretion of IFN-γ is induced by IL-12 and IL-18 from antigen presenting cells137. On 
encountering a pathogen macrophages produce IL-12 and macrophage 
inflammatory protein (MIP) - 1α which attracts NK cells to the site of inflammation 
and IL-12 promotes the production of IFN-γ in these cells138. Continued production 
of IL-12 and IL-18 by macrophages, NK and T cells further enhances the expression 
of IFN-γ139. Increased production of IFN-γ has been associated with enhanced 
resistance to pathogens. On the other hand, IL-4, IL-10, transforming growth factor 
(TGF)-β and glucocorticoids suppress the production of IFN-γ139-141.  
 
Function of interferon-gamma. IFN-γ up-regulates the MHC I142 enhancing the ability 
of cytotoxic T cells to recognise foreign proteins, which is important for host ability 
defences against intra-cellular pathogens and the initiation of cell mediated 
immunity. IFN-γ also up-regulates the expression of class II MHC on the cell surface 
of CD4+ T cells, B cells, dendritic cells, monocytes and macrophages143.  
 
Specific cytotoxic immunity induced by IFN-γ is promoted via direct and indirect 
mechanisms. Directly, IFN-γ induces the cytotoxic mechanisms in helper T cells (Th) 
– 1 which promote innate cell mediated immunity (via NK cells), specific cytotoxic 
immunity (via T cells) and macrophage activation144. Indirectly, IFN-γ up-regulates 
antigen processing, presentation and co-stimulation molecules on antigen 
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presenting cells to increase CD4+ differentiation. Also, IFN-γ promotes differentiation 
of naive CD4+ into Th-1 phenotype through IL12 production145, 146. IFN-γ and its 
inducer IL-12 coordinate the link between pathogen recognition by the innate 
immune cells and the induction of cell specific adaptive immunity by forming a 
positive feedback loop perpetuating and magnifying the Th-1 response. 
 
Another function of IFN-γ is activation of the bactericidal effector functions of 
macrophages namely pinocytosis, receptor mediated phagocytosis and bactericidal 
abilities147. These bactericidal actions in macrophages include the production of 
reactive oxygen species, nitric oxide and lysosomal enzymes release with a similar 
effect on neutrophils148. IFN-γ also provides a survival signal for macrophages136. 
 
Leucocyte trafficking to the site of inflammation is also induced by IFN-γ through the 
up-regulation of adhesion molecules (e.g. ICAM-1)149or indirectly through enhanced 
cytokine production (e.g. monocyte chemoattractant protein (MCP)-1, CXCL-9, MIP-
1)150-152. 
 
IFN-γ enhances the innate immune response to inflammation as well as providing a 
link between innate immunity and the more specific adaptive immune response. 
 
Interferon-gamma as a therapeutic agent. IFN-γ has been tested as a therapeutic 
agent in many diseases. In most of these trials a genetically engineered form of 
human IFN-γ has been used (IFN-1b)153. 
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In cancer, studies have shown that IFN-γ is crucial to tumour surveillance, tumour 
regression, inhibition of tumour angiogenesis and proliferation and sensitisation of 
tumour cells to apoptosis. IFN-γ also stimulates anti-tumour immune activity via the 
up-regulation of MHC class I and II. In recurrent bladder cancer, intravesical injection 
of IFN-γ resulted in a reduction in tumour recurrence154. In ovarian malignancy, the 
combination of IFN-γ and standard treatment may be more effective than standard 
treatment alone, although other studies have shown the reverse155, 156. IFN-γ is also 
an approved treatment for adult T-cell leukaemia in Japan where it is reported to 
induce remission when injected locally into the lesion156.  
 
Tuberculosis (TB) is another disease where IFN-γ is being tested. IFN-γ activates 
alveolar macrophages, which constitutes an important defence mechanism against 
TB157. In multidrug resistant TB, IFN-γ was found to stabilise patients’ body weight, 
render sputum smears negative and decrease mycobacterium burden, as well as 
reducing the size of pulmonary lesions158.  
 
In hepatitis B (HBV), IFN-γ was found not to have a significant impact, despite 
immune system modulation159. On the other hand, in hepatitis C (HCV) infection 
when used as a pre-treatment to the standard regime, IFN-γ enhanced immune 
activity and seemed to improve viral clearance160. IFN-γ also reduced hepatic fibrosis 
caused by HBV161 and HCV in a selected group of patients162. 
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In immune-compromised patients, opportunistic infections are a major cause of 
morbidity and mortality. IFN-γ was found to reduce cryptococcal neoformans burden 
in the cerebral spinal fluid of HIV positive patients following 2 weeks of treatment163. 
In conjunction with standard treatment, IFN- γ was reduced all opportunistic 
infections in HIV patients as well as improving their survival, although these effects 
did not reach statistical significance164. Candida, herpes and cytomegalovirus 
infections seem to be especially vulnerable to IFN-γ treatment164. 
 
IFN-γ has a potential role as an adjuvant therapeutic agent in many diseases, but 
further research is required to better target patients that would benefit from this 
immune-modulatory cytokine. 
 
Interferon-gamma in sepsis. Trials of IFN-γ in sepsis have yielded conflicting 
results50. Some studies have shown that production of IFN- γ and TNF-α by in-vitro 
stimulated whole blood obtained from septic patients was markedly suppressed in 
comparison to control patients and healthy volunteers165. Furthermore, in a murine 
model of severe sepsis, serum levels of IFN-γ and IL-12 were reduced in comparison 
to control166. Also, peripheral blood mononuclear cells (PBMC) obtained from septic 
patients produced markedly reduced levels of IFN-γ in comparison to control. 
Interestingly, this effect was reversed when the cells was rested in fresh medium 
prior to stimulation. Furthermore, PBMCs obtained from septic patients who 
developed a second infection and those who died produced less IFN-γ when 
stimulated in-vitro in comparison to rest of the cohort.  These findings suggest that 
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impaired IFN-γ production by PBMCs in sepsis may be reversible, the degree of this 
impairment may influence the effectiveness of immune system and those with the 
most severe impairment are more likely to die167. 
 
Therapeutically, IFN-γ was found to enhance in-vitro TNF-α production in ex-vivo 
monocytes obtained from septic patients. Subsequently, IFN-γ was tested in a small 
group of septic patients with reduced monocyte HLA-DR expression. Treatment with 
IFN-γ enhanced HLA-DR expression, increased serum TNF-α and improved 
outcome168. These observations were confirmed in another small study in which IL-
6 serum levels were also increased confirming the immune-stimulatory effects of 
IFN-γ in severe sepsis169. 
 
On the other hand a phase III multicentre placebo controlled trial did not find any 
benefit of IFN- γ in terms of reducing nosocomial infections acquired by severe burns 
patients170. In another multicentre placebo controlled trial examining the effect of 
IFN- γ on infections associated with severe injuries showed a statistically significant 
decrease in the number of infections in the treatment arm and a trend towards lower 
deaths related to infection, although there was no effect on overall mortality171. 
 
These results are suggest that IFN-γ may useful as adjuvant therapy in severe 
sepsis, particularly in patients with immune-paresis evidenced by biomarkers such 
as decreased monocyte expression of HLA-DR. Ongoing clinical trials are exploring 
further the potential of IFN-γ in this subset of sepsis patients172. 
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1.3 Microparticles 
1.3.1 Introduction 
Cell-to-cell communication is a vital aspect of an effective host response to insults 
such as bacterial invasion. Thus, cell‐to‐cell communication is crucial to activate 
alerting and protective mechanisms both in the affected site and systemically. A 
novel means of non‐soluble communication has recently emerged focused on 
plasma membrane‐shed vesicles, called microparticles (MP) or ectosomes. MPs 
were first described by Wolf in 1967173. At the time MP were thought to be simple, 
non-specific cell debris produced during cell death and were called “platelet dust”. 
However, it is now evident that MP play a role in a variety of biological functions; 
including coagulation, inflammation, cellular homeostasis and cell survival, 
intercellular communication, and transport. There is increasing evidence that MP are 
“multipurpose carriers” facilitating the intercellular exchange of trans-membrane 
receptors, mRNA, microRNA, and signalling molecules. Furthermore they promote 
cellular survival by removing dangerous or redundant intracellular compounds 174-
176(Figure 1.2). 
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Figure 1.2. Biological effects of microparticles. APC: activated protein C. MMP: 
metalloproteinase. miRNA: micro ribonucleic acid. NO: nitiric oxide. PS: phosphatidylserine.  RNA: 
ribonucleic acid.   TXA2: thromboxane A2. TF: tissue factor. uPA: urokinase-like plasminogen 
activator. uPAR: urokinase-like plasminogen activator receptor. vWF: von-Willibrand factor. 
 
1.3.2 Microparticle formation 
Upon cell activation the endoplasmic reticulum and the plasmatic calcium channels 
are open, leading to calcium influx into the cytosol with activation of scramblase and 
inhibition of flippase enzymes. These enzymes act on the cell wall resulting in the 
loss of normal lipid symmetry and the exteriorization of Phosphatidylserine (PS).  
During the translocation of the membrane phospholipids, the bonds that stabilise the 
intracellular skeletal proteins are disturbed promoting plasma membrane budding. 
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This in turn triggers the activation of proteolytic calpains and lipid-binding gelsoins 
that result in cytoskeleton remodelling, cell surface vesiculation and membrane 
phospholipid hydrolysis 177 culminating in MP formation and shedding (Figure 1.3).  
 
 
Figure 1.3. Microparticle formation. A: Basal conditions. B: Upon activation. MP: microparticles 
 
1.3.2.1 Lipid membrane remodelling 
Cell membrane is the first structure to be involved in MP formation. Under resting 
conditions phosphatidylserine and phosphatidylethanolamine are the main 
components of the outer layer while phosphatidylcholine and sphingomyelin 
compose the inner leaflet of the cell membrane bi-layer. This distribution is not 
constant, but it is an active process governed by ATP-dependent enzymes to reach 
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equilibrium 178.  Phosphatidylserine and phosphatidylethanolamine are kept on the 
inner layer of the membrane by the enzyme amino-phospholipid translocase (or 
flippase) while phosphatidylcholine and sphingomyelin are kept on the outer layer 
by the enzyme floppase179. Another enzyme (scramblase) acts to disturb this 
distribution. Upon activation, calcium membrane channels and cytoplasmic reticulum 
are open allowing calcium influx into the cytosol; resulting in the inhibition of flippase 
enzyme and activation of scramblase. This process results in disturbance of the 
“normal” distribution of lipids on the cell surface and the expression of 
phosphatidylserine on the outer layer of the membrane surface180.  
 
1.3.2.2 Cytoskeletal disruption 
The cytoskeleton is formed of a protein network which maintains stability through 
protein-protein and protein-lipid interactions. Cell membrane lipids are connected to 
actin via the protein spectrin. When lipid translocation commences following calcium 
influx, the links anchoring membrane lipids to spectrin are disrupted resulting in 
membrane budding. This process results in actin regulatory proteins activation which 
further enhances calcium influx to perpetuate the process181.  Calpins are another 
group of enzymes activated by cytosolic calcium influx. Calpins cleave cytoskeletal 
filaments (talin and α-actin) aiding membrane vesiculation leading to MP formation. 
When this process is inhibited by calpeptin, MP production is reduced182.  Other 
mechanisms are involved in MP formation as calpins inhibition does not completely 
inhibit MP production. One of these mechanisms is dependent on p21-activated 
protein kinases (PAK) reorganisation of actin facilitating MP formation183. This 
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pathway is triggered by cell membrane lipid changes184. Another calpins 
independent pathway is mediated via mitogen-activated protein kinases (MAPK). 
The p38 MAPK is involved in inflammatory conditions such as sepsis and rheumatoid 
arthritis associated with increased MP production acting as downstream messenger 
for TNF-α. Inhibition of p38 MAPK results in reduction of MP production185. Another 
mechanism is triggered during apoptosis as the enzyme caspase-3 cleaving the 
Rho-kinase ROCK-1 resulting in phosphorylation of myosin light chain leading to cell 
membrane contraction and MP release186. In response to thrombin and in the 
absence of apoptosis, another Rho-kinase (ROCK-2) activated by caspase 2 
induces cytoskeletal remodelling and MP shedding187. This pathway was inhibited 
by fluvastatin which was found to reduce MP production from endothelial cells188.  
The variety in the pathways leading to cytoskeletal changes leading to MP release 
probably is determined by the stimulus for their release and the parent cell189. 
 
1.3.2.3 Microparticles content 
MP express a variety of bioactive substances, transmembrane receptors and 
adhesion molecules on their surface reflecting the parent cell membrane. During MP 
formation, the membrane engulfs a wide array of cytokines, chemokines, enzymes, 
growth factors and signalling proteins190, 191 as well as functional genetic material 
such as microRNA192.  
 
Although MP transmembrane proteins and cargo resemble the parent cell, some 
components are selectively enriched depending on the parent cell and the stimulus 
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for MP release191, 193, 194. As an example MP produced by activated neutrophils 
express 10 times more integrin αMβ2 compared to MP derived from resting 
neutrophils195. Also endothelial cells when activated produced MP enriched with E-
selectin and ICAM-1 while apoptotic cells produced MP enriched with CD105 and 
PECAM-1196.  
 
In chemotherapy resistant cancer, the malignant cells produce MP rich in the 
chemotherapeutic agent doxorubicin and these cells were found to have higher 
profile of genes related to MP production compared to chemotherapy sensitive 
cells197.  A similar observation was found in ovarian cancer cells resistant to 
cisplatin198. These observation suggest a genetic mechanism behind the preferential 
loading of MP with chemotherapeutic agents in chemotherapy resistant cancer cells. 
 
Confocal microscopy analysis of cells stimulated with complement C5b-9 
demonstrated an orchestrated mechanism of MP formation and shedding that 
produced MP enriched in C5b-9199 which suggests that MP content packaging is not 
a random process. 
 
Lipid rafts are plasma membrane micro domains rich in certain proteins and lipids. 
Raft domains and lateral plasma membrane organisation segregate proteins and 
lipids resulting in inclusive or exclusive sorting200. Studies have shown that 
endothelial cells express lipid rafts rich in PECAM-1 and this response varies 
according to the stimulus. Also this raft expression correlated with subsequent MP 
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release rich in PECAM-1 surface expression201. Stimulated monocytes also 
developed lipid rafts rich in tissue factor and PSGL-1 which was subsequently found 
to be preferentially expressed on the produced MP202. This suggests a role for lipid 
rafts in MP enrichment. 
 
These observations taken together suggest that MP content packing is probably an 
active process with multiple underlying mechanisms that depend on the cell of origin 
and its state as well as the stimulus for MP release. 
 
1.3.3 Microparticle function 
MP are important contributors to, but play a paradoxical role in coagulation. They 
are generally pro-coagulant due to the expression of PS on their surface, which 
triggers the intravascular coagulation cascade. This property is estimated to be 50 
to 100 fold more powerful than the effect of activated platelets. Moreover, some MP 
express tissue factor (TF) on their surface rendering them even more pro-coagulant. 
MP originating from platelets can transfer membrane proteins such as integrins, P-
selectin and von Willibrand factor as well as thromboxane A2 to distant cells 
triggering coagulation signals 177.  Conversely, a recent study has shown that 
Activated Protein C can induce the release of anticoagulant MP from the 
endothelium that express the protein C receptor203. Also recent research has shown 
that endothelial MPs can be pro-fibrinolytic as they provide a catalytic surface for the 
cleavage of plasminogen into plasmin by expressing urokinase-type plasminogen 
activator (uPA) and its receptor (uPAR). uPA and uPAR can also activate matrix 
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metaloprotinases (MMP) which in turn promote cell migration and angiogenesis. The 
activation of MMP by MP encourages extracellular matrix degradation and turn over 
in clinical situations such as tumour progression177.  
 
Several studies have shown that MP contain a variety of nucleic acids which could 
be transferred to other cell lines. Some MP contain up to 4730 human gene 
transcripts associated with cell-to-cell signalling, cellular growth, regulation of gene 
expression and lipid metabolism including CASP8AP2, EIF2C2(AGO2), CREG2, 
and VASP. One of the main nucleic acids present in MP is micro RNA (miRNA) that 
enables communication between cells and organs to modify gene expression in the 
target tissues177, 204. 
 
MP may also play a role in tissue repair. MP derived from mesenchymal stem cells 
(MSC) were as effective as MSC themselves in the stimulation of renal tubular 
epithelial cell proliferation and the inhibition of apoptosis in vitro. Moreover, they were 
similarly effective in accelerating the functional and morphological recovery from 
acute kidney injury (AKI) in immune-deficient mice. This effect was abolished when 
MP RNA was destroyed; suggesting that this regenerative effect is mediated via 
RNA transfer205. In another study by the same group, it was found that MP derived 
from MSC produce the same protective effect in immuno-competent rats, in which 
AKI was induced by ischaemia reperfusion injury206.  MP derived from human liver 
stem cells enhance the proliferation, with concomitant inhibition of apoptosis of 
human and rat hepatocytes in vitro. In the same study it was found that these MP 
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when injected in vivo induced morphological and functional recovery of rats that had 
undergone 70% hepatectomy. These effects were again found to be related to RNA 
transfer and were abolished when MP RNA was destroyed204. These studies suggest 
that MP play a role in tissue repair and regeneration, probably through RNA transfer 
between the cells of origin and target cells. These findings indicate that MP may 
have therapeutic potential. 
 
Altogether the studies discussed above, which are a small representative sample of 
the many investigations conducted on MP, are indicative of the considerable 
potential of MP both for therapy and as biomarkers in a variety of diseases from 
rheumatic to cardiovascular disease, from diabetes mellitus to renal disease, from 
malignancy to malaria and also in sepsis which is the focus of the investigations 
described herein. 
 
1.3.4 Microparticles in disease 
1.3.4.1 Microparticles in rheumatic diseases 
Several studies in patients with rheumatic disease have found elevated circulating 
levels of MP and in particular platelet derived MP (PMP) and endothelial MP (EMP). 
MP levels are most raised in conditions with a strong vascular component such as 
rheumatoid arthritis (RA)207.   
 
In RA and other arthritides (psoriatic arthropathy, gout and juvenile idiopathic 
arthritis) high concentrations of MP are found in the synovial fluid (SF) of the affected 
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joints. PMP were the most abundant MP population in the SF (much higher than in 
plasma from the same patients) and MP from immune cells were also present, but 
at much lower concentrations. These MP were found to be pro-inflammatory and in 
mice induced cytokine production from synovial fibroblasts via IL-1. These 
investigators found that collagen receptor glycoprotein IV was a key trigger for PMP 
release in arthritis208.  
 
Along with their pro-inflammatory and pro-thrombotic roles, MP may contribute to the 
pathogenesis of rheumatic diseases through the formation of immune complexes. In 
one study MP bound to complement components (C1q, C3, C4) were abundant in 
the SF with lower levels of the same MP population in the same patients’ plasma. 
Also the MP expressing complement activator molecules (IgG and IgM) were more 
abundant in the SF of the RA patients than in plasma and when compared to 
controls. These results suggest that MP contribute to the RA disease process by 
activating complement system in the synovial compartment209. A recent study has 
shown increased numbers of T lymphocyte derived MP in the RA patients’ synovial 
fluid of RA patients when compared to those with osteoarthritis210. 
 
Studies also have shown that MP can have a paradoxical relationship with disease 
severity. In systemic sclerosis the total number of circulating MP was significantly 
higher than in healthy controls, whereas MP numbers were inversely correlated to 
skin thickness (a measure of disease severity) and patients with skin ulcers (severe 
 69 
disease) had particularly low MP levels 211. In SLE the total number of MP was found 
to be lower in patients in comparison to healthy volunteers 212.  
 
These studies suggest that MP play a significant role in rheumatic diseases and that 
in the future MP have potential to act as biomarkers for these diseases and perhaps 
as therapeutic target.  
 
1.3.4.2 Microparticles in cardiovascular diseases 
Circulating microparticles are considered to be useful biomarkers for vascular injury 
and have been shown to correlate with disease severity in many cardiovascular 
diseases including acute myocardial infarction, atherosclerosis, pre-eclampsia, 
metabolic syndrome and hypertension. For example PMP, EMP and MP derived 
from erythrocytes (EryMP) were found to be raised in individuals with metabolic 
syndrome in comparison to healthy volunteers213. Other studies have suggested that 
EMP may have potential as predictive biomarkers in ischaemic stroke complicating 
diabetes214.  
 
MP can operate as effectors in many cardiovascular diseases. Circulating plasma 
MP isolated from patients with myocardial infarction, diabetes mellitus, pre-
eclampsia, metabolic syndrome and obstructive sleep apnoea (OSA) have been 
shown to cause endothelial dysfunction via decreased NO signalling, enhanced 
protein nitration on endothelial cells and increased plasmatic oxidative stress215. In 
a rat model of pulmonary hypertension induced by hypoxia, MP decreased eNOS 
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activity and increased oxidative stress in pulmonary endothelial cells resulting in 
decreased NO bioavailability216.  
 
It has been suggested that MP isolated from the vitreous fluid of patients with 
diabetic retinopathy may impact on disease progression. These MP enhanced 
endothelial cell proliferation and new vessel formation when injected into mice. MP 
isolated from atherosclerotic plaques in humans may also contribute to the disease 
as they increase the initial endothelial dysfunction, promote intra-plaque new vessel 
formation and increase plaque thrombogenicty resulting in increased plaque 
progression217.  
 
Various medications have been investigated as means of reducing the deleterious 
effects of MP in cardiovascular diseases. A combination of pitavastatin and 
eicosapentaneoic acid (an omega-3 fatty acid from fish oil) significantly lowered the 
PMP numbers in the plasma in comparison to eicosapentaneoic acid alone in 
diabetic patients with hyperlipidaemia218. Atorvastatin was found to lower the 
expression of pro-coagulant proteins and adhesion molecules on PMP in patients 
with peripheral vascular disease219. Diabetic patients who are receiving pioglitazone 
were shown to have lower plasma levels of EMP 220.  
 
Other interventions also could lower circulating MP in cardiovascular disease. 
Weight reduction by reducing food intake was shown to reverse PMP overproduction 
in obese patients221. Also continuous positive airway pressure treatment for patients 
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with OSA has improved endothelial dysfunction and lowered plasma levels of EMP, 
in particular those expressing E-selectin222.  
 
Therefore, it can be concluded that MP seem to play a key role in the pathogenesis, 
course and outcome of cardiovascular disease.  
 
1.3.4.3 Microparticles in cancer 
There is accumulating evidence that MP play a role in the survival of malignant cells, 
tumour invasiveness and metastatic disease. MP promote cancer cell survival 
through ridding the cells of stress chemicals such as caspase 3, which promote 
apoptosis223. MP also contribute to multi-drug resistance in cancer as these tumour 
cells secrete MP with high concentration of chemotherapeutics in comparison to 
cancer cells that are not multi-drug resistant198. Another mechanism is through MP 
suppression of immune cells as they induce T cell apoptosis and inhibit immune cell 
proliferation224-226. Tumour cells could also escape the immune system by receiving 
proteins from MP derived from cells other than their own and thereby imitating 
normal host cells (e.g. transfer of CD41 from platelet MP to cancer cells)227. It is also 
proposed that the pro-coagulant properties of some MP could help cancer cells 
evade the immune system by forming a thrombotic layer which coats and protects 
the tumour from detection228, 229.  
 
MP may enhance tumour invasiveness by participating in extracellular matrix 
degradation. MP carry proteases such as MMP-2, MMP-9 and uPA that may assist 
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in tumour cell invasion, metastatic disease and angiogenesis229, 230. In a study of 
ascites-derived MP in ovarian cancer, the activity of the enzymes MMP-2, MMP-9 
and uPA was concentrated in the MP and the late stage MP showed higher activity 
of these enzymes than those from early stage tumours231. MP play a role in tumour 
metastasis, as the tumour MP transfer oncogenes or other genetic information from 
the primary tumour site to distant sites, causing malignant transformation of these 
cells232.  
 
In the future MP may have a role as biomarkers or as therapeutic targets in cancer. 
In one study, higher PMP levels were associated with shorter survival in patients 
with refractory prostate cancer233. Other studies investigating gastric, pancreatic and 
breast cancer found high PMP levels to be associated with more advanced disease 
and shorter survival times. On the therapeutic front, inhibition of MP release could 
be a potential treatment target in cancer229.  
 
1.3.5 Microparticles in sepsis 
Attempts have been made to characterise microparticles in septic plasma but the 
results of these studies were varied and sometimes even contradictory. Others have 
attempted to investigate the pathophysiological effects of MP in relation to sepsis. 
 
1.3.5.1 Characterisation of microparticles 
Many studies have focused on platelet derived MP (PMP) as it is the most 
abundant MP population in plasma. These papers reported conflicting results when 
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the PMP count in septic patients was compared to healthy volunteers. Some 
reported that PMP increase in septic patients234-236, whereas others reported that 
there were no differences237, 238. In one study it was reported that PMP counts 
might be reduced in sepsis239. Results were also inconsistent when MP 
populations derived from leucocytes, granulocytes, monocytes and endothelium 
were studied. Finally, some investigators were unable to detect these MP 
populations (Table 1.1). 
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MP 
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nd et al 
– 
2000234 
AV/CD61 AV/CD62E  AV/CD4 
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5 
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b- 
     
Table 1.1. Studies describing microparticle population in sepsis. AV: Annexin V, MP: 
microparticles, ND: not detected, : increased, : decreased, =: no difference. 
 
Many factors may be contributing to these conflicting findings, including the 
heterogeneity of the septic population and differences in the methods employed to 
separate microparticles from whole blood. Even though all these investigators used 
flow-cytometry to detect MP, they used flow-cytometers from different 
manufacturers, different size definitions and surface markers to identify MP 
populations (Table 1.1).  
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Renal impairment is one of the commonest complications of sepsis. An association 
was found between renal impairment and a high PMP count compared to septic 
patients without renal impairment242. Although, this observation was non-specific 
and could have been attributed to other factors, a conclusion reached by the authors 
themselves in a subsequent study241. In this latter publication an association was 
found between higher PMP counts and sepsis due to fungal infection. 
 
DIC is another common and serious complication of sepsis. In one study, MP derived 
from endothelial cells and leucocytes were increased in patients with this 
complication and increases in EMP were strongly associated with early DIC244.  
 
MP were also examined in one study for a possible correlation with disease outcome 
but none could be demonstrated238. 
 
In all the above investigations circulating plasma MP were the focus of investigation, 
however MP can also be detected in fluid obtained from infected foci. Broncho-
alveolar lavage (BAL) fluid and abdominal washings collected from patients with 
pneumonia and intra-abdominal infection respectively were found to be rich in 
neutrophil derived microparticles whilst other MP subtypes could not be detected245.  
 
1.3.5.2 Pathophysiological role of microparticles in sepsis 
Effects on coagulation. MP may play a role in sepsis-induced coagulopathy. This 
phenomenon may be related in part to the expression of tissue factor (TF) on the 
surface of microparticles; an effect that has been demonstrated in a murine model 
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of endotoxaemia. The MP produced in response to intra-abdominal injection of 
lipopolysaccharide (LPS) had more pronounced pro-coagulant activity, which was 
abolished with TF antibody. In vivo, the activation of coagulation in endotoxaemic 
correlated with MP TF activity246. 
 
In a model of endotoxaemia in man, in which small doses LPS was administered to 
healthy volunteers, there was an 8-fold increase in MP dependent TF activity 
peaking at 3 hours post exposure to LPS, which returned to baseline at 8 hours; 
these changes were concomitant to a 25-fold increase in TF mRNA at 3 hours which 
returned to baseline at 24 hours247. The peak activity coincided with peak levels of 
the cytokines IL-6, IL-8 (pro-inflammatory) and IL-10 (anti-inflammatory). The peak 
also coincided with increases in TAT and prothrombin fragments indicating activation 
of the coagulation system246. Consistently in studies, a high inter-individual variability 
in MP-TF activity was noted which might be due to the “high” and “low” LPS 
responder phenomenon.  
 
MP-TF activity is thought to be mainly attributed to monocyte derived MP. Monocytes 
stimulated with LPS produced MP that can shorten clot formation time. This effect 
can be abolished with the use of anti-TF antibodies suggesting that the shortened 
clotting time is due to TF expression on these MP and that monocyte derived 
microparticles have a role to play in sepsis induced coagulopathy248.  
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In patients with septic shock secondary to meningococcal disease, the thrombin 
generation capacity of MP was greater than in patients with meningitis249.  In these 
patients the plasma concentration of LPS, correlated positively with thrombin 
generation and the pro-coagulant activity of MP was significantly higher than in 
patients with meningitis only. In vitro, a shorter clot formation time was observed in 
the septic shock cohort. Both the thrombin generation capacity and the clot formation 
time were reduced when anti TF antibody was used, suggesting that these effects 
are probably due to TF expression on the MP surface249. This study also found large 
inter-individual variation in the pro-coagulant capacity of MP. This variability was also 
noted in an earlier study investigating the thrombin generation capacity of MP from 
patient with multi-organ failure239. 
 
Effects on inflammation. MP from septic rats (sMP) elicit a pro-inflammatory reaction 
when injected into healthy rats. The mean arterial pressure of the rats injected with 
sMP was significantly lower compared to controls and many of them died while all 
the controls survived. This could be explained by increased iNOS expression and 
the consequent vasodilation and hypotension250.  
 
In mice injected with human sMP there is differential expression of molecules 
associated with inflammation. Enhanced expression of eNOS, iNOS, COX-1, COX-
2, NFκB and extra-cellular superoxide dismutase (EC-SOD) was observed in the 
hearts and lungs of these mice, while this effect was not detected in the livers and 
kidneys. In contrast to the previous study there was no increase in NO production in 
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response to sMP but there was increased O2-production preferentially in the heart 
and liver251. 
 
Human platelet MPs seem to express two subunits of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase. This expression was two-fold higher in 
septic patients compared to healthy volunteers. Also MP from septic patients 
generated more superoxide when added to NADPH, which might contribute to MP 
induced vascular cell apoptosis237.  
 
Further exploration of the function of MP from septic patients function has revealed 
that when injected in mice they can potentiate the effect of vasoconstrictor agents 
such as serotonin while they did not alter the function of vasodilators such as 
acetylcholine. This increased responsiveness could be mediated through the 
vasoconstrictor metabolites of COX-1 such as thromboxane. Also sMP induce the 
production of thromboxane A2, which seemed to protect against vascular hypo-
reactivity. These effects seemed to be evoked by MP of non-platelet origin236. In 
another study the same group found that sMP significantly increased IL-10 mRNA 
expression in tissue engineered vascular media (TEVM). When tested IL-10 
significantly enhanced histamine induced contraction in LPS treated TEVM and 
improved the survival of mice injected with LPS by protecting them against septic 
shock and preventing LPS induced vascular hypo-reactivity236. 
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Activated protein C (aPC) possesses cytoprotective functions in sepsis and other 
inflammatory conditions. In an interesting recent study, administration of aPC to 
septic rats generated a distinct MP profile252. These MP from septic rats given aPC 
when injected into healthy rats did not induce the hypotensive picture produced by 
MP from septic rats without aPC. This protective effect was found to be due the high 
thromboxane A2 content MP induced in response to aPC. Further investigation 
revealed that MP induced in reponse to aPC reduced the expression of the pro-
inflammatory NFκB and iNOS. This suggests that aPC has modulates the MP 
production in septic rats and these MP might have a protective role in sepsis252. 
 
1.3.6 Alpha-2-macroglobulin positive microparticles 
Investigations conducted by this research group, before the start of the project 
described in this report, have shown that neutrophils stimulated in suspension (fluid 
phase) or when adherent to an endothelial monolayer produced MP with different 
protein contents. About 30% of the protein content was uniquely expressed in each 
of the MP populations253. The adherent MP contained significant amounts of alpha-
2-macroglobulin (A2M) and ceruloplasmin (CERU) while those in suspension 
contained more of the heat shock 70 kDa protein (Figure 1.4). Both subsets 
contained the same quantity of annexin A1, lactoferrin and β-actin. These proteins 
were also expressed on the surface of the MP as determined by flow-cytometry253.  
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Figure 1.4. Neutrophil MP A2M levels within 
24hr of admission to intensive care are 
elevated in patients that survive a septic 
event. Surface expression of HSP70, A2M, CP 
and AnxA1 was assessed on neutrophil 
(CD66b+) MP in plasma samples from healthy 
volunteer (HV), patients that survived the septic 
event (SS) and septic non-survivors (SNS). The 
percentage of double positive microparticles 
was assessed using flow cytometry. Results are 
mean ± SEM 10 individuals per group. 
(*P<0.05; **P<0.01 vs. HV plasma or SNS 
plasma, #P<0.05 vs. SNS as appropriate by 
one-way ANOVA). 
 
 
To assess the translational value of these in vivo observations, the MP expressing 
the proteins mentioned above were quantified in the plasma of community acquired 
pneumonia (CAP) patients. In this cohort of patients, plasma levels of neutrophil 
derived MP expressing A2M and CERU were higher than in healthy controls. When 
incubated with HUVEC, these MP modified gene expression producing a longer 
lasting. The adherence of MP up-regulated the expression of pro-inflammatory 
genes such IL-1β and STAT3, while the fluid phase neutrophil MP down-regulated 
other pro-inflammatory genes such as STAT1 and CXCL6. 
 
Taken together these results provide compelling evidence that MP derived from the 
same cell type under different conditions vary in their protein content, surface 
expression and effect on target cells. The A2M containing and expressing NMP 
appear to be endowed with protective actions in sepsis253. 
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In a follow up study, A2M enriched MP (A2M-E) were generated as a form of 
nanomedicine and tested in a murine model of sepsis, in comparison to the free A2M 
protein and vehicle. The A2M-E MP were found to reduce bacterial load both locally 
and systemically, reduced neutrophil count locally, increased pro-resolving and 
reduced pro-inflammatory lipid mediators, reduced neutrophil infiltration of the lungs 
and reduced overall mortality. These actions were lost when A2M was blocked. The 
effect of A2M-E on human neutrophils was also tested. They increased the exposure 
and activation of CD11b on the surface of human neutrophils. Neutrophil recruitment 
and adhesion to HUVEC was also enhanced254. 
 
1.3.5 Other extra-cellular vesicles 
Cells produce vesicles other than MP including exosome and apoptotic bodies. 
These vesicles play a similar role to MP in intercellular communication as well as 
waste management and coagulation255.   
 
1.3.5.1 Exosomes 
Exosomes are smaller than MP with a reported diameter of 0.1 micron produced by 
most cells and could be detected in body fluids including blood, urine and 
cerebrospinal fluid. In contrast to MP they are produced via the inward budding of 
endosomal membranes resulting in the accumulation of vesicles within large multi-
vesicular bodies (MVB) inside the cells. MVB are either degraded within the cell by 
fusing with lysosomes or they fuse with the cell membrane releasing the vesicles 
into the cellular microenvironment. Once released, the vesicles are termed 
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exosomes256. The exosomes express parent cell membrane components on their 
surface and include genetic material within, acting as inter-cellular messengers256. 
 
Exosomes are also surrounded by a phospholipid membrane that has a same 
orientation to the parent cells in comparison to MP which tend to have a phospholipid 
membrane with a reverse orientation of phospholipids. The exosomes membrane is 
also rich in cholesterol, sphingomyelin and ceramide189. Exsosomes contain 
characteristic set of proteins including proteins involved in membrane transport and 
fusion (e.g. GTPase, annexins and flotillin), components of the endoscomal sorting 
complex required for transport complex (e.g. Alix), tumour susceptibility gene 101, 
heat shock proteins, integrins and tetraspanins (e.g. CD63, CD81 and CD82)257.  
 
1.3.5.2. Apoptotic bodies 
 When cells undergo apoptosis they produce vesicles expressing phosphatidylserine 
on their surface with a diameter between 1 and 5 microns rendering them larger than 
MP and are called apoptotic bodies189. Differentiating between apoptotic bodies and 
platelets is rather difficult as they have a similar size ranges and both express 
phosphatidylserine189.  
 
Cells produce two distinct types of apoptotic bodies derived from either plasma 
membranes or from endoplasmic reticulum. The apoptotic bodies derived from 
plasma membrane contain DNA and histones, while those derived from endoplasmic 
reticulum do not possess DNA and histones but express immature glycoepitopes258.  
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Apototic bodies are thought to play a role in the immune process where the defective 
clearance of these vesicles could lead to the development of auto-immune diseases 
such as systemic lupus erythematosus (SLE)259. 
 
Similar to MP, apoptotic bodies act as a multi-purpose carrier. Proteomic analysis of 
apoptotic bodies revealed that they share a significant number of proteins with 
MP260.   Also, similar to MP they contain microRNA that have an effect on target 
cells261.  
 
1.4 Detection of microparticles 
Many modalities can be employed to characterise MP and each of these detection 
tools have its strengths and weaknesses. This choice of a tool or a group of tools 
will depend on the aims of each study. Other factors have to be taken into 
consideration when choosing a tool such as availability, local expertise and cost. 
These tools are usually categorised into optical and non-optical detection methods. 
 
1.4.1 Optical methods 
Most modalities employ light based methods in order to detect MP including the tool 
most commonly used to detect these vesicles which is flow-cytometry. 
 
Optical microscopy. The sample is illuminated by visible light in a bright-field 
microscope. The light scattered on MP is collected by a lens on a charge-coupled 
device camera. This method could detect MP down to 0.2 micron in diameter. 
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Measuring a concentration of MP in a specific volume is possible but would be very 
time consuming and would offer no information regarding proteins expression or 
biochemical composition of MP.  
 
Some optical microscopes are able to detect fluorescence using a spectral filter prior 
to detection by charge-coupled device camera and thus allowing the detection of MP 
surface protein expression using a fluorescent probe262. This also could be used for 
calculating the concentration of a certain MP population that have been labelled with 
fluorescent probe in a sample. This method would not be suitable for high throughput 
studies as it is time consuming. 
 
Dynamic light scattering. This method could potentially detect particles ranging in 
size between 1 nm and 6 microns263. Dynamic light scattering relies on Brownian 
motion of particles in a fluid and the smaller particles have higher Brownian motion. 
The Brownian motion will cause intensity fluctuation of the scattered light that could 
be detected. This modality performs well in detecting MP of the same size. When 
the sample contains MP with different sizes dynamic light scattering tool tends 
towards detection of larger particles. This tool risks missing the smaller size MP and 
it does not provide any information about cellular origin or composition264. 
 
Scattering and fluorescence flow-cytometry. This is the most commonly used 
modality for MP characterisation. It will be discussed in details later in this section. 
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Nanoparticle tracking analysis. Particles in a fluid are illuminated by laser beam and 
the scattered light is collected by an optical microscope. It can detect particles as 
small as 50 nm. The particles show as moving bright spots and this movement is 
detected over several minutes using special software265. This method allows 
accurate detection of size distribution of MP in a sample, but it is time consuming 
and does not offer any characterisation information. 
 
Combining this method with fluorescence detection allows for further 
characterisation of MP. 
 
Raman spectroscopy. The sample is illuminated with a laser light. The vibration of a 
molecule in the sample will result in a change in the wave length of the scattered 
light, which can be detected by spectrometers. The pattern of vibration is molecule 
specific. Also the signal strength correlates with the number of molecules. This 
method allows the detection of molecular composition of MP without labelling and it 
can estimate the size of MP. Raman spectroscopy can determine the concentration 
of MP in a known volume174. This modality requires several hours for each sample. 
 
Stimulated emission depletion microscopy. It is a high resolution fluorescence 
microscopy with high resolution. This method can determine the size and 
fluorescence labels of MP but also potentially could offer information on the 
morphology and the distribution of labelled epitopes on MP surface. Currently this 
method has been employed to characterise organelles such the endoplasmic 
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reticulum inside a living cell266. This method is still under development and is 
estimated to require several hours for MP detection and characterisation. 
 
Fluorescence correlation spectroscopy. This method was originally introduced to 
measure molecular diffusion parameters. It can determine the absolute size 
distribution and fluorescence signal of particles in a fluid through detecting the 
fluorescence intensity fluctuation caused by the Brownian motion of particles. It can 
detect vesicles smaller the 50 nm174. This modality could detect size distribution and 
concentration as well as phenotypes of MP. 
 
1.4.2 Non-optical methods 
Transmission electron microscopy. This tool uses electrons instead of photons. As 
the wavelength of electrons is much smaller than photons, the electron microscope 
has a much higher resolution rendering it capable of determining the size and 
morphology of microvesicles. This modality requires the sample to be fixed and 
dehydrated which will affect the size and morphology of the particles. Also it requires 
the concentration of particles, which will have an effect on the results making 
determining the concentration of particles in the original sample not possible. 
Immuno-gold labelling could afford some information regarding biochemical 
composition of particles267. 
 
Atomic force microscopy. This microscope scans a sample surface to create a three-
dimensional image with a submicron resolution. It can be used to measure the size 
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of microvesicles in their physiological state. Antibodies could be used to characterise 
the vesicles phenotype. For the microscope to detect the vesicles they have to be 
firmly bound to a flat surface which could affect the morphology of the vesicles and 
as the efficiency of the binding  process is not known, the concentration of the 
vesicles cannot be accurately measured268. 
 
1.4.3 Flow-cytometry 
When a sample is injected into a flow-cytometer the particles are dispersed into a 3 
dimensional space called the central channel, which is enclosed within an outer 
sheath that contains a faster moving fluid called the sheath fluid. The fast moving 
sheath fluid creates a massive drag on the narrower central channel which alters its 
fluid velocity, hereby creating a single file of particles; this process is called 
hydrodynamic focusing. Under optimal conditions (laminar flow) the two fluids will 
not mix (Figure 1.5)269.  
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Figure 1.5. Schematic demonstrating the process of hydrodynamic focusing inside a flow-
cytometer cell. 
 
Following hydrodynamic focusing, each particle passes through one or more beams 
of light. The flow-cytometer then gathers information about each particle based on 
the scattering of light or emission of fluorescence (if the particles are fluorochrome 
labelled). The most commonly used sources of light are either a laser or an arc lamp. 
The focus here will be on laser as a light source, as this is used in the BD 
LSRFortessa. The light scattered in the forward direction is collected by a lens known 
as the forward scatter channel (FSC) while the light scattered at a 90 degree angle 
is collected through another lens called the side scatter channel (SSC). The FSC 
intensity equates to the particle size and the SSC one provides information about 
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particle granularity. Both FSC and SSC are unique to each particle and can be used 
to differentiate between various particles in a heterogeneous sample.  
 
Fluorescence measurements taken at different wavelengths also provide data about 
surface receptors and protein expression of particles and cells as well. Flow-
cytometry uses separate fluorescence channels to detect the light emitted using 
either silicon photodiodes or photomultiplier tubes (PMT). The specificity of detection 
is controlled through optical filters, which block certain wavelengths and transmit 
others (Figure 1.6)269. 
 
Figure 1.6. Schematic demonstrating the light system inside a flow cytometer 
 
When a photo-detector receives light, a small current is generated with amplitude 
that is proportional to the amount of light detected. This signal is then amplified to 
allow graphical representation. Log amplification is usually used for fluorescence as 
it harmonises the signals, resulting in a distribution that can be represented as a 
histogram. The output from each detector is called the parameter (e.g. forward 
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scatter, side scatter or fluorescence) while the data acquired within each parameter 
is referred to as events, i.e. the number of particles or markers of interest.  
 
Fluorochromes: are dyes that accept light (excitation) and re-emit the light at a higher 
wavelength (emission). Emission follows excitation in a matter of a few nanoseconds 
and this process is called fluorescence. The excitation wavelength is critical to the 
amount of light a fluorochrome will absorb. A fluorochrome will have a range of 
wavelengths at which it will absorb light and within this range there is a peak at which 
the maximum amount of light is absorbed. The excitation at this peak will produce 
more intense fluorescence emission. These optimal conditions are called maximal 
absorption and maximal emission wavelengths (Figure 1.7)269. 
 
 
Figure 1.7.Schematic representing the excitation and emission curves of a fluorochrome. 
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Fluorescent probes such as fluorochrome-conjugated antibodies are useful to 
directly target a specific epitope to facilitate the measurement of its biochemical and 
biological properties using flow-cytometry. They are useful in many applications such 
as:  
 identifying and quantifying distinct populations of cells or MP, surface 
receptors and proteins or intra-cellular organelles 
 immuno-phenotyping 
 measuring enzyme activity and apoptosis studies.  
Changing the excitation light and the use of more than one fluorochrome facilitates 
the simultaneous analysis of several parameters in the same sample, which forms 
the basis for multi-colour fluorescence studies. There are a large and expanding 
number of fluorochromes that can be used in flow-cytometry269.  
 
The use of more than one fluorochrome in the same study carries the risk of emission 
profile overlap, rendering the measurement of each distinct fluorochrome emission 
more difficult. Using fluorochromes with very different emission spectra could rectify 
the problem, but this approach is not always practical.  Another solution is to apply 
fluorescence compensation. Compensation calculation is based on measuring how 
much of each fluorochrome “spills” into the other fluorochrome channels through 
control measurements using single fluorochrome experiments. This mathematical 
compensation is then applied to the multi-colour studies269.  
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Gating is an important flow-cytometry technique in which the groups of cells or MP 
of interest are selectively visualised while eliminating results from unwanted particles 
or noise. Gating was traditionally achieved according to physical characteristics on 
a typical graph of SSC versus FSC. Newer gating strategies use florescence 
combined with scatter parameters269.  
 
One of the most commonly used ways to present flow-cytometry data is as a 
histogram. These histograms display a single measurement parameter 
(fluorescence or light scatter intensity) on the x-axis and the number of events on 
the y-axis. Histograms are useful in enumerating the number of cells or particles that 
possess a physical property or which express the marker of interest. The cells or 
particles expressing this physical property are called the positive dataset. Under 
optimal conditions a flow-cytometer would produce a histogram with a distinct peak 
that would represent the positive dataset, but frequently a multi-peak histogram is 
produced making identifying the desired positive data set difficult. This problem can 
be overcome through the use of negative isotype controls 269 which are subtracted 
from the positive dataset to reveal the “true positive” events. 
 
1.4 The project 
 
1.4.1 Proteins 
Microparticles express proteins on their surface that reflect their parent cell and other 
proteins that may have a role in their function. Detection of these proteins will 
facilitate microparticles characterisation. The proteins used in this project are:  
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A2M: is a member of the alpha-macroglobulin superfamily and is present in the body 
fluids of humans and other species. A2M is a high molecular weight (720 kDa) 
homotetrameric glycoprotein formed of 4 identical subunits (180 kDa each). This 
protein has a variety of complex functions, but most important is the inhibition of a 
wide range of proteases, which does not involve blocking the active site of these 
enzymes. A2M is also involved in the transport and regulation of many proteins such 
as transferrin, defensins and myelin. In addition A2M binds and modifies the activity 
of many important cytokines such as platelet-derived growth factor, nerve growth 
factor, IL-1 and IL-6. A2M also binds and regulates the activity of hormones. 
Moreover, this glycoprotein said to be protective against various infections. Binding 
of A2M to these mediators (e.g. IL-1 and IL-6) may alter its conformation to enable 
binding to a specific receptor, termed LRP1, a member of the family of low-density 
lipoprotein receptors. A2M may also have diagnostic and prognostic utility in many 
conditions including cardiac diseases, pancreatitis and gastric cancer. Finally, A2M 
may be used as a vehicle for vaccine and medications. This protein could be 
damaged by reactive species produced by the host and/or the invading organism 
resulting in pathological effects 270. 
 
CD66b: is a trans-membrane protein with a cytoplasmic tail and is considered to be 
part of the immunoglobulin superfamily and the carcinoembryonic antigen like 
subfamily. The molecular weight pf CD66 is ~95-100 kDa. It is expressed on the 
surface of neutrophils and other granulocytes. CD66b is known to be involved in 
neutrophil adhesion, aggregation and activation271.  
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CD14: is a 55kDa glycoprotein expressed on the surface of macrophages and 
monocytes. It acts as an receptor for LPS, facilitating its interaction with TLR, thus 
resulting in macrophage activation 272.  
 
CD3: consists of 4 distinct chains (CD3γ, CD3δ and two CD3ε) and is associated 
with T-cell receptors (TCR).  CD3 is found on all mature T cells, natural killer T cells 
and some thymocytes. CD3 is also known as T3 and is a member of the 
immunoglobulin super family that plays a role in antigen recognition, signal 
transduction and T cell activation.  
 
CD235a: is also known as glycophorin A and is a member of the glycophorin family. 
It is a type I sialoglycoprotein present in the cell membrane as a homodimer. CD235a 
is expressed by erythroid precursors and erythrocytes. It bears the antigenic 
determinants of the MNS blood groups and is thought to be an inhibitor of 
haemagglutination and haemolysis. This protein is a binding site for plasmodium 
falciprum, influenza virus and hepatitis A virus.   
 
CD41: is 125/25 kDa alpha subunit of the gpII/IIIa (CD41/61) complex. CD41 is a 
member of the integrin family and is a heterodimer of a heavy chain and a light chain 
linked by a disulphide bond. It is primarily expressed on platelets and 
megakaryocytes and it is involved in platelet aggregation and attachment. CD41/61 
is a receptor for fibrinogen, fibronectin, von Willebrand factor and thrombin. 
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CD31: is also known as Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1). 
PECAM-1 is a trans-membrane glycoprotein with a molecular weight of 130-140 kDa 
and is a member of the immunoglobulin superfamily of adhesion molecules. It is 
highly expressed on the surface of endothelial and haematopoietic cells. CD31 plays 
an important role in the regulation of the immune response as it has both pro- and 
anti-inflammatory functions. Its pro-inflammatory function is mainly to facilitate the 
trans-endothelial migration of leucocytes while its anti-inflammatory properties 
include dampening of leucocyte activation, suppression of pro-inflammatory 
mediators production and maintaining the integrity of the endothelial barrier 273.  
 
CD51: is also known as integrin alpha v (ITGAV) and vitronectin receptor alpha 
chain. ITGAV is a type I integral membrane glycoprotein which forms a heterodimer 
with integrin β1, β3, β5, β6 and β8. Thus, CD51 contains two disulphide-linked sub 
units of 125 kDa and 24 kDa and is expressed on endothelial cells, fibroblasts, 
macrophages, platelets and osteoclasts among others. CD51 binds vitronectin, von 
Willebrand factor, fibronectin, thrombospondin, osteopontin, fibrinogen and laminin. 
As an adhesion molecule it plays important roles in leukocytes homing and rolling. 
CD51 also mediates bone absorption and angiogenesis.  
 
CD146: is also known as melanoma cell adhesion molecule (Mel-CAM), MUC18, S-
Endo-1, MCAM. Mel-CAM is a membrane glycoprotein and is considered to be part 
of the immunoglobulin superfamily. CD146 is expressed on endothelial cells, smooth 
muscle cells and myofibroblasts among others. It is also expressed on many 
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malignant cells including melanoma cells. Mel-CAM mediates heterophilic cell-cell 
adhesion and participates in signal transduction. It is involved in outside-in signalling 
and may contribute to local adhesion, re-organisation of cytoskeletal structures, 
maintaining cell form as well as control of cell migration and proliferation274.  
 
1.4.2 Overview 
The objective of the work described in this thesis was to better understand the role 
of MP in the pathogenesis, evolution and outcome of sepsis. I planned to quantify 
and characterise circulating MP in the plasma of septic patients, with particular 
attention to neutrophil-derived MP and their surface protein expression. I then 
investigated putative associations between the number and characteristics of the 
MP and clinical outcome. The investigations build on the findings of recent studies 
performed by our group in which my supervisors have shown that the protein content 
and surface expression of neutrophil-derived MP vary according to the environment 
and the nature of the stimulus. Moreover, in a small group of patients with septic 
shock, the number of neutrophil derived MP expressing alpha-2-macroglobulin 
(A2M) was significantly higher in survivors than in non-survivors. Members of our 
group have also demonstrated that A2M/CD66b positive MP can activate endothelial 
cells and promote the adhesion of freshly prepared leucocytes. These findings, 
coupled with the observation that administration of MP enriched with A2M, packaged 
as a nanomedicine, improved outcome and enhanced bacterial clearance in a 
murine model of sepsis, indicate the potential of certain subsets of MP to ameliorate 
the immune paresis characteristic of sepsis, and perhaps thereby improve outcome. 
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Intriguingly, MP prepared from the plasma of septic shock survivors (which 
expressed higher levels of A2M on the CD66b positive MP subset), but not those 
from non-survivors, could activate endothelial monolayers and increase leucocyte 
adhesion.  
 
My goal, was to extend these observations and further explore the potential of MP 
to impact on the clinical management of patients with sepsis. This thesis will focus 
on two well-defined cohorts of septic patients with sepsis due to CAP and faecal 
peritonitis.  
 
Besides neutrophil derived MP I characterised and quantified MP derived from other 
cells that have a role in sepsis. Specifically, I examined MP derived from monocytes, 
lymphocytes, platelets, erythrocytes and endothelium. I also investigated the 
changes in these MP over time as well the relation between the levels of these MP 
and the severity of sepsis and outcome.  
 
The main population of MP I have studied were neutrophil MP (CD66b+) and their 
surface expression of A2M. I also investigated monocyte (CD14+), lymphocyte 
(CD3+), erythrocyte (CD235+) and platelet (CD41+) derived MP and their A2M 
surface expression. I also quantified endothelium derived MP utilising more than one 
marker (  CD146, CD31 and CD51) as these markers have been shown to correlate 
to acute and chronic conditions, respectively275. Also CD31 positive MP have been 
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shown to correlate with illness severity and outcome in many diseases, particularly 
conditions affecting the cardiovascular system276.  
 
1.4.3 Hypotheses: 
1. Circulating cell derived microparticle concentrations are increased in severe 
sepsis.  
2. The alpha-2-macroglobulin positive neutrophil microparticles are related to 
disease severity and outcome in severe sepsis. 
3. Microparticles expressing alpha-2-macrogloulin derived from other cells are 
also related to disease severity and outcome.  
4. Microparticle plasma concentration and alpha-2-macroglobulin expression 
change as sepsis evolves. 
5. Microparticle profiles in severe sepsis will differ according to the source of 
infection. 
6. Microparticles derived from stimulated whole blood possess immune-
modulatory effects. 
 
1.4.4 Objectives: 
1. To quantify and characterise circulating cell derived microparticles in the 
plasma of two well defined cohorts of severe sepsis patients (community 
acquired pneumonia and faecal peritonitis). 
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2. To quantify neutrophil derived microparticles positive for alpha-2-
macroglobulin in the same cohorts and confirm or refute their relationship to 
outcome. 
3. To quantify and characterise (alpha-2-macroglobulin surface expression) 
microparticles derived from cells other than neutrophils (monocytes, 
lymphocytes, erythrocytes, and platelets) in these patients. 
4. To relate the number and protein expression of microparticles derived from 
cells other than neutrophils (monocytes, lymphocytes, erythrocytes, platelets 
and endothelial cells) to outcome in the same groups of patients. 
5. To document changes over time in microparticle numbers and alpha-2-
macroglobulin expression in these patients. 
6. To explore the effect of novel therapeutic adjuvant agents on whole blood 
production of alpha-2-macroglobulin expressing microparticles and their cells 
of origin. 
7. To examine the effects of microparticles obtained from stimulated whole blood 
on aspects of neutrophil and endothelial function. 
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Chapter 2: Materials and 
methods 
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2.1 Materials 
2.1.1 Cell Culture 
Dulbecco’s phosphate buffered saline (DPBS) with calcium and magnesium, foetal 
bovine serum (FBS), fungizone, human Serum, medium 199 with Earle’s salts with 
L-glutamine (M199), Penicillin/Streptomycin and Roswell park memorial institute 
medium 1640 (RPMI) with L-glutamine were purchased from GE healthcare, 
Buckinghamshire, UK. Trypsin/EDTA (0.025%/0.01%) was purchased from 
Invitrogen, Paisley, UK. Dextran (molecular weight 450,000-650,000), gelatine Type 
B from bovine Skin, Hanks balanced salt Solution 10X, Histopaque 1077, phosphate 
buffered saline (PBS) and sodium citrate were purchased from Sigma-Aldrich, Poole, 
UK. Lipopolysaccharide from Escherichia Coli strain 0111:B4 purchased from 
Sigma-Aldrich, Poole, UK. Granulocyte macrophage colony stimulating factor and 
interferon gamma were purchased for Peprotech, London, UK.  
 
2.1.2 Flow-cytometry antibodies for microparticles characterisation 
Antigen Isotype Fluorochrome Working 
Concentration 
Clone Source 
CD66b Mouse IgM, κ PE 0.125 μg/ml G10F5 Biolegend 
CD146 Mouse IgG2a, κ APC 0.50 μg/ml SHM-57 Biolegend 
CD14 Mouse IgG1, κ APC 0.50 μg/ml 61D3 eBioscience 
CD31 Mouse IgG1, κ PE 0.25 μg/ml WM59 Biolegend 
CD51 Mouse IgG2, κ FITC 0.1 μg/ml NKI-M9 Biolegend 
CD3 Mouse IgG2a, κ PE 0.375 μg/ml HIT3a eBioscience 
CD235 Mouse IgG2b, κ PE 0.75 μg/ml HIR2 eBioscience 
LAIR1 Mouse IgG1 PE 0.12 μg/ml NKTA255 eBioscience 
Annexin A7 Rabbit IgG PE-CY5 1 μg/ml Polyclonal Bioss 
CD41 Mouse IgG1, κ FITC or PE 0.25 μg/ml HIP8 Biolegend 
A2M Mouse IgG1 FITC 1 μg/ml IA5 BioMac 
Table 2.1. Monoclonal antibodies used for microparticle detection. APC: allophycocyanin, A2M: 
alpha-2-macroglobulin, FITC: fluoroesceinisothiocyanate, LAIR1: leucocyte associated 
immunoglobulin like receptor 1, PE: phycoerythrin, PE-CY5: phycoerythrin-cascade yellow 5. 
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2.1.3 Flow-cytometry antibodies for cell characterisation 
Antigen Isotype Fluorochrome Working 
Concentration 
Clone Source 
CD11b Mouse IgG1, κ  APC 0.1 μg/ml  ICRF44 eBioscience 
CD62L Mouse IgG1, κ PE-Cy5 0.1 μg/ml  DREG-56 eBioscience 
ICAM-1 Mouse IgG1, κ PE 0.1 μg/ml HA58 eBioscience 
VCAM-1 Mouse IgG1 FITC 0.1 μg/ml 1.G11B1 AbdSerotec 
E-Selectin Mouse IgG1 FITC 0.1 μg/ml 1.2B6  AbdSerotec 
Tissue factor Mouse IgG1, κ APC 0.1 μg/ml HTF-1 eBioscience 
Table 2.2. Monoclonal antibodies used for cell antigen detection. APC: allophycocyanin, FITC: 
fluoroesceinisothiocyanate, ICAM-1: intra cellular adhesion molecule-1, PE: phycoerythrin, PE-CY5: 
phycoerythrin-cascade yellow 5, VACM-1: vascular cell adhesion molecule-1. 
 
2.1.4 Flow-cytometry proteins for microparticles characterisation 
Protein Fluorochrome Working 
concentration 
Source 
Annexin V Pacific Blue 0.2 μg/ml Biolegend 
Table 2.3. Annexin V used for microparticle detection. 
 
 
2.1.5 Other media 
Annexin V binding buffer 10X was purchased from BD Pharmingen, San Diego, 
USA. Fluorescein isothiocyanate (FITC)-Dextran MW 40,000 was purchased from 
Sigma-Aldrich, Poole, UK. 
 
 
2.1.6 Flow-cytometer 
 
The flow-cytometer used in this project is BD LSRFortessa manufactured by BD 
Bioscience, San Diego, Ca, USA. This device contains 4 lasers with wavelengths 
355nm, 405nm, 488nm, 640nm. The flow rates for this flow-cytometer are low: 12 
μl/min, medium: 35 μl/min and hi: 60 μl/min. The flow-cytometer is calibrated daily 
by the specialist flow-cytometry laboratory staff. 
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2.2 Patients and samples 
Patients admitted to intensive care units with severe sepsis or septic shock 
secondary to community acquired pneumonia or faecal peritonitis were recruited into 
the Genomic Advances in Sepsis (GAinS) study. Plasma obtained from the recruited 
patients was stored in a bio-bank at the Wellcome Trust Centre for Human Genetics. 
Colleagues from the Wellcome Trust Centre, with whom I am collaborating, provided 
the plasma at the time points required for each patient. They provided clinical data 
recorded using a comprehensive electronic web-based Case Report Form (eCRF), 
including demographics, comorbidities, differential white cell count, platelet count 
and illness severity scores.   
 
2.2.1 GAinS study inclusion criteria 
Patients recruited to the study were more than 18 years of age admitted to the high 
dependency units (HDU) or intensive care units (ICU) in the participating centres, 
with community acquired pneumonia (CAP) [defined as in reference 277 – febrile 
illness associated with cough, sputum production, breathlessness, leucocytosis and 
radiological features of pneumonia acquired in the community or within less than 2 
days of hospital admission] or faecal peritonitis (FP) defined as inflammation of the 
serosal membrane lining the abdominal cavity secondary to contamination by faeces 
as diagnosed at laparotomy. 
 
The use of standard diagnostic criteria for CAP and an unambiguous definition of 
FP, together with adjudication by two experienced clinicians ensured accurate 
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diagnosis. The causative organism of the CAP (where known) was documented. 
These patients may be admitted with, or may later develop, and progress through 
the spectrum of responses to infection, sepsis/severe sepsis/septic shock defined 
according to the extensively validated and widely accepted “Society of Critical Care 
Medicine/American College of Chest Physicians” consensus criteria definitions 278 
and may be admitted with, or later develop specific organ failures (e.g. Acute lung 
injury/Acute respiratory distress syndrome as defined in reference 279) which will be 
scored using the extensively validated and widely accepted “Sepsis-related Organ 
Failure Assessment” (SOFA) methodology 280. 
 
2.2.2 GAinS study exclusion criteria 
Patients were excluded when: patient, next-of-kin or legal representative unwilling 
or unable to give informed consent, the patient was less than 18 years of age, the 
patient was already enrolled in an interventional research study of a novel / 
unlicensed drug / therapy (patients enrolled in interventional studies examining the 
clinical application or therapeutic effects of widely accepted, “standard” treatments” 
are not excluded), the patient was pregnant, had an advanced directive to withhold 
or withdraw life sustaining treatment or was admitted for palliative care only, the 
patient was immune-compromised (known regular systemic corticosteroid therapy, 
exceeding 7mg/kg/day of hydrocortisone or equivalent, within three months of 
admission and prior to acute episode, known regular therapy with other 
immunosuppressive agents, e.g. azathioprine, known to be HIV positive or have 
acquired immunodeficiency syndrome as defined by the Centre for Disease Control, 
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patient had a neutrophil count less than 1 x 109/L due to any cause including 
metastatic disease and haematological malignancies or chemotherapy, but 
excluding severe sepsis and organ or bone marrow transplant receiving immuno-
suppressive therapy). 
 
2.2.3 Sample handling and storage 
Following consent or assent, 10 ml whole blood was collected into 
ethylenediaminetetraacetic acid (EDTA) tubes on days 1, 3, and 5 of ICU admission. 
Samples were cold-centrifuged at 2,500 g for ten minutes. The resulting platelet poor 
plasma (PPP) was immediately (within 15 minutes) frozen and stored at -80 C as 
eight (500μL each) aliquots of which 100μL was sent to me for MP analysis. I then 
re-centrifuged the PPP at 13000 g for two minutes to generate platelet free plasma 
(PFP) suitable for microparticle detection by flow-cytometry. 
 
 
2.3 Flow-cytometry 
Flow-cytometry was the method used to identify and characterise microparticles 
(MP) in plasma. 
 
2.3.1 Sample staining for flow-cytometry 
Fluorescent monoclonal antibodies were incubated with 5 μL of platelet free plasma 
(PFP) in the dark for thirty minutes at room temperature. The antibodies and the PFP 
were diluted in medium up to a volume of 10 μL for accuracy of pipetting. Annexin V 
was added to the reaction as a general marker for MP. The staining combinations 
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are detailed in Table 2.4. The antibody combinations are formulated so as to 
minimise interference between various fluorochromes on flow-cytometry and to 
reduce the need for compensation.  
 
Staining combinations Cell of origin 
Annexin V (Pacific Blue) + anti CD66b (PE) + anti A2M (FITC) Neutrophils 
Annexin V + anti CD14 (APC) + Anti A2M  (FITC) Monocytes 
Annexin V + anti CD41 (PE) + Anti A2M (FITC) Platelets 
Annexin V + Anti CD3 (PE) + Anti A2M (FITC) Lymphocytes 
Annexin V+ Anti CD235 (PE) + Anti A2M (FITC) Erythrocytes 
Annexin V + Anti CD31 (PE) Endothelial 
Annexin V + Anti CD146 (APC) Endothelial 
Annexin V+ Anti CD51 (FITC) Endothelial 
Table 2.4. Staining combination for microparticles detection by flow-cytometry and 
conjugated fluorochromes. A2M: alpha-2-macroglobulin, APC: Allophycocyanin, FITC: 
FluoroesceinIsothocyanate, PE: Phycoerythrin 
 
 
2.3.2 Reducing noise 
As explained in the introduction, the sheath fluid plays an important role in the 
process of hydrodynamic focusing and also carries the cells or particles through the 
light source; contaminants in sheath fluid could, therefore, be counted as positive 
events. The standard sheath fluid that was used in our flow-cytometry laboratory was 
distilled water or phosphate buffered solution (PBS). By literature review it was noted 
that some researchers have used filtered sheath fluid and others have used 
degassed double filtered sheath fluid in order to minimise any possible false positive 
results due to contaminants in the sheath fluid. In preliminary experiments standard 
distilled water sheath fluid and double filtered degassed sheath fluid were compared.  
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Distilled water was passed through a 0.4 μm filter into a glass container and then 
applied negative pressure to the container in order to extract as many of air bubbles 
as possible. The filtered, degassed sheath fluid was poured into the flow-cytometer 
sheath fluid container and another filter of 0.2 μm pore size is installed in the tubing 
between the sheath fluid container and the machine. Then 10,000 events were 
acquired and the time taken to acquire this number of events between the standard 
sheath fluid and the double filtered degassed fluid was compared. Using the filtered 
sheath fluid 185 seconds were required to acquire 10000 events while with the 
standard sheath fluid the same number of events were acquired over a 15 seconds 
period. It was concluded that more accurate results would be obtained by using the 
double filtered degassed sheath fluid (Figure 2.1). 
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Figure 2.1.Flow-cytometry SSC/FSC plots comparing acquisition of 10,000 with standard and 
double filtered degassed sheath fluids. Sterile double filtered phosphate buffered saline (PBS) 
was subjected to flow-cytometry using either standard sheath fluid or double filtered, degassed fluid. 
a. The SSC/FSC plot for the 10,000 events acquired with the standard sheath fluid. b. The SSC/Time 
plot showing the time taken to acquire 10,000 events (15 seconds). c. The SSC/FSC plot for 10,000 
events from the same sample acquired with the double filtered degassed sheath fluid. d. The 
SSC/Time plot showing the time taken to acquire 10,000 events (185 seconds). FSC: forward scatter, 
SSC: side scatter 
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2.3.3 Further noise reduction 
To further reduce the noise that could interfere with microparticle detection, various 
cleaning methods of the flow-cytometer were employed.  
 
Cleaning the flow-cytometer to achieve a low noise level in preliminary experiments 
was proving rather difficult even with running flow-cytometer rinse for up to an hour 
before every analysis. This method produced variable degrees of cleanliness.  
Then a deep cleaning method was employed where the sheath fluid was replaced 
with rinse as well as using it in through the sample probe and again that produced 
variable results in terms of noise reduction. 
 
Then I tried double filtering the rinse fluid through 0.22 μm filters and that seemed to 
consistently reduce the noise to an acceptable level (Figure 2.2). 
 
Figure 2.2. Comparison of double filtered flow-cytometer rinse fluid to standard rinse fluid. 
Both kinds of rinse fluid were processed through the flow-cytometer to acquire 10000 events. Double 
filtered rinse fluid took 3 times longer to acquire 10,000 events in comparison to standard rinse fluid. 
A: SSC/Time plot of the double filtered rinse fluid demonstrating that 10,000 events were acquired in 
over 30 seconds. B: SSC/Time plot of the standard rinse fluid demonstrating that 10,000 events were 
acquired in just over 10 seconds. SSC: side scatter. 
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2.3.4 Flow-cytometer threshold 
An electronic threshold in the flow-cytometer can be set to limit the number of events 
acquired; this threshold is usually set to one parameter (e.g. FSC, SSC). The 
function of the electronic threshold is to eliminate events that are thought of as noise 
such as cell debris and electronic noise. For the acquisition of cells on the flow-
cytometer I used a threshold of 5,000 set to both FSC and SSC, but for microparticles 
(MP) the standard threshold was 500 for both parameters. Therefore running the 
experiments on a threshold of 500 risked missing the smaller MP. In preliminary 
experiments the same sample was acquired using the standard threshold and the 
lowest possible electronic threshold (200) to compare the differences in MP count. 
The sample was double stained with annexin V (AV) and anti-CD66b PE antibody. 
Lowering the threshold to 200 significantly increased the events detected (Table 
2.5).  
 
 Threshold 500 Threshold 200 Fold increase 
Annexin V positive 177 1875 11 
Anti-CD66b positive 251 1543 6 
Annexin V/Anti-CD66b 
positive 
5 74 15 
Table 2.5. The effects of reducing the flow-cytometer threshold on the number of 
microparticles detected. Healthy volunteers’ plasma was stained using Annexin V – Pacific blue 
and anti-CD66b - PE fluorescent monoclonal antibodies and processed using flow-cytometry. The 
table shows events acquired at flow-cytometer thresholds of 500 and 200 and the increase expressed 
as folds. The data here is expressed as microparticles/μL (n=1). PE: phycoerythrin.  
 
 
2.3.5 Size calibration in flow-cytometry 
When a sample is acquired through a flow-cytometer, an SSC/FSC dot plot is 
produced representing all the acquired events. This dot plot does not directly indicate 
the size of the events acquired. Fluorescent polystyrene beads of a known size are 
usually used as a comparator to map the sizes on the FSC plot so that a gate can 
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be constructed around these beads that will include all particles of the desired size. 
This strategy is used to minimise noise and to exclude small size platelets and even 
smaller particles such as exosomes.   
 
MP range in size between 0.1 to 1 μm. In order to formulate a population gate that 
would include these MP, I used 0.1 and 1 μm FITC fluorescent polystyrene beads. 
Also a batch of 0.5 μm was used to demonstrate that the flow-cytometer could 
differentiate between all three sizes of beads, so making it likely that it would be able 
to differentiate between MP of various sizes.  
 
The beads come in highly concentrated solutions requiring dilution. In preliminary 
experiments I titrated the three beads sizes that I would use later for size calibration. 
The concentrations used and the optimum concentrations (Table 2.6) were selected 
based on as tight a population of beads as possible either on SSC/FSC or SSC/FITC 
plots (Figures 2.3, 2.4, 2.5).  
 
Bead concentration Bead size  
1 x 104 / ml   
5 x 104 / ml   
1 x 105 / ml   
5 x 105 / ml 1 μm  
1 x 106/ ml 0.5 μm, 0.1 μm  
5 x 106/ ml   
10 x 106 / ml   
Table 2.6. The concentrations used for polystyrene bead titration and the optimum 
concentration for each bead size. Bead size is denoted next to the optimum concentration for its 
use. 
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Figure 2.3. Titration of 1 μm polystyrene FITC fluorescent beads. Various concentrations of the 
1μm beads acquired through flow-cytometry to find the tightest population of beads using both 
SSC/FSC and SSC/FITC. Beads are enclosed by an ellipse. A: SSC/FSC plot of 1 x 107/ml where 
the bead population was not so tight. B: SSC/FSC plot of 5 x 105/ml where the beads population was 
tightest. C: SSC/FITC plot of 1 x 107/ml where the bead population was no so tight. D: SSC/FITC plot 
of 5 x 105/ml where the bead population was tightest. FITC: fluorescein isothiocyanate, FSC: forward 
scatter channel, SSC: side scatter channel. 
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Figure 2.4. Titration of 0.5 μm polystyrene FITC fluorescent beads. Various concentrations of the 
0.5μm beads acquired through flow-cytometry to find the tightest population of beads using both 
SSC/FSC and SSC/FITC. SSC/FSC could not resolve the bead population adequately, but the 
SSC/FITC could. Beads are enclosed by an ellipse. A: SSC/FSC plot of 1 x 107/ml where the bead 
population was not so tight. B: SSC/FSC plot of 1 x 106/ml where the bead population was tighter, 
but was not tight enough. C: SSC/FITC plot of 10 x 106/ml where the bead population was not so 
tight. D: SSC/FITC plot of 1 x 106/ml where the bead population was tightest. FITC: fluorescein 
isothiocyanate, FSC: forward scatter channel, SSC: side scatter channel. 
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Figure 2.5. Titration of 0.1 μm polystyrene FITC fluorescent beads. Various concentrations of the 
0.1μm beads acquired through flow-cytometry to find the tightest population of beads using both 
SSC/FSC and SSC/FITC. SSC/FSC could not resolve the bead population adequately, but the 
SSC/FITC could. A: SSC/FSC plot of 1 x 107/ml where the bead population was widely scattered. B: 
SSC/FSC plot of 1 x 106/ml where the bead population was hidden inside the noise cloud. C: 
SSC/FITC plot of 1 x 107/ml where the bead population was no so tight. D: SSC/FITC plot of 1 x 
106/ml where the bead population was tightest. FITC: fluorescein isothiocyanate, FSC: forward scatter 
channel, SSC: side scatter channel. 
 
 
2.3.6 Particle size resolution in flow-cytometry 
The forward scatter channel (FSC) is usually used for size detection. Preliminary 
experiments demonstrated that the flow-cytometer I am using could not adequately 
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differentiate between the various sizes of beads in FSC histogram and that they 
overlap (Figure 2.6).  
 
 
Figure 2.6. SSC/FSC dot plot and FSC histogram of 0.1, 0.5 and 1 μm beads acquired on flow-
cytometry showing that it is difficult to differentiate between these beads using FSC. A. 
SSC/FSC dot plot showing a distinct population of the 1μm beads in the upper right corner of the dot 
plot, 0.5μm beads as a more widely dispersed population in the middle and 0.1μm population is 
difficult to distinguish from the background noise. B. FSC histogram of the 0.1, 0.5 and 1μm beads 
showing considerable overlap. FSC: forward scatter channel, SSC: side scatter channel. 
 
Therefore, other channels that might be able to differentiate adequately between the 
various sizes of beads were tested. The side scatter channel (SSC) and the FITC 
fluorescence channel were able to differentiate between all three populations of 
beads (Figure 2.7). 
 
 116 
 
Figure 2.7. Two histograms for 0.1, 0.5 and 1 μm beads of the SSC and FITC channels showing 
that these two channels could adequately differentiate between all three populations of bead. 
A. SSC histogram showing three distinct peaks for each of the three bead populations. B. FITC 
histogram showing three distinct peaks for each of the three bead populations. FITC: fluorescein 
isothiocyanate, SSC: side scatter channel. 
 
From these preliminary experiments it was concluded that the best way to formulate 
a gate to include the desired population is to use the SSC/FITC dot plot, which is 
then back-gated to SSC/FSC and a gate is drawn to include the resultant population. 
The gate is subsequently used to identify the MP population (Figure 2.8). This 
approach is known as back gating281, 282.  
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Figure 2.8. SSC/FITC and SSC/FSC of the 0.1, 0.5 and 1 μm bead populations and the gate 
drawn around them using “back gating” to identify the MP population. The three bead sizes 
(0.1, 0.5 and 1 μm) at the optimum concentrations were acquired using flow-cytometry. a. SSC/FITC 
dot plot of the three bead populations. b. SSC/FSC dot plot of the same populations identified through 
back gating of the previous dot plot population. P1. The gate drawn around the populations that would 
be later used for MP identification. FITC: fluorescein isothiocyanate, FSC: forward scatter channel, 
SSC: side scatter channel. 
 
 
2.3.7 Sample acquisition and microparticle counting formula 
Each sample is acquired for 30 seconds on the “Hi” acquisition option of the flow-
cytometer. The high acquisition flow rate may encourage “swarm effect” which may 
risk under-estimating the number of MP. This was mitigated by ensuring good mixing 
prior to acquisition. The Hi acquisition processes 60 μL per minute. 
 
For calculation of MP count / μL of PFP:  N * 
𝑉
𝐷
=  MP/ μL.  
N is the total number of MP per sample. V is the volume acquired (usually 30 μL). D 
is the dilution (usually 1 in 40). 
 
Other researchers have used counting beads for microparticles enumeration283. 
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2.3.8 Gating strategy 
In the protocol optimisation experiments, pacific blue conjugated Annexin V (AV) 
was used as a general marker for MP. As there is no isotype control for AV, control 
values were obtained by omitting calcium in the incubation buffer (phosphate 
buffered saline with no calcium that contains the same final concentration of AV was 
used). In this way the pacific blue background noise was determined and then 
subtracted from the total events in stained plasma samples. The AV positive 
population identified from the previous step was further characterised using one or 
two monoclonal antibodies. The isotype controls for these monoclonal antibodies 
were used to identify the non-specific binding and this was subtracted from the 
positive population (Figure 2.9). 
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Figure 2.9.Gating strategy. Plasma obtained from healthy volunteers was stained with Pacific Blue 
fluorescent AV as well as PE and FITC conjugated monoclonal antibodies (anti-66b and A2M 
respectively) and processed using flow-cytometry. A. SSC/Pacific blue dot plot of a sample not 
stained with AV showing the pacific blue background noise and the quadrants drawn to subtract the 
noise from positive events. B. A sample stained with AV with the quadrants from the unstained sample 
applied, showing the positive population. P1. The AV positive population. SSC: side scatter channel. 
Healthy volunteer plasma was stained with A. Isotype control background noise gated out. B. Double 
stained sample using the quadrants formulated from the isotype controls. P1: Double positive 
population. P2: FITC positive population. P3: PE positive population. A2M: alpha-2-macroglobulin. 
FITC: Fluorescein isothiocyanate, PE: phycoerythrin 
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2.4 Microparticle preparation 
2.4.1 Whole blood stimulation for microparticle production 
Venous blood was collected from healthy volunteers using a 21 gauge needle into 
commercially available glass bottles containing 0.068 ml of 7.5% 
ethylenediaminetetraacetic acid (EDTA) solution acting as an anticoagulant. The 
blood was incubated with and without compounds as indicated in a 37oC shaking 
water bath for the specified period.  
 
2.4.2 Isolation of microparticles from whole blood 
Whole blood was centrifuged at 1500 x g for 15 minutes to pellet the cells. The 
platelet poor plasma (PPP) was then aspirated and re-centrifuged at 13000 x g for 2 
minutes to pellet the platelets. The platelet free plasma (PFP) was then aspirated 
and used for MP detection. 
 
2.4.3 Microparticle concentration 
In order to test the effect of MP on various cells, the MP had to be concentrated. This 
was achieved by centrifuging platelet free plasma at 19000 x g for 30 minutes at 4oC. 
The supernatant was subsequently discarded and the MP pellet was re-suspended 
in the same original volume in sterile double filtered phosphate buffered saline 
solution. The suspension was then re-centrifuged using the same protocol as above. 
The supernatant was again discarded and the MP pellet was then re-suspended in 
1/10 of the original plasma volume (Figure 2.10). 
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Figure 2.10.The effect of microparticle concentration on the number of microparticles per 
microliter. Platelet free plasma of 4 healthy volunteers was centrifuged twice at 19000 x g for 30 
minutes at 4oC and the microparticles pellet was re-suspended in 1/10 of the original plasma volume. 
The microparticles concentrate was stained with fluorescent Annexin V and the samples were 
analysed using flow-cytometry. MP: microparticles, PFP: platelet free plasma. 
 
2.4.4 Microparticles sorting 
In order to study the characteristics of a MP subset expressing a certain protein, the 
MP population has to be sorted to separate the desired subset from the whole 
population.  
 
In an attempted to separate MP subsets using florescence sorting, 10 ml of whole 
blood was stimulated with granulocyte macrophage colony stimulating factor (GM-
CSF) in a concentration of 100 ng/ml for half an hour. Next, platelet free plasma was 
prepared in the manner described elsewhere and then the MP were concentrated in 
1/10th of the original volume. The resultant MP concentrate was then stained for A2M 
using FITC monoclonal antibody. 
 
The sample was processed using the BD FACSARIA II cell sorter. The machine 
detected only a small number of events (about 1 million events).  
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The A2M MP were sorted in a total volume of 8 ml, which was then re-concentrated 
into 1/10th of the volume. The sample was stained for A2M using the same 
monoclonal antibody and quantified A2M MP in the sample on the more sensitive 
BD LSRFortessa. This has yielded an A2M positive population of MP that 
represented 73.6% of the all events including noise (Figure 2.11) with more than 
64,000 positive events per microliter. 
 
 
Figure 2.11. Histograms of the alpha-2-macroglobulin (A2M) sorted microparticles and thier 
isotype control. Whole blood from healthy volunteers was stimulated with granulocyte macrophage 
colony stimulating factor (GMCSF) for 30 minutes at 37oC and microparticles were concentrated. The 
A2M positive microparticles were labelled with A2M-FITC fluorescent monoclonal antibody and sorted 
to separate A2M using FACS. Following the sorting process, microparticles were stained again with 
A2M-FITC antibody and processd using flow cytometry. 73.6% of the microparticles in the sample 
positive for A2M. A2M: Alpha-2-macroglobulin, FITC: Fluorescein isothiocyanate. 
 
 
2.5 Human umbilical vein endothelial cells 
2.5.1 Isolation and culture of primary human umbilical vein endothelial cells 
(HUVEC) 
The Royal London Hospital midwifery unit was the source of the umbilical cords. 
Phosphate buffered saline (PBS) solution containing penicillin (100U), streptomycin 
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(10µg/ml) and fungizone (2.5µg/ml) was used as incubation medium for the umbilical 
cords. The cords were stored at 4oC until processing. 
 
The interior umbilical vein was digested used collagenase to isolate the HUVECs as 
described previously284. Briefly, at one end of the umbilical vein a needle was 
introduced and secured using a clamp. A sterile syringe was used to infuse 30mls of 
sterile PBS into the vein to remove any blood remaining in the lumen and to detect 
any perforations. The other end of the vein was then clamped and 20 to 25 ml of 
serum free M199 medium containing 0.1% type II collagenase, penicillin (100U), 
streptomycin (10µg/ml) and fungizone (2.5µg/ml) was introduced. The vein was 
incubated in at 37oC in a humidified incubator containing 5% CO2 for 15 minutes. 
 
The solution contained in the vein was then transferred to a 50ml falcon tube. PBS 
solution (30mls) was then used to wash the vein and added to the same tube. The 
solution was centrifuged at 300g for 10 minutes, the supernatant was discarded and 
the pelleted cells were re-suspended in 10mls of complete medium (M199 containing 
20% human serum, penicillin (100U), streptomycin (10µg/ml) and fungizone 
(2.5µg/ml)). The solution was then transferred to a 0.5% gelatine pre-coated T75 
flask (75cm2).  
 
The cells were incubated at 37oC in a humidified incubator containing 5% CO2. The 
medium was changed at 24 hours and every 48 hours thereafter until the cells 
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reached 95% confluence. This procedure yielded approximately 0.5 – 1.5 x 106 cells 
per umbilical cord. 
 
When the desired level of confluence was achieved, the cells were washed with PBS 
prior to the addition of 0.025% Trypsin/0.01% EDTA solution to detach the cells. 
Once the morphology of the cells started to change from spindle shape to oval and 
they began to detach the flask was firmly tapped to aid the detachment of the cells; 
complete medium was then added to render the trypsin inactive. The cells were split 
between T75 flasks, which were incubated at 37oC with 0.5% gelatine for 20 minutes 
prior to cell addition. Passage 3 was the maximum stage of cell culture used for 
experiments. 
 
2.5.2 Stimulation of human umbilical vein endothelial cells with microparticles 
HUVECs prepared as above were plated as indicated at least overnight to achieve 
confluence. The supernatant was aspirated and replaced with HUVEC incomplete 
medium (M199 containing penicillin (100U), streptomycin (10µg/ml) and fungizone 
(2.5µg/ml)). The MP were added at a concentration of 1 – 2 x 106/ml to the cells with 
or without lipopolysaccharide 100ng/ml and placed in an incubator containing 5% 
CO2 at 37oC for 4 hours. 
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2.5.3 Assessment of adhesion molecule and tissue factor expression on 
human umbilical cord endothelial cells by flow-cytometry 
The cells were then seeded in 12 well plates that were pre-incubated at 37oC with 
0.5% gelatine for 20 minutes prior to seeding of cells. The plates were then incubated 
in an incubator containing 5% CO2 at 37oC for 24 to 48hrs to reach confluence. Each 
well contained approximately 5 x 105 HUVEC. 
 
The HUVEC cells were stimulated with MP (1 – 2 x 106/ml) with or without 
lipopolysaccharide (LPS – 100 ng/ml) and placed in incubator containing 5% CO2 at 
37oC for 4 hours. The supernatant was then discarded and the cells were trypsinised 
and washed in complete medium as above and transferred to a 15ml falcon tube. 
The tube was then centrifuged at 300 x g for 10 minutes to pellet the cells and the 
supernatant was discarded. The cells were then plated in a 96 well plate and each 
well contained approximately 2 x 105 HUVEC cells suspended in phosphate buffered 
saline (PBS). The cells were then incubated with intra-cellular adhesion molecule - 
1 (ICAM-1) phycoerythrin (PE), vascular cell adhesion molecule – 1 (VCAM-1) – 
fluorescein isothiocyanate (FITC), E/P selectin – FITC or tissue factor – 
allophycocyanin (APC) conjugated monoclonal antibodies for 30 minutes on ice in 
the dark. The cells were subsequently washed twice with PBS and re-suspended in 
200µl of 1% Paraformaldehyde fixative (PFA) solution ready for analysis using flow-
cytometry. Isotype controls (IgG1) were used for accurate calibration of the flow-
cytometer. Adhesion molecules were expressed as median florescence intensity 
(MFI) units in the respective channel.  
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2.5.4 In-vitro flow chamber assay 
This assay was used to examine the effect of MP on neutrophil-endothelial 
interaction under flow conditions. Human umbilical vein endothelial cells (HUVEC) 
were grown to confluence in T75 flasks as described above. The cells were then 
trypsinised and washed and pelleted as described above. The HUVECs were then 
re-suspended in 700µl of complete medium (M199 containing 20% human serum, 
penicillin (100U), streptomycin (10µg/ml) and fungizone (2.5µg/ml)). The cells (100µl 
per chamber) were subsequently plated in 6 chamber μ‐Slide VI0.4 (Ibidi, Munich, 
Germany) (Figure 2.12), which were pre-incubated at 37oC with 0.5% gelatine for 20 
minutes prior to seeding of cells. The μ‐Slides were then incubated in a 37oC 
incubator containing 5% CO2 over night to reach confluence. The medium was then 
aspirated and discarded. Serum free medium, with or without lipopolysaccharides or 
MP was used (150µl per chamber) for HUVEC stimulation. The slides were 
incubated in the same conditions as above for a further 4 hours. 
 
 
Figure 2.12. Ibidi μ‐Slides containing 6 individual chambers were used for the flow chamber 
assay. 
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Neutrophils were isolated as detailed below, diluted in phosphate buffered saline 
(PBS) supplemented with Ca2+ and Mg2+ containing 1% bovine serum albumin (BSA) 
to a concentration of 1 x 106/ml and incubated in a 37oC water bath for 10 minutes 
prior to infusion over the HUVEC monolayer.  
An automated syringe pump system (Harvard Apparatus) was used to produce a 
shear stress of 1 dyne/cm2, which was calculated using an adaptation of Poiseuille’s 
law:  
 
Wall shear stress (dyne/cm2) = Mean flow velocity (mm/s) x [8/tube diameter 
(mm)] x viscosity (Poise)  
 
This takes into consideration the cylindrical vessel flow rate; the wall shear stress to 
volumetric flow rate through the chamber equation285:   
 
τw=6μQ/a2b 
 
Where: 
τw = Wall shear stress (dyne/cm2) 
μ = Coefficient of viscosity (Poise) 
Q = Volumetric flow rate (ml/s) 
a = Channel height (cm) 
b = Channel width (cm) 
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Constant volumetric flow (0.0095 ml/s) was used for these experiments using a 
programmable syringe pump. The suspension containing the cells (1 x 106/ml) and 
its temperature determine the viscosity coefficient. At a constant temperature of 
37oC, PBS had a viscosity of 0.011 Poise. The channel height and width of the flow 
chamber were constant at 0.04 cm and 0.38 cm respectively. A wall shear stress of 
1.031 dyne/cm2 was generated. 
 
A Nikon Eclipse TE3000 microscope fitted with x4, x10, x20 and x40 phase contrast 
objectives was used for these experiments. PMNs were perfused over the monolayer 
for 8 minutes and six 10 second frames were captured from random areas using a 
Q-imaging RetigaEXi digital camera (Q-imaging, Surry, Canada) and recorded in 
Image-Pro Plus capture software (Media Cybernetics, Rockville, USA) (Figure 2.13). 
The sequences were subsequently analysed using Image-ProPlus software 
package (Media Cybernetics, Rockville, USA) where PMNs were manually tagged 
and observed for migration. The total number of PMNs in the field during the 10 
second sequences was recorded as “captured” and these were subsequently 
divided into rolling and adherent (mobile through the field and stationary 
respectively) as described previously286. 
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Figure 2.13.Schematic illustrating the flow chamber experiment. Medium containing polymorph-
nuclear leucocytes (PMN) was perfused using a syringe pump into a flow chamber pre-seeded with 
a confluent layer of human umbilical cord venous endothelium (HUVEC) cells. A digital camera was 
positioned below the chamber to record the interaction between the two cell populations.  
 
 
2.5.5 Human umbilical vein endothelial cells monolayer permeability assay 
HUVEC were seeded into 8 well strip tissue culture inserts with 0.2µm porous 
membrane (NUNC, Denmark) at a final concentration of 5 x 104cells suspended in 
60 µl of complete medium per well, as per the manufacturer’s instructions. The insert 
was placed in a 96 well plate, where each well contained 150 µl of complete medium 
(Figure 2.14). During placement the insert was tilted to avoid air bubbles being 
trapped underneath. The whole set was placed over night in an incubator containing 
5% CO2 at 37oC to ensure confluence. 
 
Incomplete HUVEC medium containing MP at a concentration of 1 – 2 x 106/ml with 
or without 100ng/ml of lipopolysaccharide was used to replace the medium inside 
the insert wells. The incomplete medium was used to fill the 96 well plates. The set 
was placed in an incubator containing 5% CO2 at a 37oC for 4 hours.  
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The medium inside the insert wells was aspirated and replaced with the same 
volume of incomplete medium containing fluorescein isothiocyanate (FITC) labelled 
Dextran MW 40000 (Sigma-Aldrich, Poole, UK). Fresh incomplete medium was 
added to the bottom wells. This set was re-incubated. 
 
The insert was then removed and 50µl of the medium in the bottom plate was 
removed and placed into a fresh 96 well plate. Medium without FITC – dextran was 
added to the plate to act as a negative control. 
 
The NOVOstar plate reader (BMH LabTech, Ortenberg, Germany) was used to 
detect the fluorescence (Excitation filter: 485 and Emission filter: 520) for each 
treatment in the 96 well plate and the results were analysed using the NOVOstar 
software package.  
 
 
Figure 2.14. Schematic illustrating the human umbilical vein endothelial cell (HUVEC) 
monolayer permeability assay. 
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2.5.6 Human umbilical vein endothelial cells reactive oxygen species 
production assay 
HUVEC were seeded in a 96 well plate at a concentration of 1 x 105/well. The plates 
were pre-coated with 0.5% gelatine and incubated at 37oC for 20 minutes prior to 
seeding. The cells were placed over-night at in an incubator at 37oC containing 5% 
CO2 to reach confluence.  
 
The cells were then incubated for 30 minutes with 20 μM of 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen, Paisley, UK) 
suspended in incomplete HUVEC medium. The medium containing H2DCFDA was 
aspirated and replaced by incomplete medium containing MP (1 -2 x 106/ml) in the 
absence or presence of 100ng/ml of lipopolysaccharide. The cells were re-incubated 
at the same conditions as above for 4 hours. The cells were washed twice with 
phosphate buffered saline (PBS). PBS containing 20 μM H2DCFDA was used as a 
negative control. 
 
NOVOstar plate reader (BMH LabTech, Ortenberg, Germany) was used to detect 
the fluorescence (Excitation filter: 485 and Emission filter: 520) for each treatment in 
the 96 well plate and the results were analysed using NOVOstar software package.  
 
The negative control fluorescence values were subtracted from the treatment 
fluorescence. 
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2.5.7 Human umbilical vein endothelial cells nitrite production assay 
HUVEC were seeded in a 96 well plate at a concentration of 2 x 105/well. The plates 
were pre-coated with 0.5% gelatine and incubated at 37oC for 20 minutes prior to 
seeding. The cells were placed over night in an incubator containing 5% CO2 at a 
37oC to reach confluence.  
 
The medium was replaced with incomplete HUVEC medium containing MP (1 -2 x 
106/ml) in the absence or presence of 100ng/ml of lipopolysaccharide and the cells 
were incubated in the same conditions as above for 4 hours. 
 
A 150 μl aliquots of the supernatant was aspirated and plated in a flat bottom 96 well 
plate (Costar) for each treatment as well as 150 μl of phosphate buffered saline 
solution acting as negative control. The volume was made up to 280 μl with 
deionised water and 20 μl of Griess Reagent (Molecular Probes, Paisely, UK) was 
added in line with the manufacturer’s guidance. The plate was re-incubated for a 
further 30 minutes and subsequently NOVOstar plate reader (BMH LabTech, 
Ortenberg, Germany) was used to detect the absorbance (wavelength A492) and 
the results were analysed using the NOVOstar software package.  
 
2.5.8 Human umbilical vein endothelial cells cytokine production assay 
HUVEC were seeded in a 96 well plate at a concentration of 5 x 104/well. The plates 
were pre-coated with 0.5% gelatine and incubated at 37oC for 20 minutes prior to 
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seeding. The cells placed over night in an incubator containing 5% CO2 at a 37oC to 
reach confluence.  
 
The medium was replaced with incomplete HUVEC medium containing MP (1 -2 x 
106/ml) in the absence or presence of 100ng/ml of lipopolysaccharide. The cells were 
re-incubated at the same conditions as above for 4 hours. The supernatant was then 
collected and stored at -80oC until assayed. 
 
Commercially available enzyme-linked immunosorbent assay (ELISA) development 
kit was used for cytokine detection (Peprotech, London, UK). One hundred 
microliters of cytokine specific (IL8 and TNF α) capture antibody (0.5 μg/ml) was 
used to coat each well in a 96 well plate. The plate was sealed and incubated 
overnight at room temperature. Subsequently, the wells were aspirated and washed 
with 300 μL of wash buffer (0.05% Tween-20 in PBS) 4 times. Following the last 
wash, the plate was inverted and blotted to remove any residual buffer. Then, 300 
μL of block buffer (1% bovine serum albumin in PBS) was added to each well and 
incubated at room temperature for 1 hour. After incubation with block buffer, the plate 
was washed again 4 times with wash buffer. In each well, 100 μL of sample was 
added and incubated for 2 hours at room temperature; the plate was then washed 
again 4 times. Detection antibody diluted in diluent (0.05% Tween-20, 0.1%BSA in 
PBS) to a concentration of 0.5 μg/ml and 100 μL was added to each well and 
incubated for another 2 hours at room temperature. The plate was washed 4 times 
and 100 μL of Avidin-HRP conjugate (0.5 μg/ml in diluent) was added to each well 
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and incubated for 30 minutes. Afterwards 100 μL of 2,2’-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS) liquid substrate was added to each well 
and incubated for 30 minutes at room temperature.  
 
The plate was then read using a NOVOstar plate reader (BMH LabTech, Ortenberg, 
Germany) to detect the absorbance (wavelength A405nm) and the results were 
analysed using the NOVOstar software package. 
 
2.5.9 Detection of microparticle uptake by human umbilical vein endothelial 
cells using confocal microscopy 
HUVEC were seeded on 13 mm glass coverslips in a 24 well plate. The cover slips 
were coated with 0.5% gelatine containing 10 μg/ml of fibronectin (Millipore, Watford, 
UK) and incubated at 37oC for 2 hours. The HUVEC cells were then seeded on the 
coverslips at a concentration of 1 x 105per slip. The coverslips in the plate were 
placed over night in an incubator containing 5% CO2 at 37oC for 24 to 48 hours to 
achieve confluence.  
 
MP concentrate were stained with labelledboron-dipyrromethene (BODIPY) (2.5 μM) 
for 10 minutes and subsequently the suspension was centrifuged at 19000 x g for 
30 minutes at 4oC to pellet the MP. The supernatant containing the excess BODIPY 
was discarded and the MP pellet was re-suspended in the same original volume of 
PBS. 
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The medium was then replaced with 0.5 ml of incomplete HUVEC medium 
containing fluorescent MP at a concentration of 1 to 2 x 106/ml and incubated for 4 
hours in an incubator containing 5% CO2 at 37oC. Subsequently, the coverslips were 
washed with phosphate buffered saline (PBS) twice and the cells were fixed with 1% 
paraformaldehyde (PFA) (200 µl/coverslip) for 10 minutes. Then, PFA was aspirated 
and the coverslips were washed thrice with PBS. Subsequently, PBS containing 1% 
bovine serum albumin (BSA) was added on top of each coverslip acting as a blocking 
buffer for thirty minutes. The blocking buffer was aspirated and the cells were 
washed twice with PBS.  
 
To stain the HUVEC cell wall, wheat germ agglutinin (WGA) conjugated to Alexa 
Flour 633 (Life technologies, Paisley, UK) was used at a concentration of 5 µg/ml in 
PBS of which 200 μl was used to stain the cells in each coverslip. The plate 
containing the coverslip was re-incubated for a further 30 minutes. Following cell 
staining, the coverslips were washed twice with PBS.  
 
The coverslips were carefully removed from the plate wells, inverted and placed on 
microscope slides where a 10 μl mountant (Prolong gold anti-fade mountant, Life 
technologies, Paisley, UK) containing 4',6-diamidino-2-phenylindole (DAPI -  for 
staining HUVEC nuclei) was used to adhere the coverslips to the slide. The slides 
were incubated for a further 30 minutes in the same conditions as above. The slips 
were then stored at 4oC at least over-night prior to microscopy.  
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A Zeiss Laser scanning microscope LSM 710 was used for microscopy of the 
HUVEC using Zeiss Zen software. The following excitation/emission conditions were 
used in conjunction with x63 or x100 magnification oil immersion objectives: DAPI 
364/475-525 nm, BODIPY 488/505-530 and AlexFlour 633 at 638/658 in separate 
channels.  
 
The images acquired were analysed using supplied Zen and ImageJ software 
packages. Distinct BODIPY fluorescent (green) points identified by eye in the 
micrographs were considered as distinct MP. The software packages were used to 
measure sizes of structures such as nuclei or MP. 
 
2.5.10 Detection of microparticle uptake by human umbilical vein endothelial 
cells using imaging flow-cytometry  
HUVEC were seeded in a 6 well plate at a concentration of 5 x 105/well. The plates 
were pre-coated with 0.5% gelatine and incubated at 37oC for 20 minutes prior to 
seeding. The cells were in an incubator containing 5% CO2 at 37oC over night to 
reach confluence.  
 
MP concentrate was incubated with fluorescein isothiocyanate (FITC) labeled boron-
dipyrromethene (BODIPY) for 10 minutes. The suspension was then centrifuged at 
19000 x g for 30 minutes, the supernatant containing the excess BODIPY was 
aspirated and discarded and the MP pellet was re-suspended in sterile double 
filtered phosphate buffered saline. 
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The medium was replaced with incomplete HUVEC medium containing BODIPY 
stained MP at a concentration of 1 – 2 x 106/ml and the cells were incubated in the 
same conditions as above for 4 hours. 
 
Imagestream X mark II (Aminis, Seattle, USA) was used to detect the presence of 
microparticles inside HUVEC cells.  
 
2.5.11 Inhibition of microparticle uptake by human umbilical vein endothelial 
cells 
MP concentrates, prepared as above were incubated with Fluorescein 
isothiocyanate (FITC) labeled boron-dipyrromethene (BODIPY) for 10 minutes. The 
suspension was then centrifuged at 19000 x g for 30 minutes, the supernatant 
containing the excess BODIPY was aspirated and discarded and re-suspended in 
sterile double filtered phosphate buffered saline. The MP were then incubated with 
HUVEC cells without or without cytochalasin B (10 μM) to inhibit MP uptake. 
 
Imagestream X mark II (Aminis, Seattle, USA) was used to detect the presence of 
microparticles inside HUVEC cells.  
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2.6. Polymorphonuclear cells 
2.6.1 Isolation of human polymorphonuclear cells (PMN) from whole blood 
A 21-gaage needle was used to obtain venous blood (50 ml) from consenting healthy 
volunteers and transferred to 50ml falcon tubes. Each tube contained 3.2% sodium 
citrate solution acting as an anticoagulant at 1/10th of the donated blood volume. 
Platelet rich plasma was separated through centrifugation at 137 x g for 20 minutes 
and discarded. PBS (10ml) and 6% dextran (8ml) were gently layered respectively 
on top of blood cells. The solution was mixed gently to ensure homogeneity and left 
to stand for 30 minutes resulting in red cells sedimenting at the bottom of the tube. 
The top layer containing the leucocytes was then removed, layered over 10ml of 
Histopaque 1077 solution in a 50 ml falcon tube and centrifuged at 483 x g for 30 
minutes where layers are formed as demonstrated in Figure 2.15. 
 
 
Figure 2.15. Isolation of polymorphonuclear cells from whole blood using dextran 
sedimentation. 
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The peripheral blood mononuclear cells (PBMC) were collected and the other layers 
were discarded leaving the bottom layer containing PMN and erythrocytes. Ice-cold 
water (9ml) was mixed with the bottom layer to lyse the erythrocytes and this mixture 
was then mixed with 1 ml of 10x Hanks balanced solution to restore the isotonic 
state. PBS was added up to a volume of 50ml and centrifuged at 215 x g for 10 
minutes to pellet the PMNs. The cells were then re-suspended in 3 to 6 ml of PBS 
depending on the pellet size. A haemocytometer was used for counting, where 5 µl 
of the suspension was added to 495 µl of Turks stain and 10 µl was used for counting 
(Figure 2.16). 
 
 
Figure 2.16. Neubauer Haemocytometer counting grid. PMN were counted in each corner as 
illustrated.  
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The total number of PMNs was calculated using the following formula: 
 
𝑻𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒄𝒆𝒍𝒍𝒔 𝒊𝒏 𝒂𝒍𝒍 𝟒 𝒄𝒐𝒓𝒏𝒆𝒓𝒔
𝟒
 ×  𝟏𝟎𝟒  ×  𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓 = 𝒄𝒆𝒍𝒍𝒔 𝒑𝒆𝒓 𝒎𝒍   
 
Phosphate buffered solution was used to dilute the suspension to reach the desired 
concentration. 
 
2.6.2 Polymorphonuclear cells stimulation using microparticles 
PMNs isolated as above were suspended in 1ml of PBS at a concentration of 1 x 
106/ml. MP were added to the suspension at a concentration of 1 to 2 x 106/ml with 
or without lipopolysaccharide (LPS) at a final concentration of 100ng/ml. The 
suspension was incubated in a 37oC water bath for 1 hour. 
 
2.6.3 Polymorphonuclear cells adhesion molecule assay using flow-cytometry 
Following stimulation of PMNs, the cells were pelleted by centrifugation at 300 x g 
for 10 minutes. The pellet was then re-suspended in 400 µl of PBS and subsequently 
plated. The cells were then washed, re-suspended in solutions containing CD11b 
and CD62L fluorescent monoclonal antibodies (Allophycocyanin (APC) and 
Phycoerthryin-Cy5 (PE-Cy5) respectively) and incubated in the dark, on ice for 30 
minutes.  
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Following staining, the cells were washed twice and re-suspended in 200 µl of 1% 
paraformaldehyde fixative (PFA) solution ready for analysis using flow-cytometry. 
Isotype controls (IgG1) were used for accurate calibration of the flow-cytometer. 
Adhesion molecules were expressed as median florescence intensity (MFI) units in 
the respective channel. 
 
2.6.4 Polymorphonuclear cells reactive oxygen species (ROS) production 
assay 
The 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen, Paisley, UK) 
is a stable and non-fluorescent compound that easily permeates into PMNs. Once 
inside the cell, H2DCFDA is cleaved by intra-cellular enzymes into the non-
fluorescent dichlorodihydrofluorescein which is then rapidly oxidised in the presence 
of intra-cellular ROS (e.g. hydrogen peroxide) to the fluorescent 2',7'-
dichlorodihydrofluorescein. One million neutrophils suspended in 1ml of phosphate 
buffered saline were incubated with microparticles (1 – 2 x 106/ml) in the presence 
or absence of lipopolysaccharide (100ng/ml) (H2DCFDA) (Invitrogen, Paisley, UK) 
was added at a final concentration of 5μM. The suspension was then incubated in a 
37oC water bath for one hour. 
 
A 96 well plate was used for plating of the treatments. Each treatment was plated in 
quadruplicates (200 x 103 PMNs in each well). H2DCFDA; PBS with no cells was 
used as a negative control. 
 
 142 
A NOVOstar plate reader (BMH LabTech, Ortenberg, Germany) was used to detect 
the fluorescence (Excitation filter: 485 and Emission filter: 520) for each treatment in 
the 96 well plate and the results were analysed using the NOVOstar software 
package.  
 
The negative control fluorescence values were subtracted from the samples 
fluorescence. 
 
2.6.5 Polymorphonuclear cells phagocytosis assay 
Heat killed Escherichia coli strain K12 (EC1-5G, Sigma-Aldrich, Poole, UK) were 
weighed and dissolved in phosphate buffered saline at a concentration of 8 mg/ml. 
The suspension was then incubated with fluorescent boron-dipyrromethene 
(BODIPY) 576/589 (Invitrogen, Paisley, UK) at a final concentration of 1μM for 5 
minutes in the dark. Following incubation, the suspension was centrifuged at 300 x 
g for 10 minutes to pellet the fluorescent E. Coli and the supernatant containing the 
excess BODIPY was discarded. The E. Coli was then re-suspended in sterile filtered 
phosphate buffered saline at the same original concentration.   
 
A 96 well plate was used for plating the PMN. Each treatment was plated in 
quadruplicate (2 x 105 PMNs /well) in a 200μl volume. One million neutrophils 
suspended in 1ml of phosphate buffered saline were incubated with microparticles 
(1 – 2 x 106/ml) in the presence or absence of lipopolysaccharide (100ng/ml). The 
suspension was then incubated in a 37oC water bath for one hour. The supernatant 
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was subsequently discarded and the fluorescent E. Coli were then added to each 
well at a final concentration of 1 mg/ml. PMN with no E. Coli were also plated to act 
as negative control. The plate was then placed for 30 minutes in an incubator 
containing 5% CO2 at 37oC. Following incubation the supernatant was removed to 
discard the excess fluorescent E. Coli and the cells were subsequently washed twice 
with PBS.  
 
A NOVOstar plate reader (BMH LabTech, Ortenberg, Germany) was used to detect 
the fluorescence (Excitation filter: 560 and Emission filter: 590) for each treatment in 
the 96 well plate and the results were analysed using the NOVOstar software 
package. The negative control fluorescence values were subtracted from the 
samples fluorescence.  
 
2.6.6 Polymorphonuclear cells chemotaxis assay 
As described before287, a NeuroprobeChemoTx®plate96-well plate (Receptor 
Technologies Ltd, Adderbury, U.K.) with polycarbonate membrane filters and 3μm 
pores in the membrane was used for this assay (Figure 2.17). PMNs suspended in 
PBS were treated as indicated (4 x 106/ml). Formyl-Methionyl-Leucyl-Phenylalanine 
(fMLP) was used as chemo-attractant at a final concentration of 1 μM. fMLP or 
medium was added to the bottom wells (27 μl), the filters were placed on top of the 
wells and 25 μl PMNs cell suspension was added on the upper surface of the filter 
membrane in quadruplets (Figure 2.18). The plates were incubated for 60 minutes 
in a 37oC incubator containing 5% CO2.  
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Figure 2.17. Polymorph nuclear cells migration assay plate. NeuroprobeChemoTx®plate 96-well 
plate (Receptor Technologies Ltd, Adderbury, U.K.) and polycarbonate membrane filters with 3μm 
pores were used for polymorph nuclear leucocytes chemotaxis assay. Formyl-Methionyl-Leucyl-
Phenylalanine (fMLP) was used as a chemo-attractant at final concentration 1 μM. fMLP or medium 
was added to the bottom wells (27 μl), the filters were placed on top of the wells and 25μl PMNs cells 
suspension was added on the upper surface of the filter membrane in quadruplicates. 
 
 
 
Figure 2.18. Schematic for polymorph nuclear leucocytes (PMN) chemotaxis assay using 
Neuroprobe ChemoTx®plate. Formyl-Methionyl-Leucyl-Phenylalanine (fMLP) was added to the 
wells (27 μl) at a final concentration of 1 μM acting as a chemo-attractant and 3 μm pore 
polycarbonate membrane filters were placed on top of the wells. Subsequently 25 μl of the PMN 
suspension (4 x 106/ml final concentration) was placed on top of the filters. The PMNs migrated across 
the filter pores towards the fMLP.    
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Following incubation, excess cells were removed by absorption using cotton buds 
and the surface of the filter was washed with 25 μl PBS per well and subsequently 
removed. 
 
Centrifugation (312 x g for 1 minute) was used to pellet the cells. Subsequently the 
filter was removed and the cells were re-suspended. PrestoBlue® fluorescent dye 
(Life Technologies, U.K.) solution (30 μl of pre-diluted dye 1 in 5 in PBS) was mixed 
with 20 μl cells aliquots in quadruplicates in a 96-well plate. PrestoBlue® is a cell 
viability reagent which is modified by the reducing environment of the cell, turning a 
highly fluorescent red.  
 
A standard curve was constructed using 0 to 4 x 106 PMNs and processed using the 
same method as above.  
 
A NOVOstar plate reader (BMH LabTech, Ortenberg, Germany) was used to detect 
the fluorescence (Excitation filter: 530 and Emission filter: 590) and the results were 
analysed using the NOVOstar software package. The standard curve was used to 
interpolate the unknown values.  
 
2.7 Statistical analysis 
Data was expressed as mean ± standard deviation or mean ± standard error of the 
mean for normally distributed data. For mean comparisons two tailed unpaired 
Student’s t tests were used. One or Two way ANOVA was used for comparison of 
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normally distributed data and the Bonferroni test was used for column comparisons. 
When data not normally distrusted, the data was represented as median. Mann-
Whitney U, Kurskal-Wallis and Dunn’s tests were used for comparisons of this data 
as appropriate. Comparison of proportions was performed using two-tailed Fisher’s 
exact method.  
 
In all cases a p value of < 0.05 was considered statistically significant to reject the 
null hypothesis. 
 
GraphPad prism 4 for Macintosh (La Jolla, Ca, USA) was the software package used 
for statistical analysis. 
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Chapter 3: Microparticles 
characterisation in 
severe sepsis patients’ 
plasma 
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3.1: Protocol optimisation 
3.1.1 Preparation of plasma for microparticle characterisation 
This project started by performing preliminary experiments to identify the optimum 
methodology for characterising microparticles (MP) in plasma. Literature review 
revealed that several centrifugation strategies were used to produce PFP from whole 
blood for the purpose of MP characterisation288.  The most commonly used 
centrifugation protocol in studies similar to mine consisted of two steps, the first was 
centrifugation at 1500 x g for 15 minutes to produce platelet rich plasma (PRP) and 
then 13000 x g for 2 minutes to produce PFP 289, 290. When this protocol was tested 
PFP stained with anti-CD66b (PE conjugated) there was a clear separation between 
stained sample and isotype controls (Figure 3.1). Therefore this differential 
centrifugation protocol was adopted for all subsequent experiments.  
 
Figure 3.1. Representative flow-cytometry histogram of microparticles analysed in PFP of 
healthy volunteers produced through an optimized centrifugation protocol (1500 x g for 15 
minutes followed by 13000 x g for 2 minutes). Microparticles were stained within PFP (5 μl) using 
Anti-CD66b PE (93.75 ng/ml) for 30 minutes at room temperature and analysed by flow-cytometry. 
The overlaid histograms of CD66b+ microparticles and isotype control show a clear separation using 
this centrifugation protocol.  
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3.1.2 Antibody Titration 
Using blood from healthy volunteers, the optimum concentrations of each 
monoclonal antibody with relevant isotype controls were identified by titrations. Table 
3.1 lists these antibodies whilst Figure 3.2 reports the data obtained from these 
analyses. 
Monoclonal Antibody Optimum concentration 
Annexin V 200 ng/ml 
Anti-CD66b 93.75 ng/ml 
Anti-CD41 250 ng/ml 
Anti-CD14 500 ng/ml 
Anti-CD235 750 ng/ml 
Anti-CD3 375 ng/ml 
Anti-CD31 93.75 ng/ml 
Anti-CD51 500 ng/ml 
Anti-CD146 375 ng/ml 
Anti-alpha-2-macrgolobulin 500 ng/ml 
Anti-LAIR-1 90 ng/ml 
Anti-Annexin A7 187.5 ng/ml 
Table 3.1. Optimum concentrations of the monoclonal antibodies employed for microparticle 
detection. LAIR1: Leucocyte associated immunoglobulin like receptor-1. 
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Figure 3.2. Antibody titrations for the various monoclonal antibodies used for microparticle 
detection. Platelet free plasma from healthy volunteers was stained using increasing concentrations 
of the respective antibody and its isotype control. Data is expressed as microparticle count per 
microliter of plasma. A2M: Alpha-2-macroglobulin, LAIR1: Leucocyte associated immunoglobulin like 
receptor 1.  
 
 
3.1.3 Optimisation of annexin V binding to microparticles 
Calcium is required for annexin V binding to phosphatidylserine. The advice of the 
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manufacturer is to use buffer containing calcium (2.5 mM), but this advice relates to 
binding cells rather than MP. Therefore a literature review was performed, which 
revealed that annexin V binding to MP is enhanced by increasing calcium 
concentrations, noting also how the medium composition may interfere with 
binding291, 292. In preliminary experiments three different buffers containing 2.5mM 
Calcium were tested, two of which were prepared locally and one of which was 
commercially available. I could not detect any significant difference between the 
three buffers in the annexin V positive events counted (Table 3.2). 
Table 3.2. Various media and commercial 
Annexin V binding buffers showing no 
significant difference in the number of 
Annexin V positive events. Platelet free 
plasma from healthy volunteers was used for this 
experiment. Annexin V was used for staining at 
200 ng/ml final concentration and events were 
detected using flow-cytometry.  Data are expressed as micropartricle count per microliter of platelet 
free plasma. PBS: Phosphate buffered saline solution.  
 
In the next series of preliminary experiments the commercially available annexin V 
buffer (10x) containing 25 mM calcium was used to test if increasing the calcium 
concentration in the medium would increase annexin V binding. The following 
concentration of calcium: 2.5, 5, 15, 20 and 25mM were tested. The results showed 
that higher calcium concentration in the buffer enhanced the total count of annexin 
V positive events (Table 3.3).  
 
Medium Annexin V+ events 
PBS + CaCl2 2.5mM 461 / μl 
Hanks + CaCl2 2.5mM 472 / μl 
Commercial annexin V  
binding buffer  
458 / μl 
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Table 3.3. Titration of calcium concentration 
and the resulting annexin V positive events 
demonstrating an increase in count with 
increasing calcium concentration. Platelet 
free plasma from healthy volunteers was used 
for this experiment. Annexin V was used for 
staining at 200ng/ml final concentration and 
events were detected using flow-cytometry.  
Data is expressed as microparticle count per 
microliter of platelet free plasma. 
 
3.1.4 Effect of anticoagulant on annexin V binding 
The anticoagulant used when the blood is collected could interfere with the positive 
effect of calcium on annexin V. Heparin has been previously found to bind and inhibit 
the uptake of MP293 and thus its use as an anticoagulant in MP studies is 
discouraged by the international society for extra-cellular vesicles294. In preliminary 
experiments the effect of the three most commonly used anticoagulants (sodium 
citrate, heparin and ethylenediaminetetraacetic acid (EDTA)) were tested on the 
number of annexin V events detected in healthy volunteers’ plasma (Figure 3.3). 
Interestingly, only heparin seemed to suppress annexin V binding to MP even 
though, unlike sodium citrate and EDTA heparin is not known to bind to calcium.  
Figure 3.3. The effect of 
commonly used 
anticoagulants on annexin V 
binding to microparticles. 
Blood from healthy volunteers 
(n=21) was anticoagulated 
using 3.2% sodium citrate, 15% 
ethylenediaminetetra acetic 
(EDTA) or heparin (17 
units/ml). Platelet free plasma 
was was incubated with 
annexin V for 30 minutes at 
room temperature. Annexin V 
positive microparticles were 
counted using flow-cytometry. 
Data is expressed as 
microparticle count per 
microliter of platelet free plasma. Data compared using Kurskal-Wallis test and Dunn’s comparisons. 
**: p < 0.01 
Calcium concentration Annexin V+ 
events 
2.5 mM 458 / μl 
5 mM 399 / μl 
10 mM 1584 / μl 
15 mM 15762 / μl 
20 mM 16213 / μl 
25 mM 16817 / μl 
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3.2 Characterisation of microparticles in plasma from 
patient with severe sepsis 
 
 
3.2.1 Patient characteristics 
 
One hundred patients recruited to the Genomic Advances in Sepsis (GAinS) study 
with severe sepsis due to community-acquired pneumonia (CAP) or faecal peritonitis 
(FP) were included in this study. By selection, half of each cohort survived beyond 
28 days. 
 
The baseline demographic characteristics, comorbidities, severity scores and cell 
counts on admission to intensive care unit were comparable between both patients’ 
cohorts (Table 3.4). Healthy volunteers (HV) were significantly younger than both 
patient groups and their PMN count was significantly lower, while the HV 
lymphocytes were significantly higher in HV than in both patient groups. 
 
When comparing CAP non-survivors to survivors of the CAP cohort, the non-
survivors were older and had higher severity scores on admission (Table 3.5). 
Similarly, the FP non-survivors were also significantly older and had higher severity 
scores compared to FP survivors (Table 3.6).  
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 Community acquired 
pneumonia (n=60) 
Faecal Peritonitis 
(n=40) 
Healthy volunteers 
Age in years mean ± SD  64.4 ± 16.3  68.6 ± 17.2  40.2 ± 14.7 *** 
Gender F/M ratio 25/35 20/20 5/5 
Comorbidities 
Cardiovascular 
1. Angina, n (%)  
2. Arrhythmia, n (%) 
3. Valvular, n (%) 
4. MI, n (%) 
5. CHF, n (%) 
6. PVD, n (%) 
Respiratory 
7. Asthma, n (%) 
8. COPD, n (%) 
Neurological 
9. Stroke, n (%) 
10. Dementia, n (%) 
Rheumatological 
11. RA, n (%) 
12. SLE, n (%) 
Gastrointestinal, n (%) 
Diabetes Mellitus, n (%) 
Renal, n (%) 
Malignancy, n (%) 
 
 
5 (8.3%) 
5 (8.3%) 
1 (1.7%) 
6 (10%) 
4 (6.7%) 
0 
 
5 (8.3%) 
16 (26.7%) 
 
2 (3.3%) 
0 
 
3 (5%) 
0 
4 (6.7%) 
11 (18.3%) 
4 (6.7%) 
6 (10%) 
 
 
4 (10%) 
4 (10%) 
2 (5%) 
0 
1 (2.5%) 
2 (5%) 
 
2 (5%) 
6 (15%) 
 
3 (7.5%) 
0 
 
0 
0 
5 (12.5%) 
9 (22.5%) 
3 (7.5%) 
9 (22.5%)  
 
 
 
Causative organism 
1. S. pneumoniae, n 
2. S. aureus, n 
3. H. influenza, n 
4. E. coli, n 
5. Legionella, n 
6. Viral, n 
7. Unknown, n 
 
14 
2 
3 
1 
2 
2 
36 
  
Severity score on admission 
mean ± SD 
1. APACHE II 
2. SOFA 
 
 
18 ± 5.8 
8 ± 4 
 
 
17 ± 6.8 
9 ± 4.3 
 
 
 
Cell count on admission 
mean ± SD  
1. PMN x 109/L 
2. Monocytes x 109/L 
3. Lymphocytes x 109/L 
4. Platelets x 109/L 
 
 
12.1 ± 6.6 
0.63 ± 0.52 
0.76 ± 0.54 
205 ± 119.7 
 
 
9.6 ± 7.4 
0.54 ± 0.55 
0.75 ± 0.47 
211 ± 128.6 
 
 
3.2 ± 1.3 *** 
0.85 ± 0.68 
1.36 ± 0.68 ** 
238 ± 60.4 
Table 3.4. Baseline patient parameters on admission to intensive care. Continuous variable were 
expressed as mean ± standard deviation (SD) and two-tail unpaired Student t test or one-way ANOVA 
was used to compare the means. Quantities are expressed as ratio or percentage and compared 
using Fischer’s exact method. Differences are considered statistically significant when p < 0.05. 
APACHE II: acute physiological and chronic health evaluation II, COPD: Chronic obstructive 
pulmonary disease, CHF: congestive heart failure, E. coli: Escherichia coli, H. influenza: Haemophilus 
influenza, MI: myocardial infarction, NS: not significant, PMN: polymorph-nuclear leucocytes, PVD: 
peripheral vascular disease, RA: rheumatoid arthritis, S. aureus: staphylococcus aureus, S. 
pneumonia: streptococcal pneumoniae, SLE: systemic lupus erythematosus. P < 0.05 was 
considered statistically significant. *: p < 0.05, **: p < 0.01, ***: p < 0.001.  
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 Non-survivors of community 
acquired pneumonia (n=30) 
Survivors of community 
acquired pneumonia (n=30) 
Age in years mean ± SD  70.26 ± 14.07 * 58.3 ± 16.74 
Gender F/M ratio 9/21 16/14 
Comorbidities 
Cardiovascular 
5. Angina, n (%)  
6. Arrhythmia, n (%) 
7. Valvular, n (%) 
8. MI, n (%) 
9. CHF, n (%) 
10. PVD, n (%) 
Respiratory 
11. Asthma, n (%) 
12. COPD, n (%) 
Neurological 
13. Stroke, n (%) 
14. Dementia, n (%) 
Rheumatological 
15. RA, n (%) 
16. SLE, n (%) 
Gastrointestinal, n (%) 
Diabetes Mellitus, n (%) 
Renal, n (%) 
Malignancy, n (%) 
 
 
3 (10%) 
5 (16.7%) 
1 (3.3%) 
3 (10%) 
3 (10%) 
0 
 
5 (16.7%) 
0 
 
2 (6.7%) 
0 
 
1 (3.3%) 
0 
1 (3.3%) 
6 (20%) 
2 (6.7%) 
2 (6.7%) 
 
 
2 (6.7%) 
0 
0 
3 (10%) 
1 (3.3%) 
0 
 
11 (36.7%) 
5 (16.7%) 
 
0 
0 
 
2 (6.7%) 
0 
3 (10%) 
5 (16.7%) 
2 (6.7%) 
4 (13.3%) 
Causative organism 
17. S. pneumoniae, n 
18. S. aureus, n 
19. H. influenza, n 
20. E. coli, n 
21. Legionella, n 
22. Viral, n 
23. Unknown, n 
 
10 (33.3%) 
2 (6.7%) 
0 
1 (3.3%) 
0 
2 (6.7%) 
15 (50%) 
 
4 (13.3%) 
0 
3 (10%) 
0 
2 (6.7%) 
0 
21 (70%) 
Severity score on admission mean 
± SD 
24. APACHE II 
25. SOFA 
 
 
21 ± 6.37 
9.19 ± 4.24 
 
 
16.43 ± 4.2 ** 
6.93 ± 3.47 * 
Cell count on admission mean ± 
SD  
26. PMN x 109/L 
27. Monocytes x 109/L 
28. Lymphocytes x 109/L 
29. Platelets x 109/L 
 
 
10.23 ± 6.9 
0.54 ± 0.42 
0.68 ± 0.54 
198.5 ± 137.1 
 
 
13.61 ± 6.0 
0.71 ± 0.59 
0.96 ± 0.57 
212.5 ± 100.6 
Table 3.5. Baseline community acquired pneumonia patient (non-survivors and survivors) 
demographics on admission to intensive care. Continuous variables are expressed as mean ± 
standard deviation (SD) and two-tail unpaired Student t test is used to compare the means. Quantities 
are expressed as ratio or percentage and compared using Fischer’s exact method. Differences are 
considered statistically significant when p < 0.05. APACHE II: acute physiological and chronic health 
evaluation II, COPD: Chronic obstructive pulmonary disease, CHF: congestive heart failure, E. coli: 
Escherichia coli, H. influenza: haemophilus influenza, MI: myocardial infarction, NS: not significant, 
PMN: peripheral mononuclear leucocytes, PVD: peripheral vascular disease, RA: rheumatoid 
arthritis, S. aureus: staphylococcal aureus, S. pneumonia: streptococcus pneumoniae, SLE: systemic 
lupus erythematosus. P < 0.05 was considered statistically significant. *: p < 0.05, **: p < 0.01, ***: p 
< 0.001. 
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 Non-survivors of faecal 
peritonitis 
Survivors of faecal peritonitis 
Age in years mean ± SD  74.4 ± 15.77 * 62.7 ± 16.92 
Gender F/M ratio 9/11 11/9 
Comorbidities 
Cardiovascular 
30. Angina, n (%)  
31. Arrhythmia, n (%) 
32. Valvular, n (%) 
33. MI, n (%) 
34. CHF, n (%) 
35. PVD, n (%) 
Respiratory 
36. Asthma, n (%) 
37. COPD, n (%) 
Neurological 
38. Stroke, n (%) 
39. Dementia, n (%) 
Rheumatological 
40. RA, n (%) 
41. SLE, n (%) 
Gastrointestinal, n (%) 
Diabetes Mellitus, n (%) 
Renal, n (%) 
Malignancy, n (%) 
 
 
3 (7.5%) 
2 (5%) 
2 (5%) 
0 
1 (2.5%) 
0 
 
1 (2.5%) 
2 (5%) 
 
2 (5%) 
0 
 
0 
0 
4 (10%) 
4 (10%) 
0 
6 (15%) 
 
 
1 (2.5%) 
2 (5%) 
0 
0 
0 
2 (5) 
 
1 (2.5%) 
4 (10%) 
 
1 (2.5%) 
0 
 
0 
0 
1 (2.5) 
4 (10%) 
3 (7.5%) 
3 (7.5%) 
Severity score on admission mean 
± SD 
42. APACHE II 
43. SOFA 
 
 
21.53 ± 7.13 
9.4 ± 3.25 
 
 
13.8 ± 3.72 *** 
4.9 ± 2.88 *** 
Cell count on admission mean ± 
SD  
44. PMN x 109/L 
45. Monocytes x 109/L 
46. Lymphocytes x 109/L 
47. Platelets x 109/L 
 
 
8.64 ± 8.17 
0.48 ± 0.63 
0.69 ± 0.42 
172.2 ± 99 
 
 
10.59 ± 6.51 
0.61 ± 0.47 
0.81 ± 0.52 
250.2 ± 144.6 
Table 3.6. Baseline faecal peritonitis patient (non-survivors and survivors) demographics on 
admission to intensive care. Continuous variables are expressed as mean ± standard deviation 
(SD) and two-tail unpaired Student t test is used to compare the means. Quantities are expressed as 
ratio or percentage and compared using Fischer’s exact method. Differences are considered 
statistically significant when p < 0.05. APACHE II: acute physiological and chronic health evaluation 
II, COPD: Chronic obstructive pulmonary disease, CHF: congestive heart failure, MI: myocardial 
infarction, NS: not significant, PMN: peripheral mononuclear leucocytes, PVD: peripheral vascular 
disease, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus. P < 0.05 was considered 
statistically significant. *: p < 0.05, **: p < 0.01, ***: p < 0.001. 
 
 
3.2.2 Effect of severe sepsis on plasma microparticles at day 1 post admission 
to ICU 
 
MP were measured in platelet free plasma of all three cohorts (CAP, FP and HV). 
The plasma was collected on day 1 of admission to intensive care and the MP were 
characterised according to their cell of origin. Following quantification of the MP 
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according to their cells of origin using reliable markers, secondary staining was also 
performed to attempt further stratification. Thus, MP derived from blood cells were 
further characterised according to their expression of the protein alpha-2-
macroglobulin (A2M) as we have previously in found in a small cohort of CAP severe 
sepsis patients that plasma levels of granulocyte derived MP expressing A2M were 
higher in survivors191. Here a larger cohort of CAP patients was examined and 
compared to another cohort of patients with severe sepsis secondary to FP as well 
as to HV. Also, the profiles of MP expressing A2M derived from other blood cells 
(monocytes, lymphocyte, platelets and erythrocytes) was investigated as well as 
examining the total population of A2M MP from all sources. 
 
Even though there was no significant difference in granulocyte counts between the 
three cohorts, granulocyte MP (620±101/μl) were significantly higher in CAP 
compared to FP (34±7/μl) and HV (11±3/μl) with p < 0.001. Monocyte and 
lymphocyte count was observed to be lower in CAP and FP compared to HV, despite 
that MP number derived from these two cell lines was significantly higher in CAP 
(112±67/µl, 130±42/μl) compared to the other two cohorts (p <0.001), while FP 
(9±8/µl, 46±7/μl) numbers were not significantly different in comparison to HV 
(3±1/μl, 83±14/μl) with p of < 0.001.   Platelet and erythrocyte MP numbers did not 
vary significantly between the cohorts, but there was trend towards higher numbers 
in CAP (2370±1473/μl, 249±369/μl) and FP (1020±955/μl, 160±40/μl) in comparison 
to HV (2027±486/μl, 155±39/μl). MP derived from endothelial cells was significantly 
elevated in CAP patients (142±121/μl) compared to HV (52±5/μl), while in FP there 
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was a trend towards higher count (103±22/μl) but it did not reach significance.  There 
was some overlap between CAP and FP in the endothelial MP numbers (Figure 3.4). 
This would suggest that MP numbers does not directly correlate to the number of 
their cell of origin but perhaps to these cells state of activation.  It was also observed 
that, even though monocytes and lymphocytes were lower in number, they produced 
more MP relative to their number (Table 3.4) compared to granulocytes suggesting 
that monocytes and lymphocytes were more efficient in producing MP. 
 
MP were then further characterised according not only to their cell of origin and but 
also according to their A2M expression. CAP had a significantly higher number of 
A2M+ MP (371±137/μl) from all sources compared to FP (90±22/μl) and HV 
(107±17/μl) with p value < 0.01 and < 0.001 respectively. There was some overlap 
between CAP and FP in the total A2M+ MP numbers despite the significant 
difference.  The profile observed in granulocyte, monocyte and lymphocyte MP was 
replicated here where the A2M+ MP derived from these cells was significantly higher 
in CAP (11±10/μl, 9±21/μl, 35±48/μl) compared to the other FP (3±1/μl, 1±1/μl, 
1±6/μl) and HV (3±1/μl, 0±0/μl, 0±1/μl) despite some overlap. Interestingly, A2M+ MP 
derived from platelets and erythrocyte were also significantly higher in CAP 
(62±22/μl, 54 ±46/μl) compared to FP (9±3/μl, 5±13/μl) and HV (8±2/μl, 4±2/μl) 
despite the lack of significant difference between MP subsets (positive and negative 
for A2M) derived from these cells (Figure 3.5). Also, A2M+ MP number from all 
sources was higher than cell derived A2M+ MP characterised here suggesting that 
A2M+ MP were derived from sources other the cell sources described here. 
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Figure 3.4. Microparticle subsets in patient with severe sepsis secondary to community 
acquired pneumonia or faecal peritonitis and in healthy volunteers at day 1 post admission to 
ICU. Platelet free plasma from all three cohorts was obtained by differential centrifugation of whole 
blood. The plasma (5 μL per test) was incubated with cell specific fluorochrome conjugated 
monoclonal antibodies as indicated and annexin V for half an hour at room temperature and the 
reaction was stopped by adding binding buffer up to a volume of 200 μL. The samples were 
subsequently acquired using flow-cytometry. Kruskal-Wallis and Dunn’s tests were used for 
comparisons. AV: annexin V, CAP: community acquired pneumonia, FP: faecal peritonitis, HV: 
healthy volunteers, MP: microparticles. *: p < 0.05, **: p< 0.01. ***: p < 0.001.  
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Figure 3.5. Number of alpha-2-macroglobulin positive microparticles in patients severe sepsis 
secondary to community acquired pneumonia or faecal peritonitis and in healthy volunteers 
at day 1 post admission to ICU. Platelet free plasma from all three cohorts was obtained by 
differential centrifugation of whole blood. The plasma (5 μL per test) was incubated with anti alpha-
2-macroglobulin monoclonal antibody with or without cell specific fluorochrome conjugated 
monoclonal antibodies as indicated and annexin V for half an hour at room temperature. The reaction 
was stopped by adding binding buffer up to a volume of 200 μL. The samples were then acquired 
using flow-cytometry. The results are expressed as microparticles count / μL of platelet free plasma.  
Kruskal-Wallis and Dunn’s tests were used for comparison. A2M: alpha-2-macroglobulin, AV: annexin 
V, CAP: community acquired pneumonia, FP: faecal peritonitis, HV: healthy volunteers, MP: 
microparticles. *: p < 0.05, **: p< 0.01. ***: p < 0.001. 
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3.2.3 Association between plasma microparticle subsets at day 1 post 
admission to ICU and mortality in severe sepsis secondary to community 
acquired pneumonia 
 
Next the CAP cohort was divided into non-survivors and survivors; patients were 
considered survivors when they were alive at 28 days post admission to ICU. Then 
cell derived MP subsets of these two cohorts were compared. Granulocyte MP was 
higher in survivors (694±120/μl) compared to non-survivors (528±122/μl) despite no 
difference in their cell of origin (Table 3.5), but this trend did not reach significance. 
On the other hand, endothelial MP (AV+/CD51+) was found to be significantly higher 
in non-survivors (173±203/μl) compared to survivors (113±144/μl) with a p < 0.05. 
The comparison revealed no significant difference in the other MP subsets (Figure 
3.6).  
 
The number of A2M+ MP from all sources was significantly higher in survivors 
(541±213/μl) compared to non-survivors (254±148/μl) with a p < 0.05. Granulocyte 
and monocyte derived A2M+ MP were also significantly higher in survivors (14±17/μl, 
37±35/μl) compared to non-survivors (6±9/μl, 5±4/μl) with p values < 0.01 and < 0.01 
respectively. There was no difference in the number of MPs positive for A2M derived 
from lymphocytes, platelets or erythrocytes between survivors (16±57/μl, 62±20/μl, 
27±72/μl) and non-survivors (51±84/μl, 61±36/μl, 66±45/μl) (Figure 3.7).  
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Figure 3.6. Microparticle subsets in patient in with severe sepsis secondary to community 
acquired pneumonia 28 day non-survivors compared to survivors at day 1 post admission to 
ICU. Platelet free plasma from the two cohorts was obtained by differential centrifugation of whole 
blood. The plasma (5 μL) was incubated with cell specific fluorochrome conjugated monoclonal 
antibodies as indicated and annexin V for half an hour at room temperature. The reaction was stopped 
by adding binding buffer up to a volume of 200 μL. The samples were subsequently acquired using 
flow-cytometry. The results are expressed as microparticle count/μL of platelet free plasma. Mann 
Whitney test was used for comparisons.  AV: annexin V, MP: microparticles. *: p < 0.05. 
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Figure 3.7. Number of alpha-2-macroglobulin positive microparticles in patients with severe 
sepsis secondary to community acquired pneumonia 28 day non-survivors compared to 
survivors at day 1 post admission to ICU. Platelet free plasma from the two cohorts was obtained 
by differential centrifugation of whole blood. The plasma (5 μL per test) was incubated with cell 
specific fluorochrome conjugated monoclonal antibodies as indicated and annexin V for half an hour 
at room temperature. The reaction was stopped by adding binding buffer up to a volume of 200 μL. 
The samples were subsequently acquired using flow-cytometry. The results are expressed as 
microparticles count/μL of platelet free plasma. Mann Whitney test was used for comparisons. A2M: 
alpha-2-macroglobulin, AV: annexin V, MP: microparticles. *: p < 0.05, **: p < 0.01. 
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3.2.4 Association between plasma microparticle subsets at day 1 post 
admission to ICU and outcome in severe sepsis secondary to faecal peritonitis 
Patients who did not survive severe sepsis secondary to FP had significantly higher 
levels of granulocyte MP (81±28/μl) in comparison to those who survived the disease 
(28±9/μl) with a p < 0.01 (Figure 3.8). Interestingly, erythrocyte derived MP was also 
significantly higher in non-survivors (231±58/μl) compared to survivors (107±55/μl) 
with a p < 0.05. Granulocyte count did not vary between both cohorts (Table 3.6). 
Erythrocyte A2M+ MP was significantly higher in non-survivors (10±11/μl) compared 
to survivors (2±11/μl) with a p < 0.05. Platelet derived A2M+ MP showed a trend 
towards a higher count in non-survivors, but this did not reach statistical significance 
(Figure 3.9). Here also, there was no difference between cells of origin between FP 
severe sepsis non-survivors and survivors (Table 3.6).   
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Figure 3.8. Microparticle subsets in patient in with severe sepsis secondary to faecal 
peritonitis 28 day non-survivors compared to survivors at day 1 post admission to ICU. Platelet 
free plasma from the two cohorts was obtained by differential centrifugation of whole blood. The 
plasma (5 μL) was incubated with cell specific fluorochrome conjugated monoclonal antibodies as 
indicated and annexin V for half an hour at room temperature. The reaction was stopped by adding 
binding buffer up to a volume of 200 μL. The samples were subsequently acquired using flow-
cytometry. The results are expressed as microparticle count/μL of platelet free plasma. Mann Whitney 
test was used for comparisons.  AV: annexin V, MP: microparticles. *: p < 0.05, **: p < 0.01. 
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Figure 3.9. Number of alpha-2-macroglobulin positive microparticles in patients with severe 
sepsis secondary to faecal peritonitis 28 day non-survivors compared to survivors at day 1 
post admission to ICU. Platelet free plasma from the two cohorts was obtained by differential 
centrifugation of whole blood. The plasma (5 μL per test) was incubated with cell specific 
fluorochrome conjugated monoclonal antibodies as indicated and annexin V for half an hour at room 
temperature. The reaction was stopped by adding binding buffer up to a volume of 200 μL. The 
samples were subsequently acquired using flow-cytometry. The results are expressed as 
microparticles count/μL of platelet free plasma. Mann Whitney test was used for comparisons. A2M: 
alpha-2-macroglobulin, AV: annexin V, MP: microparticles. *: p < 0.05. 
 
 
 
 167 
3.2.5 Sequential changes in plasma microparticle subsets in patients with 
severe sepsis secondary to community acquired pneumonia; comparison 
between 28 day non-survivors and survivors  
 
Subsequently, sequential changes in cell derived MP concentrations in non-
survivors and survivors of severe sepsis secondary to community acquired 
pneumonia were examined. The results initially did not show clear trends, but when 
the numbers were log transformed clearer trends started to emerge. At day 1, 
survivors had a significantly higher granulocyte MP count a difference which 
persisted at day 3 and day 5. Although, the non-survivors had a higher lymphocyte 
MP count at day 1, this difference did not persist over the subsequent two time 
points. One subset of endothelial MP (AV+/CD51+) was higher in non-survivors at 
day 1 and day 5, although at day 3 this subset of MP was almost identical between 
the two cohorts (Figure 3.10). 
 
When MP were further characterized according to alpha-2-macroglobulin expression 
a clearer picture emerged. Survivors had a higher count of total alpha-2-
macroglobulin MP, as well as granulocyte and monocyte MP expressing A2M across 
all the time points, while the other MP subsets did not vary between the two cohorts 
at any time point (Figure 3.11).  
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Figure 3.10. Sequential changes in microparticle subsets in patients with severe sepsis 
secondary to community acquired pneumonia; comparison between 28 day non-survivors and 
survivors. Platelet free plasma from the two cohorts was obtained by differential centrifugation of 
whole blood collected at day 1, day 3 and day 5 post admission to ICU. The plasma (5 μL per test) 
was incubated with cell specific fluorochrome conjugated monoclonal antibodies as indicated and 
annexin V for half an hour at room temperature and the reaction was stopped by adding binding buffer 
up to a volume of 200 μL (n=60). Non-survivors: Day 1 (n=30), Day 3 (n=25), Day 5 (n=13), Survivors 
Day 1, 3, 5 (n=30). The samples were subsequently acquired using flow-cytometry. The results were 
log transformed and compared using unpaired t test. AV: annexin V, MP: microparticles, *: p < 0.05. 
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Figure 3.11. Sequential changes in microparticle subsets expressing alpha-2-macroglobulin 
in patients with severe sepsis secondary to community acquired pneumonia; comparison 
between 28 day non-survivors and survivors. Platelet free plasma from the two cohorts was 
obtained by differential centrifugation of whole blood collected at day 1, day 3 and day 5 post 
admission to ICU. The plasma (5 μL per test) was incubated with cell specific fluorochrome 
conjugated monoclonal antibodies as indicated, anti alpha-2-macroglobulin antibody and annexin V 
for half an hour at room temperature and the reaction was stopped by adding binding buffer up to a 
volume of 200 μL (n=60). Non-survivors: Day 1 (n=30), Day 3 (n=25), Day 5 (n=13), Survivors Day 
1, 3, 5 (n=30). The samples were subsequently acquired using flow-cytometry. The results were log 
transformed and compared using unpaired t test. A2M: alpha-2-macroglobulin. AV: annexin V, MP: 
microparticles, *: p < 0.05, **: p < 0.01. 
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In summary, these result demonstrate that cell derived MP and A2M+ MP profiles 
differed significantly between CAP and FP patients at day 1 post admission to ICU. 
CAP patients had significantly higher granulocyte, monocyte and lymphocyte 
derived MP compared to FP and HV at day 1, while FP patients MP profile was not 
significantly different comparted to HV. CAP patients also had a higher A2M+ MP 
compared to FP and HV at day 1 post admission. 
 
When each cohort was divided into survivors and non-survivors comparisons at day 
1 revealed that endothelial MP were significantly higher in non-survivors of CAP 
while total A2M+ MP, granulocyte derived A2M+ MP and monocyte derived A2M+ MP 
were higher in survivors of CAP. In FP, granulocyte and erythrocyte derived MP were 
significantly higher in non-survivors of FP as well as erythrocyte A2M+ MP were also 
significantly higher in non-survivors. 
 
Endothelial MP remained significantly raised in non-survivors of CAP at day 5 post 
admission to ICU. Total A2M+ MP, granulocyte A2M+ MP and monocyte A2M+ MP 
were consistently raised in CAP survivors across day 1, 3 and 5 post admission to 
ICU. 
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Chapter 4: The effect of 
granulocyte macrophage 
colony stimulating factor 
(GM-CSF) and interferon-
gamma (IFN-γ) on whole 
blood microparticles 
phenotype 
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GM-CSF and IFN-γ have been tested as adjuvant therapies in severe sepsis and 
their immune-stimulating effects are similar to the effects we previously found for MP 
expressing alpha-2-macroglobulin (A2M+ MP)191, 254. Therefore, in this project the 
effects of whole blood stimulation with GM-CSF and IFN-γ were examined to 
establish whether they could modulate A2M+ MP production. The functional activities 
of the MP produced in this way were tested using human umbilical vein endothelial 
cells and neutrophils. 
 
4.1 Concentration response and time course for microparticle production from 
whole blood stimulated with granulocyte-macrophage colony stimulating 
factor or interferon-γ.  
To test the effects of GM-CSF and IFN-γ on production of A2M+MP, whole blood 
obtained from healthy volunteers was incubated with increasing concentrations of 
these immune stimulants, above and below the concentrations used previously to 
produce MP192 (10, 50 or 100 ng/ml) and subsequently measured A2M+MP at 
various time points (30, 60, or 180 min). Vehicle was used as control. GM-CSF 
produced the highest number of A2M+MP when whole blood was incubated with 100 
ng/ml for 30 minutes, while incubation with IFN-γ 50 ng/ml for 180 minutes produced 
the highest number of MP. The experiments were repeated at the selected time 
points and concentration ranges to ensure reproducibility (Figure 4.1). 
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Figure 4.1. Effect of whole blood stimulation with either granulocyte macrophage colony-
stimulating factor (GM-CSF) or interferon-γ (IFN-γ) on the number of microparticles expressing 
alpha-2-macroglobulin (A2M+MP). Whole blood obtained from healthy volunteers was incubated at 
37oC with or without GM-CSF or IFN-γ using increasing concentrations (10, 50 or 100 ng/ml). The 
number of A2M+MP was determined at various time points (30, 60 or 180 min). Differential 
centrifugation was employed to produce platelet free plasma from whole blood, which was 
subsequently stained with Annexin V and anti-alpha-2-macroglobulin antibody and processed using 
flow-cytometry. Experiments were repeated at the identified time points to ensure reproducibility. A: 
Effect of increasing concentrations of GM-CSF at various time points on A2M+MP production from 
whole blood (n=1). B: Effect of increasing concentrations of GM-CSF at 30 minutes (n=4). C: Effect 
of increasing concentrations of IFN-γ at various time points on A2M+MP production from whole blood 
(n=1). D: Effect of increasing concentrations of IFN-γ at 180 minutes (n=4). Data are expressed as 
microparticles count per microliter for platelet free plasma. Values are compared with these previously 
found in plasma of healthy volunteers. Kruskal-Wallis and Dunn’s tests were used for comparisons. 
Ctrl: control, HV: healthy volunteers *: p<0.05, ***: p<0.001. 
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4.2 Identification of cell specific microparticles generated from whole blood 
stimulated with granulocyte macrophage colony-stimulating factor or 
interferon-γ.  
As GM-CSF and IFN-γ have been and continue to be tested as adjuvant therapies 
in severe sepsis133, 168, in this project it was aimed to establish whether these 
cytokines modulate MP phenotype upon addition to human whole blood. In the 
previous set of experiments, it was demonstrated that GM-CSF and IFN-γ enhance 
the production of MP expressing A2M from whole blood as well as defining the 
optimum concentration and incubation time. Subsequently, the effect of these two 
agents at the identified concentration and incubation period on blood cell MP profiles 
as well as the cellular origin of the A2M+ MP cellular origin was examined.   
 
Whole blood aliquots from healthy volunteers was incubated with GMCSF (100 ng/ml 
for 30 min) or IFN-γ (50 ng/ml for 180 minutes) and MP were characterised according 
to their cell of origin and A2M expression. In these experiments stimulation with GM-
CSF and IFN-γ led to a significant increase in the number of granulocyte and 
monocyte MP and a trend towards increase in the number of lymphocyte and 
erythrocyte MP which did not reach statistical significance (Figure 4.2). When MP 
were characterised according to their cell of origin and A2M expression, both GM-
CSF and IFN-γ produced more granulocyte, monocyte, erythrocyte and platelet MP 
expressing A2M, while IFN-γ produced more lymphocyte derived A2M+MP 
compared to control (Figure 4.3). 
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Figure 4.2. Identification of cell-specific microparticles in whole blood following stimulation 
with granulocyte macrophage colony-stimulating factor (GM-CSF) or interferon-γ (IFN-γ). 
Whole blood aliquots obtained from healthy volunteers were incubated at 37oC with or without GM-
CSF or IFN-γ (100 ng/ml for 30 min, 50 ng/ml for 180 min respectively). Differential centrifugation was 
employed to produce platelet free plasma from whole blood, which was subsequently stained with 
annexin V and cell specific monoclonal antibodies for granulocytes, monocytes, lymphocytes, 
erythrocytes and platelet (CD66b, CD14, CD3, CD235, CD41 respectively) and processed using flow-
cytometry (n=6). Data are expressed as microparticle count per microliter of platelet free plasma. 
Kruskal-Wallis and Dunn’s tests were used for comparisons.  GM-CSF: granulocyte macrophage 
colony-stimulating factor, IFN-γ: interferon-γ, MP: microparticles. *: p<0.05, **: p<0.01. 
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Figure 4.3. Identification of cell-specific microparticles positive for alpha-2-macroglobulin 
(A2M) in whole blood following stimulation with granulocyte macrophage colony-stimulating 
factor (GM-CSF) or interferon-γ (IFN-γ). Whole blood obtained from healthy volunteers was 
incubated at 37oC with or without GM-CSF or IFN-γ (100 ng/ml for 30 min, 50 ng/ml for 180 min 
respectively). Differential centrifugation was employed to produce platelet free plasma from whole 
blood, which was subsequently stained with annexin V, cell specific monoclonal antibodies for 
granulocytes, monocytes, lymphocytes, erythrocytes and platelet (CD66b, CD14, CD3, CD235, CD41 
respectively) and anti-A2M antibody and processed using flow-cytometry (n=6 experiments with 
distinct donors run in triplicates). Data are expressed as microparticle count per microliter of platelet 
free plasma. Kruskal-Wallis and Dunn’s tests were used for comparison. A2M: alpha-2-
macroglobulin, GM-CSF: granulocyte macrophage colony-stimulating factor, IFN-γ: interferon-γ, MP: 
microparticles. *: p<0.05, **: p<0.01. 
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4.3 Microparticle uptake by human umbilical vein endothelial cells (HUVEC) 
The endothelium plays an integral role in homeostasis and is an essential element 
in the host’s defence against invading pathogens. In severe sepsis, the endothelium 
becomes severely dysfunctional. Because the endothelium may be the 
microenvironment in which GM-CSF and IFN-γ exert some of their actions, Iit was 
examined whether HUVEC would take up MP derived from whole blood stimulated 
with these agents. Whole blood MP were collected, concentrated and stained using 
boron-dipyrromethene (BODIPY). The MP (1 – 2 x 106/ml) were subsequently 
incubated with HUVEC (5 x 105) for 4 hours. In some cases, HUVECs were pre-
treated with cytochalasin B (10 μM) to inhibit their endocytic pathways before adding 
the fluorescent MP. In addition unstained MP were also incubated with HUVEC to 
act as a control for baseline fluorescence. Cells were examined using imaging flow-
cytometry to determine the percentage of HUVEC which had engulfed MP and also 
the level of fluorescent staining.  
 
More than 85% of HUVEC incubated with labelled MP were FITC positive, whereas 
only 15% of HUVEC pre-treated with cytochalasin B were positive. HUVEC 
incubated with control MP which exhibited almost no fluorescence (0.05%).  
 
The same pattern was observed when the fluorescence intensity was measured 
indicating that HUVEC uptake of MP was maximal without cytochalasin B (Figure 
4.4).   
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Figure 4.4. Human umbilical vein endothelial cells (HUVEC) uptake of microparticles. Whole 
blood from healthy volunteers was incubated with GM-CSF (100 ng/ml) for 30 minutes at 37oC and 
platelet free plasma was obtained by differential centrifugation. Microparticles were pelleted and 
washed with phosphate buffered saline (PBS) twice and re-suspended in 1/10th of the original plasma 
volume in PBS. The microparticle (MP) concentrate was stained with fluorescein isothiocyanate 
(FITC) labelled boron-dipyrromethene (BODIPY) for 15 minutes and subsequently the MP were 
pelleted and re-suspended in PBS to wash off excess dye. The FITC+ MP were incubated with 
HUVEC (5 x 105) at a concentration of 1 – 2 x 106 /ml in 6 well plates. The cells were incubated for 4 
hours at 37oC with 5% CO2. The cells were then trypsinised, fixed, suspended in PBS and processed 
using imaging flow-cytometry. Another set of HUVEC were pre-treated for 10 minutes with 10 μM 
cytochalasin B to inhibit phagocytosis and subsequently treated as above. Another group of HUVEC 
cells were incubated with unstained microparticles to act as control (n=3). A. HUVEC uptake of FITC 
fluorescent MP (% of positive cells). B. Fluorescence intensity of the FITC+ HUVEC treated with FITC 
stained MP. The results are expressed as mean ± SEM of n=4 experiments performed in triplicates 
of median fluorescence intensity units as quantified by flow-cytometry. One way ANOVA and 
Bonferroni tests were used for comparison. FITC: fluorescein isothiocyanate, MFI: median 
fluorescence intensity, MP: microparticles. **: p<0.01, ***: p<0.001. 
 
 
In another set of experiments designed to confirm the HUVEC uptake of MP, HUVEC 
were incubated with fluorescent MP for 2 hours and then the cells were then fixed 
and stained with Alexa-Flor 633 labelled wheat germ agglutinin to identify the cell 
membrane. Then counterstained with 4',6-diamidino-2-phenylindole (DAPI) to 
identify the nuclei. The slides were then visualised using confocal microscopy, 
showing that MP were present within the HUVEC (Figure 4.5, 4.6, 4.7).  
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Figure 4.5. Confocal image of human umbilical vein endothelial cells (HUVEC) to assess the 
intracellular uptake of microparticles. Whole blood from healthy volunteers was incubated with 
GM-CSF (100 ng/ml) for 30 minutes and platelet free plasma was produced by differential 
centrifugation. Microparticles were pelleted and washed with phosphate buffered saline (PBS) twice 
and re-suspended in 1/10th of the original plasma volume in PBS. The MP concentrate was stained 
with Fluorescein isothiocyanate (FITC) labelled boron-dipyrromethene (BODIPY) for 15 minutes and 
subsequently the MP were pelleted and re-suspended in PBS.  The fluorescent MP were incubated 
with HUVEC seeded on 13mm slide coverslips for 2 hours in protein free medium at a concentration 
of 1 - 2 x 106/ml. Alexa-flor 633 labelled wheat germ agglutinin and 4',6-diamidino-2-phenylindole 
(DAPI) were used for staining the cell wall and nuclei of the fixed HUVEC red and blue respectively. 
The slide were then visualised using confocal microscopy. Experiments were repeated three time to 
ensure reproducibility. Multiple HUVEC containing microparticles. The microparticles are annotated 
with arrows. 
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Figure 4.6. Confocal split images of human umbilical vein endothelial cells (HUVEC) to assess 
the intracellular uptake of microparticles. Whole blood from healthy volunteers was incubated with 
GM-CSF (100 ng/ml) for 30 minutes and platelet free plasma was produced by differential 
centrifugation. Microparticles were pelleted and washed with phosphate buffered saline (PBS) twice 
and re-suspended in 1/10th of the original plasma volume in PBS. The MP concentrate was stained 
with Fluorescein isothiocyanate (FITC) labelled boron-dipyrromethene (BODIPY) for 15 minutes and 
subsequently the MP were pelleted and re-suspended in PBS.  The fluorescent MP were incubated 
with HUVEC seeded on 13mm slide coverslips for 2 hours in protein free medium at a concentration 
of 1 - 2 x 106/ml. Alexa-flor 633 labelled wheat germ agglutinin and 4',6-diamidino-2-phenylindole 
(DAPI) were used for staining the cell wall and nuclei of the fixed HUVEC red and blue respectively. 
The slide were then visualised using confocal microscopy. Experiments were repeated three time to 
ensure reproducibility. HUVEC containing microparticles in split channels and overlaid. Blue: DAPI 
stained nuclei, Green: BODIPY stained microparticles, Red: AlexaFlor 633 stained cell wall.  
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Figure 4.7. Confocal Z-stack analysis of human umbilical vein endothelial cells (HUVEC) to 
assess the uptake of microparticles. Whole blood from healthy volunteers was incubated with GM-
CSF (100 ng/ml) for 30 minutes and platelet free plasma was produced by differential centrifugation. 
Microparticles were pelleted and washed with phosphate buffered saline (PBS) twice and re-
suspended in 1/10th of the original plasma volume in PBS. The MP concentrate was stained with 
Fluorescein isothiocyanate (FITC) labelled boron-dipyrromethene (BODIPY) for 15 minutes and 
subsequently the MP were pelleted and re-suspended in PBS.  The fluorescent MP were incubated 
with HUVEC seeded on 13mm slide coverslips for 2 hours in protein free medium at a concentration 
of 1 - 2 x 106/ml. Alexa-flor 633 labelled wheat germ agglutinin and 4',6-diamidino-2-phenylindole 
(DAPI) were used for staining the cell wall and nuclei of the fixed HUVEC red and blue respectively. 
The slide were then visualised using confocal microscopy. Experiments were repeated three time to 
ensure reproducibility. Serial confocal images taken through the HUVEC from top to bottom showing 
the microparticles to be inside the cells. 
 
 
 
4.4 Effect of whole blood microparticles on human umbilical vein endothelial 
cells adhesion molecule and tissue factor expression 
Then the effect of whole blood MP on HUVEC expression of adhesion molecules 
and tissue factor was.  
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Figure 4.8. Effect of whole blood microparticles on human umbilical vein endothelial cells 
(HUVEC) adhesion molecule.  Whole blood obtained from healthy volunteers was incubated with or 
without either granulocyte macrophage colony-stimulating factor (GM-CSF 100ng/ml) or interferon γ 
(IFN-γ 50ng/ml) for 30 and 180 min respectively. Platelet free plasma was obtained by differential 
centrifugation and microparticles were pelleted, washed twice and suspended in 1/10th of original 
plasma volume of PBS. HUVEC were seeded in 12 well plates at a concentration of 2 x 105 / well and 
the microparticles were added to them at a concentration of 1 – 2 x 106 / ml in protein free medium. 
The plates were incubated for 4 hours in 37oC incubator containing 5% CO2. Subsequently, HUVEC 
were trypsinised, pelleted, plated in 96 well plates and stained with fluorescent monoclonal antibodies 
against intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), 
platelet-endothelial cell adhesion molecule 1 (PECAM-1), E-selectin, low density lipoprotein receptor-
related protein 1 (LRP-1) and tissue factor (TF). Data are expressed as mean and standard error of 
the mean. One way ANOVA and Bonferroni tests were used for comparison. Experiments were 
repeated at least 4 times with distinct HUVEC and MP donors. Data expressed as mean and SEM. 
Ctrl: Control, GM-CSF: granulocyte macrophage colony-stimulating factor, IFN-γ: interferon-γ, LPS: 
lipopolysaccharide, MP: microparticles.  
 
HUVEC were incubated for 4 hours with vehicle, Control MP, GM-CSF MP or IFN-γ 
MP with or without lipopolysaccharide (LPS – 100 ng/ml). The cells were 
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subsequently stained for adhesion molecules (ICAM-1, VCAM-1, PECAM-1, E-
selectin, lipoprotein receptor-related protein – 1 (LRP-1, receptor for alpha-2-
macroglobulin) and tissue factor (TF) using fluorochrome conjugated monoclonal 
antibodies and examined using flow-cytometry. The MP did not increase ICAM-1, 
VCAM-1 and PECAM-1 compared to baseline, while E-selectin, LRP-1 and TF were 
not expressed (Figure 4.8). 
 
 
4.5 Effect of whole blood microparticles on human umbilical vein endothelial 
cell production of reactive oxygen species (ROS) and nitric oxide (NO)  
The effect of whole blood microparticles on HUVEC ROS and NO production was 
also tested. HUVEC were plated in 96 well plates at a concentration of 1 x 105 / well 
and MP with or without lipopolysaccharide (LPS – 100 ng/ml) were added at a 
concentration of 1 – 2 x 106 / ml of protein free medium. The plates were incubated 
for 4 hours in a 37oC incubator containing 5% CO2. GM-CSF MP elicited significantly 
more ROS irrespective of the presence or absence of LPS. MP obtained from whole 
blood stimulated with IFN-γ showed a trend towards production of more ROS but 
this did not reach statistical significance.  
 
GM-CSF and IFN-γ microparticles alone did not stimulate the production NO. When 
the cells were incubated with GM-CSF or IFN-γ MP together with LPS NO production 
was increased significantly (Figure 4.9). 
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Figure 4.9. Effect of whole blood microparticles on human umbilical vein endothelial cell 
(HUVEC) production of reactive oxygen species (ROS) and nitiric oxide (NO).  Whole blood 
obtained from healthy volunteers was incubated with or without either granulocyte macrophage 
colony-stimulating factor (GM-CSF) or interferon γ (IFN-γ) for 30 and 180 min respectively. Platelet 
free plasma was obtained by differential centrifugation and microparticles were pelleted, washed 
twice and suspended in 1/10th of original plasma volume of PBS. HUVEC were seeded in 96 well 
plates at a concentration of 1 x 105 cells per well and the microparticles were added at a concentration 
of 1 – 2 x 106 /ml in protein free medium with and without lipopolysaccharide (LPS – 100 ng/ml). The 
plates were incubated for 4 hours in 37oC incubator containing 5% CO2. For the reactive oxygen 
species experiments, HUVEC cells were pre-incubated for 30 minutes with 20 μM of 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA), washed and incubated with microparticles. For 
nitric oxide experiments, HUVEC supernatant was incubated with Griess reagent for a further 30 
minutes. Plate reader was used to read fluorescence and absorbance for ROS and NO respectively. 
The results are expressed as arbitrary units. Experiments were repeated at least 4 times. Data 
expressed as mean and SEM. A: Effect of whole blood microparticles on HUVEC ROS production. 
B. Effect of whole blood microparticles on HUVEC NO production. One way ANOVA and Bonferroni 
tests were used for comparison. Ctrl: Control, GM-CSF: granulocyte macrophage colony-stimulating 
factor, IFN-γ: interferon-γ, LPS: lipopolysaccharide, MP: microparticles. *: p<0.05, ***: p<0.001 
 
 
4.6 Effect of whole blood microparticles on human umbilical vein endothelial 
cell cytokine production 
Next, the effect of whole blood MP on HUVEC TNF-α and IL-8 production was 
examined. HUVEC were plated in 96 well plates at a concentration of 5 x 104 cells 
per well and incubated with MP with or without LPS (100 ng/ml) at a concentration 
of 1 – 2 x 106 / ml of protein free medium. The plates were incubated for 4 hours in 
a 37oC incubator containing 5% CO2. The supernatant was collected and the 
concentration of TNF-α and IFN-γ was measured using enzyme-linked 
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immunosorbent assay (ELISA). GMCSF and IFN-γ MP increased production of TNF-
α and IL-8 with and without LPS compared to LPS alone. Interestingly, Control MP 
with LPS also produced significantly higher concentrations of IL-8 (Figure 4.10).  
 
 
Figure 4.10. Effect of whole blood microparticles on the human umbilical vein endothelial cells 
(HUVEC) cytokine production.  Whole blood obtained from healthy volunteers was incubated with 
or without either granulocyte macrophage colony-stimulating factor (GM-CSF) or interferon γ (IFN-γ) 
for 30 and 180 min respectively. Platelet free plasma was obtained by differential centrifugation and 
microparticles were pelleted, washed twice and suspended in 1/10th of original plasma volume of 
PBS. HUVEC were seeded in 96 well plates at a concentration of 1 x 105 /well and the microparticles 
were added to them at a concentration of 1 – 2 x 106 /ml in protein free medium with and without 
lipopolysaccharide (LPS – 100 ng/ml). The plates were incubated for 4 hours in 37oC incubator 
containing 5% CO2. TNF-αand IL-8 were measured in the supernatant in duplicates using enzyme-
linked immunosorbent assay (ELISA) (n=4). A: Effect of whole blood microparticles on HUVEC TNF-
αproduction. B: Effect of whole blood microparticles on HUVEC IL-8 production. Experiments were 
repeated at least 4 times and data expressed as mean and SEM. One way ANOVA and Bonferroni 
tests were used for comparison to LPS. GM-CSF: granulocyte macrophage colony-stimulating factor, 
IFN-γ: interferon-γ, LPS: lipopolysaccharide, MP: microparticles. *: p<0.05, **: p<0.01, ***: p<0.001. 
 
 
4.7 Effect of whole blood microparticles on human umbilical vein endothelial 
cell monolayer permeability 
An important function of the endothelium is to control the passage of solute from the 
blood to the tissues, ensuring the appropriate translocation of nutrients without 
precipitating tissue oedema. Inflammation increases endothelial permeability. For 
this experiment HUVEC were seeded on tissue culture insert, grew them until 
confluent and subsequently stimulated with whole blood microparticles in the 
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presence or absence of LPS. Addition of fluorescein isothiocyanate (FITC) labelled 
dextran to the top well was used to assess endothelial monolayer permeability, by 
quantifying the recovery of the tracer from the bottom well. In the presence of LPS, 
GM-CSF and IFN-γ microparticles significantly reduced the HUVEC monolayer 
permeability. Control microparticles did not have any significant effect (Figure 4.11).  
 
Figure 4.11. Effect of whole 
blood microparticles on 
human umbilical vein 
endothelial cells (HUVEC) 
monolayer permeability.  
Whole blood obtained from 
healthy volunteers was 
incubated with or without either 
granulocyte macrophage 
colony-stimulating factor (GM-
CSF) or interferon γ (IFN-γ) for 
30 and 180 min respectively. 
Platelet free plasma was 
obtained by differential 
centrifugation and 
microparticles were pelleted, 
washed twice and suspended 
in 1/10th of original plasma 
volume of PBS. HUVEC were 
seeded in tissue culture inserts 
at a concentration of 5 x 
104cells per well and the microparticles were added at a concentration of 1 – 2 x 106 /ml in protein 
free medium with and without lipopolysaccharide (LPS – 100 ng/ml). The plates were incubated for 4 
hours in 37oC incubator containing 5% CO2. Fluorescent dextran (4 x 104 kDa) was added to the 
tissue culture inserts on top of the HUVEC monolayer and incubated for further 30 minutes in new 
plates. Amount of fluorescence dextran under the tissue culture insert as measured using plate 
reader. Experiments were repeated at least 4 times and data expressed as mean and SEM. One way 
ANOVA and Bonferroni tests were used for comparison to LPS. GM-CSF: granulocyte macrophage 
colony-stimulating factor, IFN-γ: interferon-γ, LPS: lipopolysaccharide, MP: microparticles. *: p<0.05.  
 
 
 
4.8 Effect of whole blood microparticles on neutrophil function 
As it was previously demonstrated that A2M expressing MP stimulate neutrophil 
activity191, 254, the effect of whole blood MP stimulated with GM-CSF and IFN-γ on 
neutrophil function by measuring CD11b adhesion molecule expression, reactive 
 187 
oxygen species (ROS) production, phagocytosis and chemotaxis were examined. 
Neutrophils from healthy volunteers were incubated with or without MP in the 
presence or absence of LPS. In the presence of LPS, GM-CSF and IFN-γ whole 
blood MP enhanced the expression of CD11b as well as neutrophil phagocytosic 
function, but they had no significant effect on their own, Control MP did not affect 
these neutrophil functions (Figure 4.12, 4.13). GM-CSF and IFN-γ MP did not affect 
neutrophil ROS production or chemotaxis (Figure 4.14, 4.15). 
 
Figure 4.12. Effect of whole 
blood microparticles on 
neutrophil CD11b adhesion 
molecule expression. Whole 
blood from healthy volunteers 
(HV) was incubated at 37oC 
with or without GM-CSF 
(100ng/ml for 30 min) or IFN-γ 
(50ng/ml for 180 min). Platelet 
free plasma (PFP) was 
produced from whole blood by 
differential centrifugation. 
Subsequently, the MP were 
pelleted, washed twice and 
suspended in 1/10th of the 
original PFP volume. 
Neutrophils were isolated from 
HV whole blood and incubated 
for 1 hour (1 x 106/ml) with 
whole blood microparticles (1 – 
2 x 106/ml). The stimulated 
neutrophils were stained with fluorescent monoclonal antibody against CD11b for 30 minutes and 
processed using flow-cytometry. Experiments were repeated at least 4 times with distinct neutrophil 
and MP donors. Data are expressed as mean ± SEM of median fluorescence intensity (MFI) unit as 
quantified by flow-cytometry. Experiments were repeated at least 4 times. One way ANOVA and 
Bonferroni tests were used for comparison to base. GM-CSF: granulocyte macrophage colony-
stimulating factor, IFN-γ: interferon γ, LPS: lipopolysaccharide, MFI: median fluorescence intensity, 
MP: microparticles. *: p<0.05, ***: p<0.001. 
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Figure 4.13. Effect of whole 
blood microparticles on 
neutrophil phagocytosis. 
Whole blood from healthy 
volunteers (HV) was 
incubated at 37oC with or 
without GM-CSF (100ng/ml 
for 30 min) or IFN-γ (50ng/ml 
for 180 min). Platelet free 
plasma (PFP) was produced 
from whole blood by 
differential centrifugation. 
Subsequently, the MP were 
pelleted, washed twice and 
suspended in 1/10th of the 
original PFP volume. 
Neutrophils were isolated 
from HV whole blood and 
incubated for 1 hour (1 x 
106/ml) with whole blood 
microparticles (1 – 2 x 106/ml). 
Stimulated neutrophils were washed and incubated with fluorescent E. Coli (1 mg/ml) for half an hour 
in quadruplicated and the fluorescence of neutrophils as subsequently measured using a plate reader. 
Experiments were repeated at least 4 times with distinct neutrophil and MP donors. Data are 
expressed as mean ± SEM of fluorescence units as quantified by plate reader. One way ANOVA and 
Bonferroni tests were used for comparison to base. GM-CSF: granulocyte macrophage colony-
stimulating factor, IFN-γ: interferon γ, LPS: lipopolysaccharide, MP: microparticles. *: p<0.05. 
 
Figure 4.14. Effect of whole 
blood microparticles on 
neutrophil reactive oxygen 
species (ROS) production. 
Whole blood from healthy 
volunteers (HV) was 
incubated at 37oC with or 
without GM-CSF (100ng/ml 
for 30 min) or IFN-γ (50ng/ml 
for 180 min). Platelet free 
plasma (PFP) was produced 
from whole blood by 
differential centrifugation. 
Subsequently, the MP were 
pelleted, washed twice and 
suspended in 1/10th of the 
original PFP volume. 
Neutrophils were isolated 
from HV whole blood and 
incubated for 1 hour (1 x 
106/ml) with whole blood 
microparticles (1 – 2 x 106/ml). Stimulated neutrophils were washed and incubated with 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA)  for half an hour in quadruplicates and the 
fluorescence of neutrophils was subsequently measured using a plate reader. Experiments were 
repeated at least 4 times with distinct neutrophil and MP donors. Data are expressed as mean ± SEM 
of fluorescence units as quantified by plate reader. One way ANOVA and Bonferroni tests were used 
for comparison to control. GM-CSF: granulocyte macrophage colony-stimulating factor, IFN-γ: 
interferon γ, LPS: lipopolysaccharide, ROS: reactive oxygen species, MP: microparticles.  
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Figure 4.15. Effect of whole 
blood microparticles on 
neutrophil chemotaxis. 
Whole blood from healthy 
volunteers (HV) was incubated 
at 37oC with or without GM-
CSF (100ng/ml for 30 min) or 
IFN-γ (50ng/ml for 180 min). 
Platelet free plasma (PFP) 
was produced from whole 
blood by differential 
centrifugation. Subsequently, 
the MP were pelleted, washed 
twice and suspended in 1/10th 
of the original PFP volume. 
Neutrophils were isolated for 
HV whole blood and incubated 
for 1 hour (1 x 106/ml) with 
whole blood microparticles (1 
– 2 x 106/ml). Stimulated 
neutrophils were washed. 
Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) was used as chemo-attractant at 1μM final 
concentration. fMLP or medium was added to the bottom wells (27μl), filters were placed on top of 
the wells and 25μl neutrophils were added on the upper surface of the filter membrane in quadruplets 
The plates were incubated for 60 minutes in a 37oC incubator containing 5% CO2. Centrifugation (312 
x g for 1 minute) was used to pellet the cells, subsequently the filter was removed and the cells were 
re-suspended. PrestoBlue® fluorescent dye solution (30μl of pre-diluted dye 1 in 5 in PBS) was mixed 
with 20μl cells aliquots in quadruplets in a 96-well plate. The neutrophils were then quantified using 
plate reader.Experiments were repeated at least 4 times with distinct neutrophil and MP donors. Data 
are expressed as mean ± SEM of fluorescence units as quantified by plate reader. One way ANOVA 
and Bonferroni tests were used from comparisons. GM-CSF: granulocyte macrophage colony-
stimulating factor, IFN-γ: interferon γ, LPS: lipopolysaccharide, ROS: reactive oxygen species, MP: 
microparticles.  
 
4.9 Effect of whole blood microparticles on neutrophil-endothelial interaction 
under flow conditions 
Finally, these studies were concluded by investigating the effect of whole blood MP 
on neutrophil-endothelial interaction under flow conditions. HUVEC seeded on μ-
slides were stimulated with LPS with or without MP for 4 hours. Subsequently, 
neutrophils were perfused over the HUVEC monolayers. Granulocyte macrophage 
colony-stimulating factor (GM-CSF) and interferon-γ (IFN-γ) whole blood MP 
enhanced the capture of neutrophils as well as their adhesion and rolling over the 
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HUVEC monolayer; this effect was significantly greater than was seen with LPS 
alone. Also the GM-CSF and IFN-γ MP significantly increased the number of 
neutrophils transmigrating through the HUVEC monolayer when compared to LPS 
alone. Control MP did not have an effect (Figure 4.16). 
 
Figure 4.16. Effect of whole blood microparticles on neutrophil-endothelial interaction under 
flow conditions. Whole blood from healthy volunteers (HV) was incubated at 37oC with or without 
GM-CSF (100ng/ml for 30 min) or IFN-γ (50ng/ml for 180 min). Platelet free plasma (PFP) was 
produced from whole blood by differential centrifugation. Subsequently, the MP were pelleted, 
washed twice and suspended in 1/10th of the original PFP volume. To assess neutrophil-endothelial 
interaction, human umbilical cord endothelial cells (HUVEC) were plated onto μ-Slides and incubated 
at 37oC until confluent and stimulated with lipopolysaccharide (LPS) with or without MP for 4 hours. 
Human neutrophils from HV were isolated and perfused over the HUVEC monolayer at 1 dyne/cm2 
for 8 min. Six random fields were recorded for 10 s.  Neutrophils were quantified as captured, 
adherent, rolling or transmigrating. Experiments were repeated at least 4 times with distinct HUVEC, 
neutrophil and MP donors. Data are expressed as mean ± SEM. One way ANOVA and Bonferroni 
tests were used for comparisons. GM-CSF: granulocyte macrophage colony-stimulating factor, IFN-
γ: interferon γ, LPS: lipopolysaccharide, MP: microparticles. *: p<0.05, **: p<0.01, ***: p<0.001. 
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In summary, GMCSF or IFN-γ stimulation of whole blood resulted in enhanced 
production of MP particularly from granulocytes and monocytes. They also enhanced 
the production of A2M+ MP as well as the production of A2M+ MP from all blood cell 
lines.  
 
These MP were found to be endocytosed by HUVEC. From a functional point of view 
they enhanced ROS and NO production as well as TNF-α and IL-8 production. They 
also reduced HUVEC monolayer permeability. These MP had no effect of HUVEC 
adhesion molecule expression nor on tissue factor expression.  They also had an 
effect on neutrophils where they enhanced CD11b expression and neutrophil 
phagocytosis. They may have reduced neutrophil ROS production as well neutrophil 
chemotaxis. These MP were found to enhance neutrophil-endothelial interaction 
under flow conditions. 
 
Taken together these results suggest that MP produced by GMCSF and IFN-γ may 
play a role in the potential beneficial effect of these cytokines when utilised as 
adjuvant therapies in sepsis. 
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Chapter 5: Discussion 
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In this study, MP profile varied according to the cause of severe sepsis where CAP 
patients had higher concentrations of MP compared to FP. There was no clear 
association between blood cell derived MP and outcome. Endothelial derived MP 
was associated with worse outcome in CAP patients at day 1 post admission to ICU. 
All blood cell derived MP expressed A2M. There was no clear associated between 
parent cell concentration and MP production. Monocytes and lymphocytes were 
more efficient in producing A2M+ MP compared to neutrophils. Higher plasma 
concentration of A2M+ MP in the first 24 hours post admission to intensive care was 
associated with 28 day survival in patients with severe sepsis secondary to CAP. 
This rise was sustained over the time points investigated (day 1, 3 and 5). GM-CSF 
and IFN-γ enhanced the production of A2M+ MP from whole blood and these MP 
were endocytosed by HUVEC. GM-CSF and IFN-γ MP enhanced some pathogen 
clearance function of HUVEC and neutrophils, as well as neutrophil-endothelial 
interaction under flow conditions.  
 
 
Definition and detection of microparticles. MP are small in size, ranging from 0.1 to 
1 µm in diameter and are therefore difficult to detect. The method most often 
employed to characterise MP is flow-cytometry; MP are stained with fluorescent 
antibodies that are within the detection range of the available flow-cytometer. This 
process is fraught with difficulties; including sources of interference and the danger 
of false positives295-297. Due to the variability in the capabilities of flow-cytometers, 
the chosen methodologies have to be tailored to ensure maximum confidence in the 
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results. In this project, considerable time was dedicated to formulating a protocol for 
MP detection that would be reliable using the equipment available (BD 
LSRFortessa).  
 
The first step was to define what would constitute a MP for the purpose of this project. 
A microparticle was defined as a particle detected by flow-cytometer ranging in size 
between 0.1 and 1µm in diameter, positive for annexin V (AV) and at least one other 
marker. Adopting AV as a definitive general marker for MP risked discounting AV 
negative events but on balance it was concluded that defining MP using a single 
marker (e.g. CD66b+ for neutrophil derived MP) risked misclassifying cell debris as 
MP. Another advantage of using AV as a marker is that the results could be easily 
compared to other published studies236, 241, 242. Other factors considered in the 
preliminary experiments were the choice of anticoagulant, centrifugation protocol, 
size calibration and resolution, reducing noise and antibody titration. As result a 
robust protocol was established that has now been adopted by the host group and 
exploited for parallel projects. 
 
Microparticle profiles in patients with sepsis. Severe sepsis and its catastrophic 
consequences was initially thought to be due to an excessive, disseminated pro-
inflammatory response, but more recently it has be recognised as being related to a  
dysregulated host response often characterised by co-existent immune-paresis47. 
Given this state of immune dissonance understanding the role of MP as cell-to-cell 
communicators becomes even more pertinent. A pragmatic approach was applied 
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to this project and the first step would be the detailed characterisation of MP profiles 
in septic patients. Previous attempts to profile MP in severe sepsis, have yielded 
conflicting results, both in comparison to healthy volunteers and in relation to 
outcome235, 236, 238, 239. In most of previous studies, researchers have included 
patients with multiple and heterogeneous causes of sepsis (e.g. urinary tract 
infections, soft tissue infections, trauma and more). The results described here shed 
some light on the pathophysiological heterogeneity of sepsis populations as we have 
demonstrated that MP derived from immune cells and endothelium were significantly 
higher in CAP sepsis in comparison to FP patients and HV. This observation was 
particularly interesting given that CAP and FP cohorts were similar in terms of 
demographics, co-morbidities, severity scores and cells counts. Surprisingly, apart 
from granulocyte, the MP profile of FP patients was not significantly different from 
HV, even though FP patients were older, had a major illness requiring intensive care 
and higher cell counts. One cannot exclude that other circulating MP subtypes or 
from different cells of origin might be different between FP and HV. In any case, in 
association with outcome, CAP non-survivors had higher levels of endothelial MP 
while non-survivors of FP had higher granulocytes and erythrocytes derived MP.  
 
This data indicate that previous studies that have focused on establishing variations 
in MP derived from different cells have probably missed an important point, an issue 
that was addressed here which is the heterogeneity of MP. It was gratifying to 
observe that A2M staining afforded much more clear cut differences, when present, 
and this was only in part associated with the cell of origin. Coupled to the study that 
 196 
paved the way to this studentship254, the new data presented herein give substance 
to the need of stratifying MP for at least 2 or more markers if one has to attempt 
meaningful association with outcome.  
 
Heterogeneity of sepsis. The discrepancies seen here may be due to the different 
natural course of each disease; CAP patients tend to harbour the disease for a few 
days prior to ICU presentation in comparison to FP patients who generally have a 
distinct and fairly recent onset of illness prior to presentation. There are also 
important aetiological and pathological differences between the two conditions. CAP 
is generally caused by specific pathogens and is commonly preceded by viral 
infection which enhances bacterial adherence to alveolar type II cells and promotes 
the release of cytokines, facilitating the development of pneumonia. The cell walls of 
dividing bacteria bind to epithelial, endothelial and local immune cells resulting in 
production of IL-1 and the separation of endothelial cells, with leakage and 
accumulation of serous fluid in the lungs in the early stages of consolidation (called 
“engorgement”)298. “Red hepatisation” is the next stage where there is leakage of 
erythrocytes into the alveoli, with expression of tissue factor and platelet activating 
factor by endothelial cells resulting in a localised pro-coagulant state and recruitment 
of platelets and leucocytes to the area. Leucocytes are further recruited via selectin-
CD18 integrin, platelet activating factor and alternative complement pathways as 
well as via complement in a stage called “grey hepatisation”299. As leucocytes kill the 
invading bacteria there is release of microbial cell wall products and other 
components resulting in further local inflammation and a cytotoxic effect on 
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pulmonary cells. When neutrophils begin to phagocytose and kill the pathogen the 
process of consolidation resolution ensues during which monocytes are recruited to 
the area to clear debris, fibrin and apoptotic neutrophils and the lung eventually 
returns to normal function300. The outcome of this infection will to a certain extent 
depend on the host’s ability to withstand and resolve the inflammation which could 
be exaggerated and dysregulated resulting in severe sepsis picture301, 302. FP, on 
the other hand is caused by spillage of large intestinal content into the peritoneal 
cavity through anastomosis breakdown, penetrating wounds or perforated 
diverticulitis. Faecal material be localised around the affected viscous causing an 
abscess or may cause generalised peritonitis. The resident peritoneal macrophages 
encounter bacteria or bacterial components resulting in the production of pro-
inflammatory cytokines such TNF-α, IL-1, IL-6, IL-8 and IFN-γ about 2 hours 
following the initial insult303. These cytokines are found in the peritoneal exudates 
and reach the systemic circulation via lymphatic drainage. These cytokines in the 
peritoneum induce the production of nitric oxide and arachidonic acid metabolites 
resulting in activation and neutrophil recruitment304, 305. It has been shown that the 
concentration of these cytokines is much higher than in plasma, suggesting that 
there is a considerable degree of “compartmentalisation”303, 306, 307.  
 
Moreover, the majority of the causative organisms in CAP are Gram positive308 while 
FP is usually due to peritoneal inflammation and contamination with a mixture of  
Gram negative and anaerobic organisms309. The causative organism influences the 
disease course through multiple mechanisms. For example secreted toxins may 
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exacerbate the inflammatory response. Panton-Valentine leukocidin secreted by 
staphylococci contributes to the development of haemorrhagic pneumonia in some 
patients. Other toxins include toxic shock syndrome toxin 1 and exfoliative toxin 
secreted by Staphylococcus aureus310. Another mechanism by which the causative 
organism can influence the course of sepsis is via release of cell wall components. 
Toll like receptors (TLR) expressed on the surface of cells of the innate immune 
system recognise bacterial cell wall components. For example, LPS and 
lipotecichoic acid are present in the cell walls of Gram negative and Gram positive 
bacteria and they activate TLR-4 and TLR-2 respectively. There is some overlap in 
the TLR receptors by the intact micro-organism but activation by Gram negative and 
Gram positive bacteria remains dominantly TLR-4 and TLR-2 dependent 
respectively. The activation of these receptors results in the up-regulation of nuclear 
factor-κB (NF-κB), activator protein-1 and interferon response factor-1 resulting in 
the transcription of pro-inflammatory genes. This overlap in the downstream 
pathways is not complete and the response can vary between the two categories of 
bacterial infections. For example, heat killed Escherichia coli produces more IL-10 
and less interferon-gamma (IFN-γ) than staphylococci, as well as stimulating the 
production of more IL-6, IL-8, IL-1β and tumour necrosis factor (TNF)-α than heat 
killed streptococci in a whole blood model. In vivo, Gram negative infections produce 
more TNF-α and IL10 and less IFN-γ than are produced by Gram positive 
organisms310.  
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An external factor by which the course of the illness may be affected is the choice of 
antibiotics as the recommended empirical agents used for CAP differ from those 
used for FP. Also the specific antibiotic therapy that is used subsequently once the 
organism has been identified will differ between the two forms of severe sepsis. 
Macrolides such as clarithromycin are frequently used in the treatment of pneumonia 
and rarely used for FP. Recently, these compounds have been shown to possess 
anti-inflammatory actions beyond their anti-microbial properties311. Macrolides 
reduce the production of TNF-α and IL-1, inhibit the NF-κB pathway, suppress TLR 
expression and induce neutrophil apoptosis311. Moxifloxacin a quinolone antibiotic 
can reduce IL-8, IL-1β and TNF-α induction by LPS in human monocytes in vitro and 
has been shown to inhibit NF-κB and the mitogen activated protein kinases (JNK 
and ERK) pathways312. 
 
Another important consideration is that in Gram negative sepsis, circulating levels of 
LPS vary according to the source of infection. Patients with CAP were found to have 
higher plasma levels of LPS in comparison to patients with intra-abdominal sepsis313. 
Monocyte HLA-DR expression also varied according to the source of infection as 
well as apoptosis of natural killer cells and lymphocytes314.  
 
It was interesting and perhaps surprising to observe the variation in erythrocyte 
derived MP between non-survivors and survivors of FP sepsis which was not 
demonstrated in CAP. This would suggest some participation of erythrocytes MP in 
the immune process in FP. Erythrocyte MP have been previously investigated in the 
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context of stored erythrocytes for transfusion. Stored erythrocytes have been 
demonstrated to produce large number of MP in storage with a distinct proteomic 
profile315.  These MP were shown in another study to have a pro-inflammatory effect 
when injected in mice316. The stored erythrocyte MP also enhanced human 
neutrophils CD11b expression, ROS production and phagocytosis in vitro316. They 
were found to activate monocytes in vitro inducing pro-inflammatory cytokines 
production and this effect was attributed more to exosomes rather than the large 
microparticles317. Another study demonstrated a pro-coagulant effect of stored 
erythrocyte MP mediated through initiation of thrombin generation318.  Also these MP 
were shown to express phosphatidylserine and this expression increased as the age 
of the stored blood increased exerting a pro-thrombotic effect319. These studies 
consolidate the notion that erythrocyte MP have a role to play in inflammation. 
 
Taken together these findings suggest that CAP and FP are quite different diseases, 
albeit with a similar clinical phenotype presenting as severe sepsis and this may 
explain the differences in MP profiles described in this thesis and the inconsistent 
findings in previous studies.   
 
Role of microparticles expressing alpha-2-macroglobulin (A2M) in sepsis. A2M is a 
tetrameric glycoprotein consisting of four identical subunits. The main function of this 
acute phase reactant is the entrapment and inhibition of proteinases by preventing 
the attachment of large molecular weight substrates to the active site. A2M entraps 
the proteinases produced by neutrophils and other cells during inflammation as well 
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as regulating clotting and fibrinolysis via inhibition of proteolytic activity320.  A2M also 
protects the host by entrapping proteases produced by invading pathogens. 
Chymase is a protease secreted by mast cells that is involved in the activation of 
many important mediators such as angiotensin, IL-1β, endothelin and collagenase, 
as well as the induction of basement membrane degradation and inhibition of 
thrombin receptor. A2M has also been shown to inhibit and regulate chymase 
activity. Transferrin is an iron transporting protein that requires A2M for its uptake by 
cells. A2M also acts as a scavenger of inflammatory mediators such as defensins in 
order to regulate the inflammatory process and also binds cytokines such as TNF-α, 
IL-1β and IL-6 in order to protect them from degradation and deliver them to cells 
through A2M receptor pathways. A2M plays a similar role in binding, protecting and 
delivering hormones such as hepcidin (regulates transmembrane iron transport) and 
leptin (regulates appetite and energy expenditure) to cells. Some of the effects of 
A2M are mediated via the receptor low density lipoprotein receptor (LRP). Activation 
of this receptor on macrophages reduces apoptosis and induces production of 
eicosanoids. Activation of LRP inhibits the production of reactive oxygen species by 
granulocytes.  
 
It is intriguing that A2M has been considered as a potential biomarker for various 
diseases such as liver fibrosis, cardiac hypertrophy, myocardial infarction in diabetic 
patients, diabetes mellitus, pancreatitis and inflammatory bowel disease270, however 
these studies did not investigate whether this acute phage protein was encapsulated 
in vesicles or free floating in the plasma. 
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Our group has previously demonstrated that MP produced from neutrophils adherent 
to an endothelial monolayer contained and expressed A2M among other proteins191. 
The proteome of these adherent MP differed from that derived from neutrophils in 
suspension. The A2M expressing adherent MP up-regulated pro-inflammatory gene 
expression when incubated with endothelial cells and similar A2M expressing MP 
were found in the plasma of patients with sepsis191. Injection of A2M expressing MP 
into septic mice was associated with a significant reduction in mortality as well as a 
reduction in pro-inflammatory and an increase in pro-resolution lipid mediators in 
their peritoneal exudate. These A2M enriched MP also reduced local and systemic 
bacterial load and protected against hypothermia. The neutrophil count and level of 
pro-inflammatory cytokines in the peritoneal cavity were also reduced without a 
reduction in the monocyte/macrophage count. The A2M MP were also found to 
enhance neutrophil phagocytosis, the production of reactive oxygen species and 
neutrophil endothelial interaction254. The A2M MP exerted their effects through LRP-
1254, a widely expressed receptor protein that has a role in cellular endocytosis and 
signal transduction. In the lungs this receptor has a pro-inflammatory role where it 
triggers macrophage phagocytosis against foreign bodies and cytokines release. 
This receptor is also expressed on endothelial cells, where it promotes endothelial 
interaction with leucocytes and maintains vascular integrity321. Data from our group 
showed that neutrophils also express LRP-1. Another property of A2M was its 
transfer via MP to endothelial cells where it promotes endothelial neutrophil 
interaction through binding the LRP-1 on the surface of neutrophils254. Taken 
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together these experiments demonstrated an activating role for A2M expressing MP 
on the innate immune response which could have beneficial effects against the 
immune-paresis typical of severe sepsis. These observations were extended in the 
work reported in this thesis.  
 
First, it was observed that A2M+ MP are derived from all blood cells, not just 
neutrophils, an observation that is supported by previous proteomic analyses of MP 
derived from monocytes, lymphocytes, platelets and erythrocytes showing that these  
MP subsets do indeed contain A2M190, 322-324. The results of this study also suggest 
that monocytes and lymphocytes are more efficient in producing A2M+ MP, at the 
single cell level than neutrophils in patients with severe sepsis. 
 
Second, it was demonstrated that patients with CAP had higher total A2M+ MP and 
A2M MP derived from granulocytes, monocytes, lymphocytes, platelets and 
erythrocytes in comparison to patients with FP and healthy volunteers. This result 
reinforces the increasing recognition that CAP and FP are different diseases, albeit 
with a similar clinical picture of severe sepsis. There were no significant differences 
in all these A2M+ MP subsets between FP and HV.  
 
Third, when MP were further characterised according to their A2M expression in 
relation to outcome, significant differences emerged. CAP survivors had higher total 
A2M+ MP from and increased levels of granulocyte and monocyte MP expressing 
A2M compared to non-survivors, whereas in FP patients there was a significant 
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increase in erythrocyte A2M+ MP in non-survivors compared to non-survivors. The 
higher levels of A2M+ MP  in CAP survivors was sustained across all three time 
points examined in comparison to non-survivors, while non-survivors had either 
persistently low or decreasing A2M+ MP levels. This was particularly evident in the 
case of total A2M+ MP as well as granulocyte and monocyte derived MP expressing 
A2M.  
 
The higher level of MP expressing this acute phase reactant (A2M) may point 
towards the need for a more potent, targeted inflammatory response to overcome 
an invasive infection with more generalised effects. This suggestion is supported by 
the immuno-modulatory effects attributed to A2M expressing MP previously reported 
by our group 191 and in the latter part of this project. 
 
Immune-paresis in sepsis. A favourable outcome in severe sepsis is associated with 
the ability to maintain an effective immune response in the face of continuing and 
added infections as well as the ability to resolve inflammation once the offending 
pathogen has been eliminated. The antigen presenting molecule human leucocyte 
antigen (HLA)-DR, which is expressed by monocytes and is a marker of the ability 
to mount a response against invading pathogens has been shown to be linked to the 
development and outcome of severe sepsis. Reduced expression of this molecule 
on monocytes is associated with an inability to mount a TNF-α response when 
challenged with LPS (i.e. the monocytes are “deactivated”) 325, 326. Following major 
surgery, HLA-DR expression falls, but those patients in whom who HLA-DR 
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expression is rapidly restored survive without superadded infections, whereas those 
in whom HLA-DR expression is restored more slowly developed infection and in 
those whom HLA-DR expression never recovered developed severe sepsis and 
died327. This observation was confirmed in a study in trauma patients in which it was 
found that patients with lower HLA-DR expression were more likely to develop 
severe sepsis327. In severe sepsis secondary to CAP, reduced HLA-DR expression 
has been associated with worse outcome328. Higher levels of the anti-inflammatory 
cytokine IL-10 have also been associated with worse outcomes and IL-10 mRNA 
expression in leucocytes might be a useful marker for the onset of immune-paresis. 
The sustained production of IL-10 beyond the initial phase of sepsis and decreasing 
levels of the pro-inflammatory tumour necrosis factor (TNF)-α were found to be 
associated with worse outcome; thus in the same cohort a high IL-10 to TNF-α ratio 
was associated with non-survival329. This observation was confirmed in severe 
sepsis patients with CAP in whom higher levels of IL-10 were again associated with 
worse outcome328, 330. These observations support the concept that following the 
initial hyper-immune phase in severe sepsis a persistent hypo-immune response is 
associated with worse outcome.  
 
Further confirmation of the importance of immune-paresis in determining sepsis 
outcomes comes from clinical trials that attempted to neutralise pro-inflammatory 
cytokines and in effect induce hypo-immunity, a clinical approach that in many cases 
resulted in a worse outcomes331. On the other hand attempts to reverse the hypo-
immune state seen in sepsis patients have resulted in some promising results. As 
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outlined in the introduction chapter of this thesis, granulocyte-macrophage colony 
stimulating factor (GM-CSF) and interferon-γ (IFN-γ) have been shown to reverse 
the monocyte deactivation seen in sepsis and restore their ability to produce TNF-α, 
with some beneficial effects in clinical trials particularly in patients with low monocyte 
HLA-DR expression331. This results demonestrate that patients who are able to 
produce and maintain a higher level of the pro-inflammatory A2M+ MP were more 
likely to survive is in keeping with the concept that an effective therapeutic strategy 
in sepsis may entail the boosting of the immune response. 
 
GM-CSF and IFN-γ clinical trials in sepsis have shown some beneficial effects 
particularly in those with biomarkers of hypo-immunity (i.e. low monocyte HLA-DR 
expression) where they were able to reverse the monocyte deactivation state133, 168.  
In the experiments reported here, GM-CSF or IFN-γ were used to stimulate whole 
blood obtained from healthy volunteers, observing that these treatments induced the 
production of A2M+ MP. These experiments demonstrated that these MP elicited a 
pro-inflammatory effect on neutrophils and endothelial cells as well as enhancing the 
neutrophil-endothelial interactions. The effects are consistent with previous 
observations that A2M+ MP enhance pathogen clearance191, 254. These results 
indicate that some of the potential beneficial effects of GM-CSF and IFN-γ in sepsis 
could be mediated by MP. 
 
Functional effects of GM-CSF or IFN-γ induced microparticles. MP interact with 
target cells via various mechanisms including binding to membrane receptors and 
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internalisation. It has been demonstrated previously that endothelial cells uptake of 
MP depends on the phosphatidylserine expressed on their surface332, 333 and is 
independent of adhesion molecule expression on the endothelial cell surface334. The 
mechanism for this internalisation has been proposed to be via phagocytosis and 
macropinocytosis334. In this study, it was demonstrated that the vast majority of 
endothelial cells have taken up MP after 4 hours and this uptake can be largely 
prevented by cytochalasin B which inhibits the actin filament polymerisation required 
for endocytosis335. These results were corroborated further by in-vitro analyses by 
measuring the effect of cytokine-induced MP on the release of specific immune-
modulatory mediators. 
 
Reactive oxygen species (ROS) are produced by various cells as a means of 
eliminating pathogens, on the other hand excessive release can lead to tissue 
damage. MP have been shown previously to increase ROS for example by T-cells 
stimulated with actinomycin D for 24 hours336 or by circulating MP obtained from 
hypoxic mice216. In other reports MP reduced endothelial ROS production, including 
MP obtained from T-cells stimulated by phytohemagglutinin for 72 hours followed by 
phorbol-12-myristate-13 and actinomycin D for a further 24 hours337 and circulating 
MP from all sources obtained from patients with metabolic syndrome338. The same 
discrepancies are seen in sepsis where MP from septic rats induced ROS production 
in the aortas and hearts of healthy rats in one study250 while in another MP from 
septic patients did not alter endothelial ROS production in vitro237. This study has 
demonstrated that MP produced from whole blood stimulated by GM-CSF or IFN-γ 
 208 
enhance ROS production in endothelial cells and that this was further enhanced in 
the presence of LPS. The same MP reduced neutrophil ROS production. These 
findings suggest that the functional effect of MP depends on the stimulus for their 
production, the context and the target cell. In the context of a severe sepsis induced 
hypo-immune state, a robust production of ROS by endothelial cells could help fend 
off invasive pathogens while reduced neutrophil ROS production could reduce the 
risk of acute respiratory distress syndrome (ARDS). Indeed a reduction in hospital 
acquired infections and lung injury were two of the effects seen in clinical trials 
examining GM-CSF or IFN-γ as adjuvant therapies in severe sepsis133-135, 171.  
 
Nitiric oxide (NO) is a vasodilating agent produced by the endothelium and other 
cells via endothelial nitric oxide synthase (eNOS) or inducible nitric oxide synthase 
(iNOS) respectively. Severe sepsis and experimental endotoxaemia initially both 
reduce production of NO via suppression of eNOS and later in the course of the 
disease there is increased production of NO via activation of (iNOS). The initial 
reduction in endothelial NO production contributes to the vascular injury seen in 
sepsis while the later increase in NO results in excessive vasodilation and 
hypotension9. MP play a role in regulating endothelial NO production. T-cell MP, 
depending on the stimulus for their production can either increase or decrease 
endothelial NO production336, 337. Metabolic syndrome MP reduce NO levels 338, 
while the MP from Crohn’s disease patients cause over production of NO via 
enhanced iNOS activity339. MP derived from septic rats reduced eNOS activity and 
enhanced the effect of iNOS in the aortae and hearts of healthy rats250. Here, MP 
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produced in response to GM-CSF and IFN-γ enhanced the production of NO from 
endothelial cells, presumably due to up-regulation of eNOS. This effect might help 
to restore some endothelial function in sepsis patients. 
 
TNF-α is one of the principal cytokines implicated in the pathogenesis of severe 
sepsis. A surge in TNF-α levels is observed during the early systemic inflammatory 
response syndrome (SIRS) phase; this is followed by lower levels during the 
compensatory anti-inflammatory response syndrome (CARS) hypo-immune 
phase52. In clinical trials, GM-CSF and IFN-γ restored TNF-α levels and the response 
to endotoxin in patients with severe sepsis, as well as reducing the incidence of 
hospital acquired infection in some patients131, 133, 169, 340. IL-8 is another cytokine 
with an important role in inflammation and pathogen elimination via chemotactic 
attraction of neutrophils to the site of the insult. In severe sepsis, IL-8 production 
from whole blood in response to endotoxins was subdued341, a response that could 
be restored by GM-CSF131. MP were also found to have an effect on the production 
of these two cytokines; for example platelet MP produced by shear stress increased 
TNF-α and IL-8 production by endothelial cells342, as so did atheromatous plaque 
MP343. On the other hand circulating MP from patients with metabolic syndrome did 
not influence the production of these cytokines by endothelial cells338. In the present 
study the whole blood MP produced in response to GM-CSF or IFN-γ enhanced 
TNF-α and IL-8 production by endothelial cells and this effect was more marked in 
the presence of LPS. On the other hand these MP did not enhance neutrophil 
chemotaxis. These observations again highlight the role played by MP in the 
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potential beneficial effects seen in clinical trials of GM-CSF or IFN-γ and may help 
to shed some light on the mechanism of reduced neutrophil sequestration in the 
lungs.  
 
Increased endothelial permeability in severe sepsis results in tissue oedema which 
contributes to multi-organ dysfunction and eventually failure72. This effect is 
particularly pertinent in the lungs where it can lead to acute lung injury (ALI) or acute 
respiratory distress syndrome (ARDS). In experimental models of sepsis LPS was 
found to increase endothelial permeability both systemically and in the lungs 
resulting in ALI/ARDS in a murine model344-346. The effect of LPS was mediated via 
the enhanced expression of caveolin-1344 (facilities albumin endothelial 
transcytosis347) and angiotensin II345 (enhances the expression of VGEF which 
remodel the extra-cellular matrix resulting in increased permeability348). MP can 
influence endothelial permeability. Endothelial derived MP increased permeability346, 
whereas circulating MP from septic patients treated with activated protein C reduced 
permeability 349 and surprisingly LPS induced monocyte derived MP did not alter 
permeability350. GM-CSF has been shown to improve gas exchange in sepsis related 
respiratory dysfunction135 and as shown in a separate clinical investigation, its 
administration can reduce the number of days on mechanical ventilation133. Also 
GM-CSF has been demonstrated to reduce vascular permeability in burns which has 
been attributed to RhoA inhibition and maintaining VE-cadherin which enhances the 
adherens junctions between endothelial cells351.   In this study it was demonstrated 
that MP produced from whole blood stimulated by GM-CSF or IFN-γ reduced 
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endothelial monolayer permeability despite increasing TNF-α levels. This result 
mirrors, and may contribute to the effects of GM-CSF found previously.  
 
Neutrophil-endothelial interaction is vital for pathogen clearance as it facilitates 
neutrophil migration to the site of infection. This interaction is impaired in sepsis, 
where there is reduction in rolling, adherence and transmigration of neutrophils 
across the endothelium which results in failure of neutrophil migration to the site of 
infection and therefore reduced in pathogen clearance57. As a consequence, 
inflammation persists, resolution is delayed and organ damage is perpetuated. Our 
group has shown previously that A2M+ MP enhance neutrophil-endothelial 
interaction, as well as enhancing bacterial clearance and resolution of inflammation 
in a murine model of sepsis191, 254. These potential beneficial effects were found not 
to be dependent on endothelial adhesion molecule up-regulation but on A2M transfer 
via MP to endothelial cells and interactions with the LRP-1 receptor expressed on 
the surface of neutrophils254. GM-CSF or IFN-γ whole blood MP seem to have a 
similar effect, enhancing neutrophil-endothelial interaction under flow without 
increasing the expression of endothelial adhesion molecules. 
 
Limitation of the studies reported in this thesis. The study was performed 
retrospectively and MP were characterised in stored plasma even though it was 
previously demonstrated that storage and freeze/thaw cycles had no effect of the 
concentration of MP in plasma352. The study only examined two causes of severe 
sepsis. The results were compared to healthy volunteers only and less severe forms 
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of sepsis were not included and neither were causes of systemic inflammatory 
response syndrome other than infection. The experiments were conducted by a 
single operator and the operator was not blinded to outcome. Whole blood model 
used for GM-CSF and IFN-γ MP production. In this study, the incubation periods for 
whole blood was relatively short (30 or 180 minutes) but whole blood once outside 
the body starts to become hypoxic, hypoglycaemic and acidic which might influence 
MP production. Unstimulated whole blood incubated in vitro was used to produce 
control MP to mitigate the risks of the whole blood model.  
 
Mechanisms behind the effect of whole blood MP effects were not investigated. 
Blocking of A2M expressed on MP would have shed some light on the mechanisms 
however our group has previously demonstrated that blocking A2M expressed on 
MP using monoclonal antibodies abrogated many of the MP effects191, 254.  
 
Future work. The differences observed between CAP and FP MP profiles would lead 
to investigating the functional effects of CAP and FP MP on neutrophils, monocytes 
and endothelial cells in order to investigate whether these MP contribute to the 
immune process of these diseases. Also investigating whether there is a difference 
in functional effect of MP between survivors and non-survivors of CAP and the role 
of A2M in this function. This could be taken a step further by sorting the MP according 
to cell of origin in order to pin point which cell line is responsible for the effects seen. 
This could be followed by investigating the proteomic profiles of these MP 
populations as well as their microRNA content. If a specific microRNA is identified, 
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this could blocked to investigate whether the effect of these MP is microRNA 
dependent. 
 
The results of the functional effects of GM-CSF and IFN-γ would lead to investigating 
the proteomic profile of the MP as well as their microRNA content and whether the 
function of these MP is dependent on microRNA.  
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Chapter 6: Conclusions 
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Microparticle profiles in relation to source of infection. Microparticle (MP) profiles 
differed significantly according to the source of infection. Patients with severe sepsis 
due to community acquired pneumonia patients had higher plasma concentrations 
of MP in comparison to those with faecal peritonitis and healthy volunteers; this 
finding was consistent across all the measured MP subsets. Surprisingly there was 
no significant difference in MP concentrations between faecal peritonitis patients and 
healthy volunteers. This finding adds to the increasing body of evidence indicating 
that sepsis is a heterogeneous condition, emphasising the importance of studying 
more homogenous cohorts of patients and developing source targeted treatments. 
 
Microparticle profiles relation to outcome. Community acquired pneumonia non-
survivors had levels higher of endothelial MP while faecal peritonitis non-survivors 
had higher granulocyte and erythrocyte derived MP counts at day 1 post admission 
to intensive care. When MP were further characterised according to alpha-2-
macroglobulin (A2M) expression a new picture emerged. The total plasma 
concentration of A2M+ MP, as well as granulocyte and monocyte A2M+ MP plasma 
concentrations were higher in survivors of community acquired pneumonia sepsis 
compared to non-survivors at day 1; this difference was sustained across the 
examined time points (day 3 and 5).  This data highlights the potential for MP profiles 
to be used as a biomarker in severe sepsis when they are characterised not only 
according to their cell of origin but also according to protein expression. MP 
expressing the protein A2M have the potential as novel biomarkers in patients with 
severe sepsis due to community acquired pneumonia. It is envisage that a more 
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analytical follow up studies where MP from septic patients are sorted according to 
their cell of origin marker and then used for unbiased analyses (e.g. proteomics, 
lipidomics, microRNA) could allow the identification of more markers of disease to 
be used alone or in association with the A2M+ MP characterised here. 
 
Microparticles produced by stimulating whole blood with granulocyte-macrophage 
colony stimulating factor (GM-CSF) or interferon-gamma (IFN-γ) functional effects. 
The MP produced by stimulating whole blood with GM-CSF or IFN-γ had a pro 
pathogen clearance effect on neutrophils and endothelial cells, as well as enhancing 
neutrophil-endothelial interaction under flow conditions. These results shed light on 
the role of MP in the potential beneficial effect of GM-CSF and IFN-γ seen in clinical 
trials when these cytokines were used as adjuvant immune-stimulatory therapies in 
severe sepsis. 
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